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ABSTRACT
Background: HIV clinical outcomes including CD4 count, viral suppression, and healthrelated quality of life (HRQoL), are important indicators reflecting immunologic
functioning, treatment efficacy, and overall health quality. However, due, in part, to HIVrelated stigma, many people living with HIV (PLWH) experience suboptimal clinical
outcomes. The Health Stigma Framework introduced the potentially distinct mechanisms
underlying internalized, anticipated, enacted stigma and health outcomes through psychobehavioral pathways. Based on this framework, this dissertation investigated the impacts
and mechanisms of HIV-related stigma on clinical outcomes among PLWH in Guangxi,
China from a longitudinal perspective.
Methods: Data at baseline, 6-, 12-, 18- month follow-ups were derived from a
prospective cohort study among 1,198 in Guangxi, China. Hierarchical generalized linear
mixed model was employed to test the separate impacts of internalized, anticipated, and
enacted stigma on each clinical outcome after accounting for psycho-behavioral factors
(i.e., antiretroviral therapy [ART] self-efficacy, HIV symptom management self-efficacy,
ART adherence) and covariates. Latent growth curve modelling and mediation analysis
were employed to examine the mediating effects of psycho-behavioral factors between
stigma and each clinical outcome.
Results: In hierarchical generalized linear mixed models, internalized, anticipated, and
enacted stigma showed negative impacts on HRQoL but these impacts were not found in
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CD4 count and viral suppression. Mediation analyses revealed that ART self-efficacy and
ART adherence mediated the indirect pathways from HIV-related stigma to viral
suppression but these effects were not found in CD4 count. ART self-efficacy
consistently mediated the impacts of the three types of stigma on HRQoL but the
mediating effect of HIV symptom management self-efficacy was only found in the
pathway between anticipated stigma and HRQoL.
Conclusions: This dissertation provided support for the different psycho-behavioral
mechanisms of HIV-related stigma on clinical outcomes. Future stigma research should
consider the characteristics of each type of HIV-related stigma and clinical outcomes and
use the relevant theoretical knowledge to frame the pathways between them.
Interventions aiming to improve clinical outcomes should be tailored to internalized,
anticipated, and enacted stigma, target relevant psycho-behavioral pathways, and promote
the resilience of PLWH.
Keywords: Adherence, China, Clinical outcomes, HIV, Self-efficacy, Stigma
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CHAPTER 1
INTRODUCTION
1.1 General introduction to HIV epidemic
The global efforts to control and prevent Human Immunodeficiency Virus (HIV)
have significantly reduced its morbidity and mortality since 2010 (Joint United Nations
Programme on HIV/AIDS [UNAIDS], 2020a, 2020b), but the current global HIV
epidemic is still a critical public health challenge. By the end of 2019, it is estimated that
there were about 38 million people living with HIV (PLWH) and 690,000 Acquired
Immune Deficiency Syndrome (AIDS) related deaths worldwide (UNAIDS, 2020a).
Nearly 80% of PLWH and 90% of the AIDS-related deaths were found in sub-Saharan
Africa and Asia and the Pacific areas (UNAIDS, 2020b).
To control HIV-related morbidity and mortality, the Joint United Nations
Programme on HIV/AIDS (UNAIDS) launched the “90-90-90” and “95-95-95” goals in
2014 (Lima et al., 2017; Marsh et al., 2019). These goals are by 2020 and 2030,
respectively, (1) at least 90% and 95% of all PLWH will know their HIV status; (2) at
least 90% and 95% of the confirmed cases will receive antiretroviral therapy (ART); and
(3) at least 90% and 95% of the PLWH on ART will achieve viral suppression (Lima et
al., 2017; Marsh et al., 2019). However, the current progress on HIV prevention around
the world still does not meet these goals (Marsh et al., 2019). Among the 38 million
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PLWH worldwide, only 62% are currently on ART and 53% had achieved viral
suppression in 2018 (Marsh et al., 2019).
China has undertaken large efforts on HIV control and prevention, such as “Four
Frees and Once Care” policy to promote HIV treatment and care, infrastructure
development on surveillance and case management, and regular monitoring of treatment
failure and drug resistance. However, the nation still has large number of PLWH (Wu,
Chen, Scott, & McGoogan, 2019; Wu, McGoogan, & Detels, 2021). The total numbers of
PLWH in China have steadily increased since 2005, and there were more than 1.25
million cumulative cases (diagnosed and undiagnosed cases) by the end of 2018, with
nearly 80,000 new cases diagnosed during the same year (Wu et al., 2021). The
distribution of PLWH varies significantly in China with clusters in the southwestern
provinces and resource-limited areas, such as Yunnan, Sichuan, and Guangxi (Wu et al.,
2019; Wu et al., 2021). Guangxi, an autonomous region in southwestern China,
consistently ranked third in the number of HIV case among the 31 provinces in China
from 2014 to 2018 (Wu et al., 2019).
Although there was remarkable achievement in HIV control and prevention, the
progresses on the UNAIDS’ “90-90-90” and “95-95-95” goals are still unsatisfactory in
China. For example, in 2018, the ART coverage rate among PLWH was 83%, and 94%
of them achieved viral suppression (Wu, 2019). Substantial variation of viral suppression
was identified in different areas, especially in the rural provinces and resource-limited
areas, such as Guangxi (Zhao, Han, Ma, & Li, 2019). Using large representative samples
of PLWH in Guangxi, a previous study found that in 2017, only 77.3% of the PLWH
were on ART and 82.5% of them were virally suppressed (Yang et al., 2019). The failure
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to meet UNAIDS’ goals indicates that more research investigating the barriers and
facilitators of optimal clinical outcomes are needed, which could inform future clinical
efforts to reduce treatment failure, improve the health of PLWH, and limit new cases of
HIV.
1.2 Clinical outcomes among PLWH
Clinical outcomes in this dissertation were CD4 count, viral suppression, and
health-related quality of life (HRQoL). CD4 count and viral load are important indicators
of successful ART (Andersson et al., 2020; Limmade, Fransisca, Rodriguez-Fernandez,
Bangs, & Rothe, 2019). CD4 count, the total numbers of CD4 T-cells in body, represents
the immunologic functioning and ability to fight with infections (Center for Disease
Control and Prevention [CDC], 2019). Viral load, the amount of HIV virus in the body, is
an indicator of infection stage (i.e., acute HIV infection, chronic HIV infection, AIDS)
among PLWH (CDC, 2019). CD4 count and viral load are closely correlated with each
other across the three infection stages. At the beginning of infection (first 10 days or so),
the HIV will attack CD4 cells and use them inside the lymph nodes to reproduce and
replicate. During the next few weeks (two weeks or more), the viral load increases to
high levels (higher than 10 million copies/ml), and nearly 80% ~ 90% of the total CD4
cells will be killed by the virus (i-base, 2019). Then, the immune system fights back and
produces antibodies to HIV. During this period (nearly six months), the viral load drops
to lower levels, and CD4 count will recover. During this time, it is estimated that nearly
70% of the PLWH have symptoms, such as fevers and fatigue (i-base, 2019). After the
acute infection stage and without treatment, HIV enters the chronic infection stage, which
often progresses slowly. As time increases, the CD4 count will steadily drop and viral
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load will steadily increase. At any infection stages, the initiation of ART can slow disease
progression, recover immunologic functioning, and reduce the chance to develop
opportunistic infections (Fogarty et al., 2002; Nieuwkerk & Oort, 2005; Press, Tyndall,
Wood, Hogg, & Montaner, 2002). A few days after ART initiation, about 90% of the
virus will be killed, and the viral load become undetectable within one to three months (ibase, 2019). However, the CD4 count increases slowly, especially for those with low
CD4 count at the beginning of ART. The normal CD4 range for HIV negative population
is between 500 and 1,600, with higher levels of CD4 count indicating better immunologic
functioning (i-base, 2019).
HRQoL is the third important indicator of successful ART. PLWH with
considerable levels of CD4 count and viral suppression still need to contend with other
challenges, such as potential side effects of ART, the possibility of treatment failure, and
other comorbidities. Thus, HRQoL is the individual’s perceived quality of daily life
(CDC, 2018) and thus could be an important construct for PLWH under care (Andersson
et al., 2020; Lazarus et al., 2016; Webster, 2019). It reflects the disease burden across
four main dimensions (i.e., physical health, psychological health, social functioning,
perception about general health) and provides a comprehensive measure of overall health
quality among PLWH (Ashing-Giwa, 2005; Ruiz Perez et al., 2005; Wu, Hays, Kelly,
Malitz, & Bozzette, 1997).
HIV infection could compromise PLWH’s HRQoL in terms of multiple
dimensions. First, physical health is of critical importance for PLWH. If PLWH are
unable to achieve viral suppression, they are at risk for deadly opportunistic infections
and rapid disease progression—ultimately culminating in AIDS and death (Gesesew,
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Ward, Woldemichael, & Mwanri, 2018). Second, in the face of stressful events and
adversities, PLWH have high risks for mental health problems (e.g., depression and
perceived stress) and poor psychological well-being (Kidia, Ndhlovu, Jombo, Abas, &
Makadzange, 2015; Zeng et al., 2018). Third, being stigmatized and discriminated by
others may harm the social functioning of PLWH, including by causing challenges to
interpersonal relationships and limited opportunities to give and receive social support
from others (Earnshaw & Chaudoir, 2009; Turan et al., 2019; Turan et al., 2016). Finally,
given all these challenges, PLWH may have negative perceptions about their general
health.
Prior research identifies a number of psychosocial factors that may affect clinical
outcomes (i.e., CD4 count, viral load, HRQoL) among PLWH including but not limited
to stress stimuli or stressors (e.g., HIV-related stigma, daily stress) (Bhat et al., 2015;
Darlington & Hutson, 2017), psychological distress (e.g., depression, anxiety, perceived
stress) (Ajose, Mookerjee, Mills, Boulle, & Ford, 2012; Gore-Felton & Koopman, 2008;
Pence, 2009), coping strategies (e.g., avoid coping, denial coping) (Bhat et al., 2015), and
behavioral health problems (e.g., substance use, alcohol use) (Ajose et al., 2012; GoreFelton & Koopman, 2008; Pence, 2009; Sheehan et al., 2020). Among these factors,
HIV-related stigma, as a chronic stressor for PLWH, is a well-established factor
undermining clinical outcomes. Based on the Health Stigma Framework and empirical
evidences, HIV-related stigma included internalized, anticipated, and enacted stigma,
which may influence clinical outcomes through psycho-behavioral mechanisms
(Earnshaw & Chaudoir, 2009; Earnshaw, Smith, Chaudoir, Amico, & Copenhaver,
2013). The investigation on these potentially distinct mechanisms could inform tailored
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interventions on the mediators in the pathways and alleviate the negative impacts of HIVrelated stigma.
1.3 HIV-related stigma and its impacts on health outcomes
HIV-related stigma is one of the well-established barriers to good mental and
physical health of PLWH. Stigma can be defined as a “discrediting and tainting social
label”, and it has been found to inhibit health-seeking behaviors, timely diagnosis,
prevention efforts, and linkage to treatment and care (Alonzo & Reynolds, 1995;
Andersson et al., 2020; Goffman, 1963). According to the Health Stigma Framework
(Figure 1.1), being diagnosed with HIV, PLWH may experience internalized,
anticipated, and enacted stigma when they perceive prejudice, stereotypes, and
discrimination from others (Earnshaw & Chaudoir, 2009; Earnshaw et al., 2013).

Figure 1.1 Health stigma framework (Earnshaw et al., 2013)
The three types of HIV-related stigma reflect the cognitions, beliefs, and
experiences of discrimination against PLWH because of HIV (Earnshaw & Chaudoir,
2009; Earnshaw et al., 2013; Quinn & Earnshaw, 2011). Internalized stigma represents
the cognitions of being discriminated by others among PLWH because of their HIV
6

positive status. Indeed, it refers to the cognitive process of believing that the negative
attributes associated with HIV are true of the self (Earnshaw & Chaudoir, 2009;
Earnshaw et al., 2013). PLWH with high levels of internalized stigma would apply these
negative beliefs to themselves and believe that they are devalued or bad as compared to
others (Quinn & Earnshaw, 2011; Sayles, Wong, Kinsler, Martins, & Cunningham,
2009). Anticipated stigma is the perception of PLWH believing that they may experience
discrimination if others know their HIV status (Quinn & Earnshaw, 2011). It could
directly capture PLWH’s fears of being discriminated if they disclose their HIV status to
others. Enacted stigma is PLWH’s actual experience of being discriminated by others
(Quinn & Earnshaw, 2011). When HIV status is known either through voluntary
disclosure, unintended disclosure, or through information passed from one to others,
PLWH may be treated by others in stigmatizing ways.
Internalized, anticipated, and enacted stigma are closely associated with
psychological wellbeing among PLWH. Particularly, previous studies focused on the
close relationship between internalized stigma and psychological wellbeing, such as
depression (Chi, Li, Zhao, & Zhao, 2014; Zeng et al., 2018), stress (Guo et al., 2020; Zhu
et al., 2020), and self-efficacy (Zeng et al., 2020; Zhou, Li, Qiao, Shen, & Zhou, 2020).
Additionally, people (e.g., PLWH, sexual minorities) who anticipated greater stigma
and/or had experience of being stigmatized are more likely to experience greater
psychological distress (Quinn & Chaudoir, 2009), low self-esteem (Berger, Ferrans, &
Lashley, 2001), and other mental health problems.
In addition to psychological wellbeing, the three types of stigma have strong
associations with behavioral health, such as ART adherence (Sweeney & Vanable, 2016),
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healthcare utilization (Chesney & Smith, 1999), disclosure (Rongkavilit et al., 2010), and
risk behaviors (Elkington et al., 2010). Particularly, internalized, anticipated, and enacted
stigma are closely associated with ART adherence among PLWH (Camacho, Kalichman,
& Katner, 2020; Sweeney & Vanable, 2016; Zeng et al., 2020). PLWH with high levels
of internalized stigma may believe that they are devalued and not deserved to the
treatment (Quinn & Earnshaw, 2011). Additionally, they may have more negative
attitudes towards the treatment and lower recovery orientations (Ritsher, Otilingam, &
Grajales, 2003). Anticipated and enacted stigma may increase PLWH’s concerns in
healthcare settings, which in turn may impede them from utilizing healthcare resources
and adhering to medications (Peitzmeier, Grosso, Bowes, Ceesay, & Baral, 2015; Peltzer
& Ramlagan, 2011; Zeng et al., 2020).
Even though less studied than psychological wellbeing and behavioral health,
stigma has been found to directly and indirectly undermine the physical wellbeing among
people with stigmatized identities, such as PLWH, drug users, and sexual minorities. For
instance, internalized stigma among PLWH (Wolitski, Pals, Kidder, Courtenay-Quirk, &
Holtgrave, 2009) and enacted stigma in drug users (Ahern, Stuber, & Galea, 2007) are
associated with decreased overall physical health. An existing study also found that
anticipated and enacted stigma among HIV positive gay men could act as stressors and
accelerate their HIV progression, such as times to a critically low level of CD4 count
(15% of total peripheral blood lymphocytes), time to AIDS diagnosis, and time to HIVrelated mortality (Cole, Kemeny, & Taylor, 1997). Additionally, the three types of stigma
may influence physical wellbeing through the aforementioned psycho-behavioral
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mechanisms, such as self-efficacy (Zeng et al., 2020; Zhou et al., 2020), ART adherence
(Sweeney & Vanable, 2016), and healthcare utilization (Chesney & Smith, 1999).
1.4 Preview
This dissertation consists of six chapters and aims to investigate the impacts and
mechanisms of HIV-related stigma on clinical outcomes among PLWH in Guangxi,
China. Chapter 1 introduces the HIV epidemic around the world, clinical outcomes, and
HIV-related stigma. Chapter 2 presents a review of existing literature about clinical
outcomes and HIV-related stigma, literature gaps, research questions, conceptual
framework, research aims and hypotheses, and significance. Chapter 3 gives detailed
introduction to the methodology. Chapters 4 and 5 summarize the findings in the form of
two studies. Chapter 6 provides an overall discussion of the research findings, strengths
and limitations, implications, and future direction.
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CHAPTER 2
BACKGROUND AND SIGNIFICANCE
2.1 Introduction to clinical outcomes among PLWH in China
Viral load and CD4 count are critical clinical indicators for determining the
clinical stages of HIV infection, evaluating the efficacy of treatment, and changing
treatment regimens when necessary. With widespread application of ART in 1990s and
others efforts on promoting ART, although the ART coverage and viral suppression rates
have increased among PLWH in China, the overall progress still does not achieve the
“90-90-90” and “95-95-95” goals set by UNAIDS (Wu, 2019). By the end of 2015, only
67% of the diagnosed PLWH were receiving ART, and 65% of them were virally
suppressed (Ma et al., 2018; Wu, 2016). The ART coverage rate among PLWH increased
by 16%, and the viral suppression increased by 29% (Wu, 2019; Zhao et al., 2019) from
2015 to 2018. Spatial variation in viral suppression persists across different provinces of
China. For instance, in Guangdong province, a study found that the viral suppression rate
among PLWH was 93.3% after ART initiation (Huang et al., 2015). In Yunnan, a
southwestern province, Chen and colleagues (Chen et al., 2014) found that 81.3% of the
PLWH on ART reached viral suppression. In terms of CD4 count, an important indicator
of immunologic functioning, a nationwide retrospective cohort study found that nearly
80% of the PLWH who initiated ART had their CD4 counts between 200 ~ 349 cells/μl
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(Hu et al., 2017), which were still not within the typical range for a healthy immune
system (CD4 count ≥ 500 cells/μl).
HRQoL is a comprehensive construct of health and disease burden. Due to HIV,
PLWH may experience lower levels of HRQoL than the general population (Lan et al.,
2015). For example, Lan and colleagues (2015) found that using the 36-item Short Form
Health Survey health survey, the average score of HRQoL among PLWH was 64.7,
which was significantly lower than that of the general population (64.7 vs. 78.2, p <
0.001). Particularly, PLWH had much lower scores in their perception about general
health (48.3 vs. 66.0, p < 0.001) and social functioning (44.6 vs. 84.6, p < 0.001) than the
HIV-negative population (Lan et al., 2015). In terms of geographic disparities in HRQoL
among Chinese individuals, PLWH from urban areas (e.g., Beijing) have been found to
have higher levels of HRQoL than those in rural areas or resource-limited settings (e.g.,
Jiangxi) (Lan et al., 2016; Rao et al., 2012). Extant research has also documented age,
gender, and socioeconomic status (SES) disparities in HRQoL among PLWH (Lan et al.,
2015; Lan et al., 2016; Xiao, Lin, Li, & Ji, 2019). Indeed, male PLWH reported higher
levels of HRQoL than female (Xiao et al., 2019). Age is negatively associated with
HRQoL while SES has positive impact on HRQoL (Lan et al., 2015; Lan et al., 2016;
Xiao et al., 2019).
As one of the regions with high burden of HIV epidemic in China, Guangxi had
over 86,000 PLWH, ranking third in the terms of the number of HIV cases among the 31
provinces in China in 2018 (Guangxi Center for Disease Control and Prevention [CDC],
2018; Wu et al., 2019). With the scaling up of ART, there were increased trends of ART
coverage (from 72.1 to 91.2%) and CD4 count (from 318 to 357 cells/μl) among PLWH
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in Guangxi (Chen et al., 2019; Yang et al., 2019) from 2012 to 2017. However, rates of
viral suppression did not show a similar trend of improvement (Yang et al., 2019). The
challenges of viral suppression include but are not limited to low levels of ART
knowledge and treatment interruptions among PLWH in Guangxi. Besides, nearly half of
the PLWH in Guangxi had their CD4 count less than 350 cells/μl. Furthermore, although
the initiation of ART could significantly improve the overall HRQoL among PLWH in
Guangxi, China at the first 6-month, the effect size decreased after 12-month (Ming et al.,
2014). In sum, the suboptimal outcomes of viral suppression, CD4 count, and HRQoL
among PLWH on ART in Guangxi implies that more research is needed to investigate
their correlates and how various factors influence them.
2.2 HIV-related stigma in China
PLWH in China suffer from serious HIV-related stigma. The two key
characteristics, including collectivism and family responsibilities, of Chinese culture may
cultivate HIV-related stigma against PLWH in China (Liu et al., 2006). The collectivist
culture subordinates individual interests to those of the group and requires people in the
same group to maintain dignity, respect, and social status in the social structure (Hui &
Triandis, 1986; Kleinman et al., 1995; Murray-Johnson et al., 2001; Triandis, Bontempo,
& Villareal, 1988). People may be devalued or condemned if they do not comply with the
rules in collectivist culture. As HIV infection is closely related to stigmatizing behaviors,
such as commercial sex, casual sex, and injection drug use, PLWH may be devalued by
the collectivist society as the collective value is considered to be destroyed by these
individuals (Liu et al., 2006). What is more, the Chinese culture emphasizes family
responsibilities, such as maintaining and protecting family (males’ responsibilities) and
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taking care of the home, the children, and the rest of the family (females’
responsibilities). Because of HIV, PLWH who do not have access to ART may suffer
from serious health burden and may not fully take on family responsibilities. Particularly,
some PLWH who are sexual minorities may not have children to maintain the family
bloodline, which may put them at risk for stigma (Li, Holroyd, Lau, & Li, 2015).
PLWH in Guangxi are vulnerable to HIV-related stigma. Guangxi is one of the
resource-limited provinces and located in the southern China. Therefore, compared with
other developed provinces with relatively sufficient resources, Guangxi is more
conservative in regard to the Chinese culture. Additionally, the HIV epidemic in Guangxi
could be characterized as a rural phenomenon with many PLWH being rural residents,
from low socioeconomic status (SES), and being infected mostly through sexual contact
(Wang, 2013; Yang et al., 2019). Hence, due to the conservative culture, limited
knowledge of HIV infection, and local HIV epidemic, PLWH in Guangxi may experience
high levels of HIV-related stigma.
2.3 Impacts of HIV-related stigma on clinical outcomes
HIV-related stigma is one of the major barriers to viral suppression, immunologic
functioning, and HRQoL. Extant literature found that higher levels of HIV-related stigma
were associated with higher risks of detectable viral load (Berger et al., 2001; Kemp et
al., 2019; Lipira et al., 2019; Prati et al., 2015; Umar et al., 2019) and lower CD4 count
(Peltzer & Ramlagan, 2011; Walburn, Swindells, Fisher, High, & Islam, 2012). For
instance, Umar and colleagues (2019) found that among the 209 youths living with HIV
in Malawi, HIV-related stigma was positively related to detectable viral load after
adjusting for key sociodemographic characteristics. Using a qualitative research design,
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Walburn and colleagues (2012) found that HIV-related stigma negatively affected the
engagement in care and resulted in a drop in CD4 count.
HIV-related stigma could compromise PLWH’s HRQoL through its impacts on
the four dimensions (i.e., psychological health, physical health, social functioning,
perception about general health). First, HIV-related stigma, as a chronic stressor, puts
PLWH at risks of psychological distress (e.g., perceived stress, depression, anxiety) and
compromises their mental health (Abdul Bari, 2017; Alsayed, Sereika, Albrecht, Terry, &
Erlen, 2017; Song, Yan, Lin, Wang, & Wang, 2016). Second, PLWH with higher levels
of HIV-related stigma may be less likely to engage/retain in care and adhere to ART,
which in turn could impair their immunologic functioning, increase viral load, and
compromise their physical health (Abdul Bari, 2017; Alsayed et al., 2017). Third, due to
HIV-related stigma, PLWH may have fewer or poorer quality interpersonal relationships,
less social interaction, fewer and smaller social networks, less opportunity to give and
receive social support, and fewer resources to cope with their psychological distress and
to support them in their HIV care and ART adherence (Abdul Bari, 2017; Song et al.,
2016; Turan, Hatcher, et al., 2017). The negative influences of HIV-related stigma on
mental health, physical health, and social functioning may prevent PLWH from having
positive perceptions about their general health and thus result in low levels of HRQoL
(Abdul Bari, 2017).
For the relationships between different types of HIV-related stigma and clinical
outcomes, there were few research considering internalized, anticipated, and enacted
stigma at the same time and testing the separate impacts of them on the outcomes. In fact,
these impacts may be different by different types of HIV-related stigma (Kemp et al.,
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2019; Prati et al., 2015). The research findings were inconsistent. For instance, Prati and
colleagues (2015) found that viral suppression was significantly associated with
internalized stigma but not with enacted stigma while Kemp and colleagues (2019) found
the inverse. In regard to HRQoL, Fuster-Ruizdeapodaca and colleagues (2014)
investigated the impacts of enacted and internalized stigma and found that only enacted
stigma had direct effect on HRQoL among PLWH. However, an existing study among
men living with HIV in Tanzania found the inverse pattern (Parcesepe et al., 2020).
2.4 Mechanisms of HIV-related stigma and clinical outcomes
Researchers have conceptualized the mechanisms through which HIV-related
stigma may result in poor virologic and immunologic outcomes (Earnshaw & Chaudoir,
2009; Turan, Hatcher, et al., 2017). Particularly, the various types of HIV-related stigma
(i.e., internalized, anticipated, enacted stigma) may influence these outcomes through
four main pathways including interpersonal factors (e.g., social support, social isolation),
psychological distress (e.g., depression, anxiety, perceived stress), behavioral factors
(e.g., care engagement, ART adherence, disclosure), and resource access (e.g., treatmentrelated skills, knowledge, resources for coping with stressors) (Earnshaw & Chaudoir,
2009; Turan, Hatcher, et al., 2017). Psychological distress (i.e., depression) and
behavioral factors (i.e., ART adherence) are well-investigated mediators between HIVrelated stigma and virologic and immunologic outcomes although findings were
inconsistent (Katz et al., 2013; Lipira et al., 2019; Logie et al., 2019). For example,
depressive symptoms and ART adherence could mediate the relationship between overall
HIV-related stigma and CD4 count (Logie et al., 2019). However, such mediating effects
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were found between overall measures of HIV-related stigma and viral suppression (Lipira
et al., 2019).
Although prior research conceptualized and investigated the underlying
mechanisms of HIV-related stigma on HRQoL, most studies focused on the mediating
effects of psychological distress (e.g., depression) (Alsayed et al., 2017; Li et al., 2015;
Relf et al., 2019; Shrestha et al., 2017) and social functioning (e.g., social support)
(Logie, Ahmed, Tharao, & Loutfy, 2017; Logie et al., 2018; Rao et al., 2012). Research
exploring how HIV-related stigma influences HRQoL through its negative impacts on the
mediators relevant to physical health is needed. For instance, Zhou and colleagues (2020)
found that HIV symptom management self-efficacy mediated the relationship between
internalized stigma and HRQoL among PLWH in Guangxi, China. The possible reason
might be that HIV symptom management self-efficacy is closely related to the symptom
management behaviors (e.g., keeping symptoms from interfering with social functions,
adhering to medical appointment, controlling medication-induced side effects) which
may influence the physical health of PLWH.
In regard to the mechanisms through which different types of HIV-related stigma
may impact clinical outcomes, empirical evidence is still limited. Even though Earnshaw
and colleagues (2013) tested the separate effects of internalized, anticipated, and enacted
stigma on CD4 count based on Health Stigma Framework, they did not elaborate on the
mechanisms underlying them. Additionally, there is a dearth of research examining the
potentially distinct mechanisms of internalized, anticipated, and enacted stigma on
HRQoL among PLWH, which could inform targeted interventions to mitigate the
negative impacts of different types of HIV-related stigma on overall health quality.
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In sum, the well-investigated mechanisms of HIV-related stigma on clinical
outcomes were psycho-behavioral mediators, especially psychological distress. However,
these studies ignored the importance of psychological resources, such as treatmentrelated self-efficacy (Turan, Hatcher, et al., 2017). Psychological resources refer to the
tools, skills, confidences, and motivations that PLWH use to cope with stressful events,
keep daily routine, and maintain their health, and they are important mechanisms
underlying HIV-related stigma and clinical outcomes (Turan, Hatcher, et al., 2017). HIVrelated stigma may cause PLWH to believe that they are less capable and confident in
dealing with treatment-related issues (i.e., medical visits, adherence behaviors), which
may result in low self-efficacy related to ART adherence and suboptimal clinical
outcomes (Seghatol-Eslami et al., 2017). For instance, using cross-sectional data, Zeng
and colleagues found a significant indirect effect from anticipated stigma to ART
adherence through ART self-efficacy (Zeng et al., 2020). However, limited studies
investigated the mechanisms of HIV-related stigma on clinical outcomes through
psychological resources from a longitudinal perspective. Research exploring the
mediating roles of psychological resources in the pathways from HIV-related stigma to
clinical outcomes could inform future interventions to buffer stigma’s negative impacts,
promote treatment-related behaviors, and improve clinical outcomes.
2.5 Literature gaps
Based on the literature review, some research gaps need to be acknowledged.
First, most existing studies examined the bivariate relationships between HIV-related
stigma and clinical outcomes, and few studies elucidated the pathways between them
(Alsayed et al., 2017; Kemp et al., 2019; Rangarajan et al., 2016; Sumari-de Boer,
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Sprangers, Prins, & Nieuwkerk, 2012). Second, among the studies investigating how
stigma influenced clinical outcomes, many of them focused on the mediating effect of
psychological distress but ignored the importance of psychological resources, especially
the treatment-related self-efficacy (Lipira et al., 2019; Logie et al., 2019; Turan et al.,
2019). The most well-investigated mediator pertinent to treatment was adherence
behaviors (Lipira et al., 2019; Logie et al., 2019), and studies exploring other treatmentrelated pathways are needed among PLWH. Third, most studies investigating the
mechanism of HIV-related stigma on clinical outcomes used cross-sectional design
(Turan et al., 2019). Therefore, they did not have sufficient ability to confirm the
causality. Fourth, although there were some studies exploring the mechanisms underlying
stigma and health outcomes, most of them employed traditional path analysis and
examined the associations among variables of interest (Turan et al., 2019). The traditional
path analysis did not test the associations among the changes of key variables and thus
could not confirm whether the change of independent variable leads to the change of
outcome (Cheong, Mackinnon, & Khoo, 2003). Fifth, previous studies predominantly
focused on the overall measure of HIV-related stigma or one or more types (i.e.,
internalized, anticipated, enacted stigma) without considering all three types of stigma
simultaneously and examining their separate impacts or mechanisms on clinical outcomes
(Fuster-Ruizdeapodaca, Molero, Holgado, & Mayordomo, 2014; Logie et al., 2019;
Parcesepe et al., 2020). Finally, current research regarding the relationships between
HIV-related stigma and clinical outcomes concentrated in Africa (e.g., Malawi and
Tanzania) (Parcesepe et al., 2020; Umar et al., 2019), United States (Kemp et al., 2019),
or European (Prati et al., 2015). However, limited studies have been conducted in other
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resource-limited settings with conservative culture, a large HIV population, and high
levels of HIV-related stigma against PLWH, such as Guangxi, China.
2.6 Conceptual framework
To address these knowledge gaps, this dissertation developed a conceptual
framework (Figure 2.1) based on the Health Stigma Framework and extant research. In
this conceptual framework, clinical outcomes including CD4 count, viral suppression,
and HRQoL were the primary outcomes. This dissertation tested the ART specific
psycho-behavioral pathways between three types of HIV-related stigma and each clinical
outcome. ART adherence was the behavioral mediator examined in this dissertation, as
currently it is the most well-investigated mechanism of HIV-related stigma on clinical
outcomes (Lipira et al., 2019; Logie et al., 2019; Sweeney & Vanable, 2016). However,
most of the previous studies used cross-sectional design, and their findings were
inconsistent. Self-efficacy, a key psychological resource for behavioral change, may
influence clinical outcomes through improving PLWH’s confidence on adherence
behaviors (Zeng et al., 2020) and HIV symptom management (e.g., keeping symptoms
from interfering with social functions, adhering to medical appointment, controlling
medication-induced side effects) (Zhou et al., 2020). Thus, ART self-efficacy and HIV
symptom management self-efficacy were two main psychological mechanisms examined
in this dissertation.
Internalized, anticipated, and enacted stigma may influence clinical outcomes
through psycho-behavioral mechanisms (Earnshaw & Chaudoir, 2009; Earnshaw et al.,
2013; Turan, Hatcher, et al., 2017). Extant research found that the high levels of HIVrelated stigma reduced self-efficacy (Zeng et al., 2020; Zhou et al., 2020), the motivation

19

and confidence for behavioral change. The low motivation and confidence in behavioral
change resulted in the suboptimal adherence behaviors (Zeng et al., 2020) and symptom
management (Zhou et al., 2020), which in turn impaired the clinical outcomes among
PLWH on ART. Therefore, the three types of HIV-related stigma were the barriers of
optimal clinical outcomes through reducing self-efficacy for ART and symptom
management and ART adherence. Finally, based on extant findings, all three types of
HIV-related stigma were assumed to have direct impacts on the clinical outcomes.

Figure 2.1 Conceptual framework
2.7 Research aims
This dissertation addressed the knowledge gaps based on two specific aims and in
a form of two studies. The specific aims were carried out using data derived from a
prospective cohort study among PLWH in Guangxi, China. Chapter 3 gives detailed
description on the design of cohort study and data analysis. The specific aims in this
dissertation are:
Aim 1. To examine the longitudinal impacts of internalized, anticipated, and enacted
stigma on clinical outcomes among PLWH. Aim 1 examined the separate relationships
between three types of HIV-related stigma on each clinical outcome (i.e., CD4 count,
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viral suppression, HRQoL) after adjusting for psycho-behavioral factors and
sociodemographic characteristics.
According to the Health Stigma Framework (Figure 1.1), empirical evidences,
and conceptual framework of this dissertation (Figure 2.1), the hypotheses for aim 1 were
Hypothesis 1a: The three types of HIV-related stigma could explain additional variances
in clinical outcomes after controlling for psycho-behavioral factors and other covariates.
Hypothesis 1b: Internalized, anticipated, and enacted stigma would have significant and
negative impacts on the three clinical outcomes. High levels in these three types of HIVrelated stigma would result in suboptimal clinical outcomes.
Aim 2. To elucidate the longitudinal mechanisms of internalized, anticipated, and
enacted stigma on clinical outcomes through psycho-behavioral pathways. In aim 2,
this dissertation incorporated the three types of HIV-related stigma into the same model
and examined the pathways from them to each clinical outcome via psycho-behavioral
mediators.
Based on the Health Stigma Framework (Figure 1.1), empirical evidences, and
conceptual framework of this dissertation (Figure 2.1), the hypotheses for aim 2 were:
Hypothesis 2a: The direct impacts of internalized, anticipated, and enacted stigma on the
three clinical outcomes were significant and negative.
Hypothesis 2b: All three types of HIV-related stigma could influence each clinical
outcome through the mediating effects of psycho-behavioral factors. Particularly, the
serial mediating effect from HIV-related stigma, treatment-related self-efficacy, ART
adherence, and clinical outcome would be significant.
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2.8 Significances
2.8a Importance of clinical outcomes
CD4 count, viral load, and HRQoL are critical indicators for evaluating the
effectiveness of ART regimens and making further clinical decisions among PLWH
under HIV treatment and care. CD4 count reflects the immunologic functioning, and viral
suppression is the primary measure of treatment-efficacy (Limmade et al., 2019). PLWH
with ample CD4 count and undetectable viral load have good immunologic functioning,
slow their disease progression, and have their life expectancy improved (Fogarty et al.,
2002; Nieuwkerk & Oort, 2005; Press et al., 2002). Additionally, undetectable viral load
in PLWH eliminates the risk of HIV transmission and is thus a key component of efforts
to end the HIV epidemic. Compared with CD4 count and viral load, HRQoL
encompasses four main dimensions (i.e., psychological health, physical health, social
functioning, perception about general health) and gives a comprehensive assessment of
health among PLWH (Lazarus et al., 2016; Webster, 2019). Therefore, HRQoL is a goal
beyond immunologic recovery and viral suppression among PLWH on ART, and it has
been considered as a “fourth 90” goal for ending HIV epidemic (Lazarus et al., 2016).
Higher levels of HRQoL could ensure PLWH to have better physical and psychological
wellbeing, lower risk of developing comorbidities and positive perception about their
general health.
2.8b Impacts and mechanisms of HIV-related stigma on clinical outcomes
Given a large number of extant research that has only investigated the impacts
and mechanisms of overall HIV-related stigma on health outcomes, this dissertation is of
public health significance by distinguishing the separate impacts and mechanisms of
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internalized, anticipated, and enacted stigma. First, based on the Health Stigma
Framework (Earnshaw & Chaudoir, 2009; Earnshaw et al., 2013) and empirical evidence,
internalized, anticipated, and enacted stigma may have differential impacts on
psychological, behavioral, and physical wellbeing. However, limited studies conducted
these investigation. The investigation on these potentially distinct associations could
inform targeting specific type of HIV-related stigma and improving specific health
outcomes. For example, Guo and colleagues (2020) found that interventions targeting
internalized stigma could significantly reduce the depressive symptoms among PLWH in
Guangzhou, China. Second, uncovering the mechanisms of internalized, anticipated, and
enacted stigma on health outcomes through psycho-behavioral pathways could inform
future stigma reduction interventions to target specific mediator in order to alleviate the
negative impact of stigma. For instance, as depression could mediate the relationship
between internalized stigma and suicidal behaviors (Zeng et al., 2018), interventions
targeting both internalized stigma and depression may reduce the risk of suicide among
PLWH effectively. Finally, although the bivariate association between overall measure of
stigma and viral load had been verified in previous studies (Kemp et al., 2019; Lipira et
al., 2019), the underlying mechanisms between them are still unclear. This dissertation
could help to disentangle various types of stigma in order to uncover these mechanisms,
which could inform future efforts that improve clinical outcomes and the physical health
and mental health of PLWH.
2.8c Vulnerability of PLWH in Guangxi, China
The traditional sociocultural context of China and resource-limited setting in
Guangxi make PLWH vulnerable to HIV-related stigma and suboptimal clinical
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outcomes. Most of HIV cases in Guangxi are attributable to HIV-related risk behaviors
(e.g., unprotected sexual behaviors with multiple or same-sex partners, injection drug
use) that are traditionally not socially accepted in Chinese culture (Herek, 2016; Liu et
al., 2006), especially the conservative Chinese culture in Guangxi. Additionally, some
HIV-related risk behaviors (e.g., sex work, injection drug use) are illegal in China, and
PLWH with history of these risk behaviors would be punished and socially disapproved
of, which may further exacerbate their HIV-related stigma (Liu et al., 2006). Guangxi, a
rural province in southwestern China, has a large rural population. The HIV epidemic in
Guangxi could be characterized as a rural phenomenon as many PLWH are rural
residents, from low SES, and acquire HIV primarily through sexual activity (Wang,
2013). Hence, in addition to HIV-related stigma, the resource-poor setting, low SES, and
limited knowledge of HIV infection set barriers between PLWH in Guangxi and
healthcare resources and HIV treatment.
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CHAPTER 3
METHODOLOGY
3.1 Overview of cohort study
Data used in this dissertation were derived from a prospective cohort study
among 1,198 PLWH in Guangxi, China, which was funded by the National Institute of
Health/National Institute of Mental Health (Grant No. RO1MH0112376). This cohort
study aims to investigate the mechanisms underlying HIV-related stigma and clinical
outcomes among PLWH. With the assistance and collaboration of Guangxi Center for
Disease Control and Prevention (Guangxi CDC), six major public hospitals/clinics in five
cities with the largest number of HIV patients under care were selected as the study sites.
The volume of HIV patients at each study site ranged from 1,386 to 7,389 at the time of
baseline survey. A systematic sampling approach was employed to randomly select the
participants from all eligible PLWH. Specifically, the medical staff or case managers in
each site used an arbitrary number (e.g., the date of the month) to identify the first case to
be sampled from the eligible patient pool, and then every nth case was selected where n is
a pre-calculated interval for each sampling iteration (e.g., ratio of target sample size to
the total numbers of patients in the pool). The process was repeated until the target
sample size was achieved at each clinic.
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3.2 Participants
PLWH who fulfilled the eligibility were invited to participate in the cohort study.
The inclusion criteria of PLWH were PLWH who: (1) were aged between 18 and 60
years old, (2) had a confirmed diagnosis of HIV, and (3) had no plan to permanently
relocate outside of the Guangxi province in the next 12 months. The exclusion criteria
were: (1) mental and physical inability to respond to assessment questions, and (2)
currently incarcerated or institutionalized for drug use or commercial sex. PLWH who
were older than 60 years were excluded from the cohort study as they might have agingrelated health issues (e.g., multiple chronic diseases and treatments, changes in physical
and cognitive abilities, increased vulnerability to stressors) which could confound the
outcome measures (High et al., 2012).
3.3 Recruitment and data collection
Before the field data collection, all research associates from the local CDC and
hospitals/clinics received a three-day training course which covered topics on research
ethics, assessment methodology and survey skills, including how to minimize the social
desirability bias. A one-day booster training session was also conducted prior to each of
the follow-up assessments. The booster session briefly rehearsed the survey skills and
reviews research ethics. Based on the systematic sampling, once an eligible PLWH was
randomly selected, the local team members contacted patients to confirm eligibility,
discussed about the benefits and risks of the study, and invited them to participate. After
obtaining their written informed content, the face-to-face interviews were conducted in
private rooms of the clinics. An interviewer-administered questionnaire was used for data
collection. Baseline assessment was conduct from November 2017 to February 2018. The
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recruited participants would be followed up at 6-, 12-, 18-, 24-, 30-, and 36- months.
Currently, the 30- month follow-up had been finished. The attrition rate was less than 5%
of the participants for each follow-up. Longitudinal data at baseline, 6-, 12-, and 18month follow-ups were used in the dissertation. Each participant received a gift (e.g.,
household items) equivalent to US$5.00 (1 USD ≈ 6.5 Chinese Yuan at the time of the
survey) at the completion of each assessment. The study protocol was approved by the
Institutional Review Boards at both University of South Carolina in the United States and
Guangxi CDC in China.
3.4 Key measures
Key measures in this dissertation included CD4 count, viral suppression, HRQoL,
HIV-related stigma (i.e., internalized, anticipated, enacted stigma), ART self-efficacy,
HIV symptom management self-efficacy, ART adherence, sociodemographic
characteristics, depression, and anxiety.
Primary outcomes
CD4 count
CD4 count of each participant at baseline, 6-, 12-, and 18- month follow-ups were
retrieved from the electronic health records. According to the guidelines for ART in
adults and adolescents with HIV (U.S. Department of Health and Human Services &
Panel on Antiretroviral Guidelines for Adults and Adolescents, 2017), the cut-off of 500
cells/µl has clinical implication in evaluating the normal immunologic functioning.
Therefore, instead of using the original continuous measure of CD4 count, CD4 count
was categorized as a binary variable (< 500 and ≥ 500 cells/µl).
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Viral suppression
Plasma viral load of each participant was collected from the electronic health
records at each timeframe and used to define viral suppression. As viral suppression
could indicate the treatment efficacy, it was used as one of the primary outcomes rather
than the original continuous value of viral load. Viral suppression was defined as HIV
RNA less than or equal to 50 copies/ml in PLWH’s plasma (CDC & National Center for
HIV/AIDS, Viral Hepatitis, and TB Prevention, 2018).
Health-related quality of life (HRQoL)
Participants’ HRQoL were assessed using the 35- item Medical Outcomes Study
HIV Health Survey (MOS-HIV) (Wu et al., 1997). This scale measured 11 dimensions of
health including general health perception (5 items), physical functioning (6 items), role
functioning (2 items), social functioning (1 item), cognitive functioning (4 items), pain (2
items), mental health (5 items), energy/fatigue (4 items), health distress (4 items), quality
of life (1 item), and health transition (1 item). The sum score of each dimension was
calculated and transformed to the final score ranging from 0 to 100 according to formula
1 (Delate & Coons, 2001; Hays & Shapiro, 1992; Ware & Sherbourne, 1992; Wu et al.,
1997). The total score of HRQoL was calculated using the sum scores from 11
dimensions and transformed to the score ranging from 0 to 100 based on the same
formula. The Cronbach’s alpha of MOS-HIV scale was 0.93 at baseline.
Observed score-possible minimum

Final score = Possible maximum-possible minimum *100
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Formula (1)

Independent variables
Sociodemographic characteristics
In this dissertation, sociodemographic characteristics included age (year), time
since HIV diagnosis (year), duration of ART (year), gender (0 = female, 1 = male),
marital status (1 = single/separated, 2 = married/cohabitated, 3 = divorced/widowed),
ethnicity (0 = Non-Han, 1 = Han), types of residence (1 = city, 2 = county, 3 = rural),
education attainment (0 = less than or equal to middle school, 1 = high school or above),
employment (1 = unemployed, 2 = part time, 3 = full time), levels of monthly income (1
= no more than 1,999 Yuan, 2 = 2,000~3,999 Yuan, 3 = at least 4,000 Yuan),
transmission modes (0 = others [transfusion/injection drug use/unknown/others], 1 =
sexual activity), weight, and height. Body mass index (BMI) was calculated using weight
and height and categorized as underweight (less than 18.5), normal/healthy weight (18.5
~ 24.9), and overweight/obese (more than 24.9).
Internalized stigma
Internalized stigma was measured using an 8-item scale derived from the Berger
HIV Stigma Scale (Berger et al., 2001). These eight items were used to assess the
“negative self-image” among PLWH in the original scale. Participants were asked to rate
their agreement to the statement, including “I feel I’m not as good as others because I
have HIV”, “I feel guilty because I have HIV”, and “Having HIV makes me feel
unclean”. The response options were rated from “strongly disagree (1)” to “strongly
agree (4)”. The response options were rated from “strongly disagree (1)” to “strongly
agree (4)”. The total score of these eight items was used as the indicator of internalized
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stigma, with a higher score indicating a higher level of internalized stigma. This scale had
good reliability at baseline (Cronbach’s alpha = 0.94).
Anticipated stigma
Anticipated stigma was assessed using a 9-item scale derived from the Health
Stigma Framework (Earnshaw et al., 2013). This scale assessed the expectation of HIVrelated stigma from family members, community, and healthcare providers. The item
samples were “Family members will avoid touching me”, “Community managers will
refuse to provide me with social services”, and “Healthcare providers will treat me with
less respect”. The response options were “definitely not (1)”, “probably not (2)”, “not
sure (3)”, “probably (4)”, and “definitely (5)”. The sum score was used as a composite
score ranging from 9 to 45, with higher score indicating higher levels of anticipated
stigma. The Cronbach’s alpha of this scale at baseline assessment was 0.92.
Enacted stigma
Enacted stigma was evaluated using the 16-item checklist adapted from a
previous study (Yi et al., 2015). PLWH were asked whether they had some actual
experiences of being stigmatized due to HIV in the past six months, including “Being
excluded from social gathering or activities”, “Being excluded from family activities”,
and “Being physically assaulted”. Participants who answered “yes (1)” were considered
to have the experience of being stigmatized while those who answered “no (0)” were
considered to have no such experience. The total score of the 16 items was used as a
composite score, with a higher score indicating more experiences of being stigmatized in
the last six months. The enacted stigma scale also showed good reliability at baseline
(Cronbach’s alpha=0.89). In Study 1, enacted stigma was used as a continuous variable.
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It was categorized as a binary variable using zero as a cutoff and to define stigmatized
experiences (0 = No, 1 = Yes) in Study 2.
ART self-efficacy
ART self-efficacy was assessed using a 10-item scale adapted from the Selfefficacy for Appropriate Medication Use Scale (SEAMS) (Risser, Jacobson, & Kripalani,
2007; Zhang et al., 2016). PLWH were asked “How confident are you that you can take
your medicines correctly under the following scenarios”? Sample items were “When you
take several different medicines each day” and “When you are away from home”. Item
response options were ranging from “not confident (1)” to “confident (3)”. The sum score
of these ten items was used as a composite score ranging from 10 to 30, with a higher
score indicating a higher level of ART self-efficacy. The Cronbach’s alpha of this scale at
baseline assessment was 0.95.
HIV symptom management self-efficacy
HIV symptom management self-efficacy was constructed by six items from the
Self-efficacy for Managing Chronic Disease Scale (Eller et al., 2014) and four items
about participants’ confidence in symptom management (Lorig, Sobel, Ritter, Laurent, &
Hobbs, 2001). The four items evaluate participants’ confidence in keeping symptoms
from interfering with social functions, deciding when to see a doctor, forming a plan for
symptom management, and controlling medication-induced side effects (Lorig et al.,
2001). The overall scale evaluated PLWH’s efficacy in controlling HIV-related
symptoms. One sample item was “I am confident that I can manage HIV medication side
effects.” Item options ranged from “totally disagree (1)” to “totally agree (5)”. A
composited score of HIV symptom management self-efficacy was calculated by summing
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these 10 items, with higher score indicating more confidence in HIV symptom
management. The HIV symptom management self-efficacy scale had good reliability at
baseline (Cronbach’s alpha = 0.96).
ART adherence
To minimize the self-report bias related to self-report measures of ART
adherence, a multiple-item approach was employed to assess adherence to ART in
original cohort study (Chesney et al., 2000; Da, Li, Qiao, Zhou, & Shen, 2018; Simoni et
al., 2006). Five measures derived from the Adult AIDS Clinical Trials Group (AACTG)
adherence instrument and adapted to the cohort study were used to inquiry participants
about their levels of ART adherence (Chesney et al., 2000). The measure of ART
adherence had been validated in different countries and culture contexts (Chesney et al.,
2000; Da et al., 2018; Reynolds et al., 2007) and could be used as a robust instrument for
evaluating adherence behaviors among HIV population.
An overall score was calculated according to the following procedure (Da et al.,
2018) (Table 3.1). First, participants reported the days of completing their prescribed
ART doses within four specified timeframes (last three days, last weekend, last two
weeks, last month [30 days]). For the last three-day and weekend adherence measures,
participants were asked to report the number of doses taken and the number of expected
doses during these two timeframes. Percentage adherence was calculated dividing doses
taken by doses expected. For the one-month and two-week days taken measures,
participants were asked to report the number of days they took all doses of their HIV
medication as prescribed. Percentage adherence was calculated by dividing the reported
number of days by 30 days (or 14 days). These responses were then converted into a
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percentage of prescribed doses and recoded into 0 (< 90%) or 1 (≥ 90% of prescribed
doses) according to the Chinese guideline for ART treatment. Second, whether
participants adhere to their prescribed doses (1 = always, 2 = very often, 3 = sometimes, 4
= rarely, 5 = never) was used as the fifth adherence measure. Participants who always
adhered to their prescription were coded as “Yes (1)” while others were coded as “No
(0)”. Finally, by summing scores of the above five measures, a composite score was
calculated. The sum score ranges from 0 to 5. PLWH who scored 5 were considered as
optimal adherence to ART while those who scored less than 5 were considered as
suboptimal adherence to ART. The Cronbach’s alpha of this measure at baseline
assessment was 0.72. In both Studies 1 and 2, the binary measure of ART adherence was
used for the longitudinal data analysis.
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Table 3.1 Items and calculation of ART adherence
Items
1
2

3
4
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5
Sum
score

Questions
Please report the number of doses taken and the number of
expected doses in your prescribed ART during the last three days.
Please report the number of doses taken and the number of
expected doses in your prescribed ART during the last weekend.
Please report the number of days you took all doses of your
prescribed HIV medication during the last two weeks.
Please report the number of days you took all doses of your
prescribed HIV medication during the last month.
Did you always adhere to your prescription?
1. Always; 2. Very often; 3. Sometimes; 4. Rarely; 5. Never.
Sum sore = Item 1 + Item 2 + Item 3 + Item 4+ Item 5

Scoring
Number of doses taken
% = Number of expected doses*100%
If percentage adherence (%) is equal to or larger than
90%, items 1 or 2 will be coded as 1. Otherwise, these
two items will be coded as 0.
Number of days with all dose
%=
*100%
30 days or 14 days
If percentage adherence (%) is equal to or larger than
90%, items 3 or 4 will be coded as 1. Otherwise, these
two items will be coded as 0.
If the response to this item is “Always”, item 5 will be
coded as 1. Otherwise, this item will be coded as 0.

The sum sore is ranging from 0 to 5. PLWH who score 5 will be considered as having optimal adherence to ART while
those who score less than 5 will be considered as having suboptimal adherence to ART.

Depression
PLWH were assessed their levels of depression using the 10-item Center for
Epidemiologic Studies Depression (CES-D) Scale. The CES-D scale had been widely
used, and its validity and reliability had been established in Chinese population (Yu, Lin,
& Hsu, 2013). It captured depressed affect (3 items), somatic symptoms (5 items), and
positive affect (2 items). The response options ranged from “rarely or none of the time
(0)” to “all of the time (3)”. The summed score ranging from 0 to 30 was used to reflect
the levels of depression, with a higher score indicating a higher level of depression. The
CES-D scale had good reliability at baseline assessment (Cronbach’s alpha= 0.85).
Anxiety
Anxiety was measured using the Brief Anxiety Scale (Zung, 1971), which had
been validated in Chinese population (Zhang, Liu, Li, Mao, & Yuan, 2015). PLWH were
asked their feelings (e.g., “I feel easily upset or panicked”, “I experience headache and a
sore neck”) about anxiety disorders in the past week. The original scale included 20 items
which were scored from “never or seldom (1)” to “often (4)”. The total score ranged from
20 to 80. However, due to issue of translation, two items (“My hands are usually dry and
warm”, “I fall asleep easily and get a good night’s rest”) could not capture their original
meanings, which resulted in the Cronbach’s alpha of original scale equal to 0.80. After
deleting these two items, the Cronbach’s alpha was significantly improved to 0.88.
Hence, the rest of the items were used to calculate the final anxiety score ranging from 18
to 72, with a higher score indicating a higher level of anxiety.
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3.5 Data analysis
3.5a Data analysis in Study 1
First, descriptive statistics were reported on all the variables used in the
dissertation. Mean and standard deviation (SD) were used to describe the continuous
variables while frequencies and percentages were used for categorical variables. Second,
changes of clinical outcomes and independent variables across the time were tested.
Analysis of variance (ANOVA) was used to test the changes of continuous variables
while Chi-square test was used for categorical variables.
Third, hierarchical longitudinal analysis was conducted to carry out aim 1.
Hierarchical regression is a way to show if variables of interest could explain a
statistically significant amount of variance in outcome after accounting for all other
variables (Kim, 2016). During the hierarchical longitudinal analysis, the first model
included sociodemographic characteristics and other confounders. In the next step (model
2), important variables were added to model 1.
Before the multivariable analysis, bivariate analysis was conducted to examine
the relationship between each clinical outcome and independent variable using
generalized linear mixed model. Crude odds ratio (OR) or regression coefficient and the
95% confidence interval (CI) were reported in bivariate analysis for each clinical
outcome. Variables with p-values less than 0.10 were controlled as covariates in
multivariable analysis. In hierarchical longitudinal analysis, for CD4 count and viral
suppression, generalized linear mixed model with categorical outcome was employed to
examine the hypotheses. First of all, covariates and duration of ART was controlled as
confounders in model 1 after adjusting for the repeated measurements. Then, psycho-
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behavioral factors, such as ART self-efficacy, HIV symptom management self-efficacy,
depression, anxiety, and ART adherence, were added to model 1 and examined their
impacts on the outcomes (model 2). Finally, to examine the impacts of internalized,
anticipated, and enacted stigma on outcomes, these three types of stigma were added to
model 2 and tested in model 3 simultaneously. As CD4 count and viral suppression were
binary outcomes, the distribution was specified as “binomial distribution”, and link
function was defined as “logit link function”. To model the correlations of CD4 count
and viral suppression at baseline, 6-, 12-, and 18-month follow-ups, correlation structures
(e.g., unstructured covariance, autoregressive covariance, exchangeable covariance, and
independent covariance) were examined, and multiple indices (i.e., Queensland
Investment Corporation [QIC] and QICu) were used for evaluating the goodness of fit
(Cui & Qian, 2007). Model with the smallest values of the QIC and QICu were
considered as having the best model fit (Cui & Qian, 2007). If the best models selected
by QIC and QICu were inconsistent, QIC was used as the final criteria for model
selection (Cui & Qian, 2007). Adjusted OR (AOR) and its 95% CI were reported.
In terms of HRQoL, hierarchical generalized linear mixed model with continuous
outcome was used to carry out aim 1. A similar modelling procedure was conducted to
examine the impacts of sociodemographic characteristics, psycho-behavioral factors, and
HIV-related stigma on HRQoL after adjusting for the repeated measures. Besides the
covariates and potential confounders, CD4 count was adjusted during the analysis.
Correlation structures (e.g., unstructured covariance, autoregressive covariance, and
heterogeneous autoregressive covariance) were examined, and Log likelihood value,
Akaike Information Criterion [AIC], Corrected AIC [AICC], and Bayes Information
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Criterion [BIC] were used as the indicators for model selection (Fitzmaurice, Laird, &
Ware, 2011). Model with smaller AIC, AICC, BIC had better model fit (Fitzmaurice et al.,
2011). Regression coefficient (β) and its 95% CI were reported in this dissertation.
Pseudo R square (R2) was reported to evaluate percentage of variance being accounted
for in each model (Edwards, Muller, Wolfinger, Qaqish, & Schabenberger, 2008) during
the process of hierarchical longitudinal analysis. All the analyses were performed using
SAS software version 9.4 (SAS Institute, Inc., Cary, NC).
3.5b Data analysis in Study 2
Latent growth curve model (LGCM) was the major model used in Study 2. It
allows for the estimation of inter-individual variability in intra-individual change patterns
through two latent factors—the intercept (the initial value of variable of interest) and
slope (the change rate of variable of interest) (Curran, Obeidat, & Losardo, 2010; Duncan
& Duncan, 2004). It could be applied to investigate the trajectories for both continuous
and categorical variables (Wang & Wang, 2019). The change patterns (i.e., linear,
quadratic, and cubic changes) of variables of interest could be defined by designing their
time scores (Wang & Wang, 2019). Using LGCM to perform mediation analysis among
the slopes (change) of key variables has strong ability for causal inference (Cheong et al.,
2003).
First, measurement models of all key variables in conceptual model were
constructed using their original values and unconditional LGCM (Wang & Wang, 2019).
As Study 2 focused on examining the longitudinal mediating effects of psycho-behavioral
mediators, the changes of all variables of interest were defined as linear trend (time
scores: 0, 1, 2, 3). In this process, LGCM with continuous outcomes were used for
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internalized stigma, anticipated stigma, ART self-efficacy, HIV symptom management
self-efficacy, and HRQoL while LGCM with binary outcomes were used for enacted
stigma, ART adherence, CD4 count, and viral suppression. In the process of LGCM with
binary outcomes, logit link function was specified. Multiple indices, such as χ2, χ2/degree
of freedom (df), p-value, Comparative Fit Index (CFI), Root Mean Square Error of
Approximation (RMSEA), and Standardized Root Mean Residual (SRMR), were used to
evaluate the model fit of each measurement model. For continuous variables, smaller χ2
value, χ2/df ≤ 3.00, p > 0.05, CFI > 0.95, RMSEA ≤ 0.06, and SRMR ≤ 0.08 indicated
better model fit (Muthen & Muthen, 2018). In terms of binary variables, smaller χ2 value,
χ2/df ≤ 3.00, and p > 0.05 indicated better model fit (Muthen & Muthen, 2018;
Schermelleh-Engel, Moosbrugger, & Müller, 2003). Mean and standard error (SE) were
used to describe intercept and slope while r was used to describe the correlation between
them. Since all continuous variables were not in normal distribution, using their original
values to construct measurement models could not obtain good model fits and capture the
information of all participants sufficiently. Therefore, standardized transformation was
employed to re-estimate the intercepts and slopes of all continuous variables before
mediation analysis.
Second, the estimated intercepts and slopes of all key variables in conceptual
model were outputted for bivariate analysis and longitudinal mediation analysis.
Spearman correlation analysis was used to examine the correlations among intercepts or
slopes of all key variables in conceptual model. Bivariate analysis of the slopes of clinical
outcomes (i.e., CD4 count, viral suppression, and HRQoL) and sociodemographic
characteristics, depression, and anxiety were conducted. Spearman correlation analysis
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was used for examining the correlations between continuous variables while Wilcoxon
two-sample test or Kruskal-Wallis test were used for the relationships between slopes and
categorical variables.
Third, intercepts and slopes of all key variables were used for mediation analysis
after adjusting for covariates with p-values less than 0.05 in bivariate analyses. First of
all, intercept and slope were specified as correlating with each other for each key
variable, and path model was constructed based on the conceptual framework. Then,
based on the model trimming strategies (Ullman, 2001), paths with p-values larger than
0.05 were deleted. Furthermore, path model was modified to improve its model fit based
on the modification indices and theoretical knowledge (Ullman, 2001; Wang & Wang,
2019). Path coefficient and its 95%CI, standardized coefficient, and p-value were
reported. Finally, longitudinal mediating effects from the slopes of HIV-related stigma to
those of clinical outcomes through the slopes of psycho-behavioral mediators were tested
using bias-corrected bootstrap procedure based 1,000 bootstrap samples (Wang & Wang,
2019). Bias-corrected 95%CI of the indirect pathways were reported (MacKinnon,
Lockwood, Hoffman, West, & Sheets, 2002). Delta z score was used as a statistics to
evaluate indirect effects (Muthen & Muthen, 2018). Robust maximum likelihood
estimation (estimator=MLR) was used to estimate the parameters, and full information
maximum likelihood (FIML) estimation approach was used to handle missing data.
Multiple indices were used to evaluate the model fit. Same indices, such as χ2, χ2/df, pvalues, CFI, RMSEA, and SRMR, were used to assess the model fit. Bivariate analysis
was performed using SAS software version 9.4 (SAS Institute, Inc., Cary, NC). LGCM
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and mediation analysis were performed using Mplus version 7.0 (Muthen & Muthen, Los
Angeles, CA).
3.6 Overall analytic considerations for the dissertation
Prior to data analysis specific to each aim, overall analytic considerations
associated with appropriate analysis were carefully assessed and considered in data
management and cleaning. The two studies in this dissertation pursued preliminary
analyses including identification and adjustment of covariates, collinearity, missing data,
and outliers. During the longitudinal data analysis, change patterns (e.g., linear and nonlinear patterns) were evaluated and considered.
3.6a Covariates
Covariates adjusted in both Studies 1 and 2 were selected based on the bivariate
analysis and empirical evidences. Bivariate analysis was used to test the relationships
between sociodemographic characteristics and clinical outcomes. Sociodemographic
characteristics with specific p-values (p ≤ 0.10 in Study 1; p ≤ 0.05 in Study 2) were
considered as potential covariates. Potential covariates supported by empirical evidences
and associated with clinical outcomes were adjusted in the final model. As psychosocial
distress, such as depression and anxiety, were closely associated with clinical outcomes
(Andrinopoulos et al., 2011; Jain et al., 2020; Khare, Rajpoot, & Dubey, 2020; Shi et al.,
2020; Yang, Thai, & Choi, 2016), they were also adjusted as covariates in both Studies 1
and 2.
Sociodemographic characteristics and psychosocial distress were determined as
time-varying or time-invariant based on the study design. For instance, only age, time
since HIV diagnosis, duration of ART, employment, BMI, depression, and anxiety were
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collected at all four-wave datasets. Therefore, these variables were considered as timevarying covariates during the longitudinal analysis in Study 1. All potential covariates at
baseline assessment were controlled in the mediation analysis of Study 2.
3.6b Collinearity
Collinearity might exist during the longitudinal data analysis and influence the
parameter estimation. The collinearity among variables of interest were tested using
“PROC REG” process in SAS. Condition index, variance of inflation (VIF), and value of
tolerance were used to evaluate whether there was collinearity among them (Wicklin,
2020). The criteria of collinearity were: (1) condition index was larger than 30; (2) VIF
was larger than 10; and/or (3) value of tolerance was less than 0.2 or 0.1 (Wicklin, 2020).
In this dissertation, collinearity was identified between time since HIV diagnosis and
ART. As these two variables had similar conceptual meaning and strong correlation, one
of them was controlled in the final model based on their correlation with each clinical
outcome. As duration of ART had direct impacts on viral suppression and CD4 count, it
was controlled as a covariate if viral suppression and CD4 count were the major
outcomes in the analysis. In terms of the HRQoL, as it is closely associated with time
since HIV diagnosis, time since HIV diagnosis was controlled as one of the covariates in
the analysis (Patel et al., 2009).
3.6c Missing data
Missing data is a common but important issue in longitudinal data analysis. The
preliminary assessment of the four-wave datasets used in this dissertation found that the
attrition rate was less than 5% of the participants for each follow-up. As the proportions
of missing value were less than 10%, listwise deletion was used as a default method for
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handling missing data in longitudinal data analysis (Dong & Peng, 2013; Schafer, 1999).
For the generalized linear mixed model in Study 1, it deleted the observations for which
an outcome had missing data (Fitzmaurice et al., 2011).
In terms of the LGCM in Study 2, missing data was handled using FIML
estimation approach for continuous variables while listwise deletion was used for
categorical variables. FIML approach estimates the parameters using the complete
observations (Graham, 2009). Based on the assumption of missing completely at random
(MCAR) or missing at random (MAR), FIML could effectively handle missing data in
latent variable analysis (Graham, 2009). As the percentage of missing data at each
follow-up was low, MAR was assumed. FIML was used to estimate the parameters of
LGCM with continuous variables. In mediation analysis, FIML was also used to handle
the missing values as slope was a continuous variable.
3.6d Outliers
Multivariable linear regression was conducted to examine the outliers among all
continuous variables using SAS “PROC REG” process. Scatter plot, residual plot, Cook’s
distance, Leverage statistics, and Studentized residual were used to detect the outliers
among variables of interest. Observations with Cook’s distance close to or larger than 1,
Leverage statistics larger than 2*(p+1)/n (p is the number of parameters in regression
model and n is the sample size), and/or the absolute value of Studentized residual larger
than 2 were considered as outliers (Chartier & Cousineau, 2010). Once the outliers or
influential cases were identified, these observations were double-checked in the original
dataset to see whether there were any mistakes on data cleaning, coding, and
management. For the outliers or influential cases without any mistakes in data collection
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and management, they were kept for further analyses. However, for the illegitimate
outliers, they were recoded as missing values.
3.6e Change pattern
Change pattern is also an important issue to consider in longitudinal data analysis.
However, as most variables of interest only had small changes across the time and this
dissertation aims to test the impacts of independent variables on clinical outcomes, in
both Studies 1 and 2, the changes of key variables were defined as linear trends. Using
linear trend to define the change patterns of key variables in LGCM could reduce the risk
of model misidentification.
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CHAPTER 4
LONGITUDINAL IMPACTS OF INTERNALIZED, ANTICIPATED,
AND ENACTED STIGMA ON CLINICAL OUTCOMES AMONG
PLWH: A PROSPECTIVE COHORT STUDY
4.1 Abstract
As we are approaching the accomplishment of “90-90-90” goal, improving the
clinical outcomes among people living with HIV (PLWH) becomes a critical component
of HIV treatment and care continuum. Previous studies confirmed the impacts of overall
measure of HIV-related stigma on clinical outcomes. However, few studies have
distinguished the separate effects of different types of HIV-related stigma on clinical
outcomes after accounting for psycho-behavioral factors. This study aimed to investigate
the relationships between internalized, anticipated, enacted stigma and clinical outcomes
using hierarchical longitudinal approach.
A prospective cohort study was conducted in Guangxi, China among 1,198
PLWH. Data at baseline, 6-, 12-, and 18- follow-ups were used for analysis. CD4 count,
viral suppression, and health-related quality of life (HRQoL) were the major clinical
outcomes in this study. Internalized, anticipated, and enacted stigma were measured using
separate scales. Hierarchical generalized linear mixed model was used to examine the
impacts of internalized, anticipated, and enacted stigma on clinical outcomes after
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adjusting for psycho-behavioral factors (i.e., antiretroviral therapy [ART] self-efficacy,
HIV symptom management self-efficacy, ART adherence, depression, and anxiety) and
covariates.
Among the 1,198 PLWH, the viral suppression improved while HRQoL
decreased significantly. CD4 count had slight improvement over time but this change was
not significant. All three types of HIV-related stigma changed significantly. Hierarchical
analysis revealed that the three HIV-related stigma explained additional variances in
clinical outcomes after adjusting for psycho-behavioral factors and covariates.
Internalized (β=-0.78, 95% confidence interval [CI]: -1.07~-0.49), anticipated (β=-0.84,
95% CI: -1.12~-0.55), and enacted stigma (β=-0.83, 95% CI: -1.10~-0.56) could
significantly reduce HRQoL but not CD4 count and viral suppression. Psycho-behavioral
factors showed differential effects on the three clinical outcomes.
HIV-related stigma could explain additional information of clinical outcomes and
showed differential impacts. Future studies are needed to investigate the psychobehavioral mechanisms of HIV-related stigma on clinical outcomes. To improve clinical
outcomes among PLWH effectively, interventions are warrant to not only target HIVrelated stigma but also to promote resilience which could alleviate the negative impacts
of HIV-related stigma.
4.2 Introduction
Global HIV epidemic and progress in “90-90-90” goals
The widespread application of antiretroviral therapy (ART) has dramatically
reduced the mortality of HIV infection and deterred further transmission (Joint United
Nations Programme on HIV/AIDS [UNAIDS], 2020a, 2020b). However, currently the
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HIV epidemic is still a critical public health challenge globally including in China
(UNAIDS, 2020b). The number of people living with HIV (PLWH) in China has steadily
increased since 2005, and there were more than 1.25 million cumulative diagnosed and
undiagnosed cases by the end of 2018, with an estimated of 80,000 new cases diagnosed
during the same year (Wu, Chen, Scott, & McGoogan, 2019; Wu, McGoogan, & Detels,
2021).
To control the global HIV epidemic and AIDS-related deaths, the Joint United
Nations Programme on HIV/AIDS (UNAIDS) launched the “90-90-90” goals in 2014
(Marsh et al., 2019). These goals included at least 90% of the diagnosis, 90% of the
treatment, and 90% of the viral suppression among PLWH by the end of 2020 (Marsh et
al., 2019). Since 2016, research also suggested that health-related quality of life (HRQoL)
should be the fourth goal for HIV treatment and care continuum. PLWH with
considerable levels of CD4 cells and viral suppression still need to contend with other
challenges, such as potential side effects of ART, the possibility of treatment failure, and
other comorbidities (Andersson et al., 2020; Lazarus et al., 2016; Webster, 2019).
HRQoL is a comprehensive construct of health quality as it could reflect the disease
burden across four main dimensions (i.e., physical health, psychological health, social
functioning, and perception about general health) (Ashing-Giwa, 2005; Ruiz Perez et al.,
2005; Wu, Hays, Kelly, Malitz, & Bozzette, 1997). The announcement from UNAIDS
emphasized the importance of clinical outcomes (i.e., CD4 count, viral suppression, and
HRQoL) among PLWH on ART.
The progress of clinical outcomes among PLWH still does not meet the “90-9090” goals. Among the 38 million PLWH worldwide, only 62% of them were on ART and
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53% had achieved viral suppression in 2018 (Marsh et al., 2019). In China, by the end of
2018, 94.2% of the PLWH had suppressed viral load (Ma et al., 2018; Wu, 2016) but
spatial variation in viral suppression was found. PLWH from rural provinces (e.g.,
Yunnan, Guangxi) were less likely to achieve viral suppression than those from urban
provinces (e.g., Guangdong) (Chen et al., 2014; Huang et al., 2015). In terms of CD4
count, an important indicator of immunologic functioning, a nationwide retrospective
cohort study in China found that nearly 80% of the PLWH on ART had their CD4 count
between 200 ~ 349 cells/μl (Hu et al., 2017), which were still not within the typical range
for a healthy immune system (CD4 count ≥ 500 cells/μl). Due to HIV, PLWH also
experience lower levels of HRQoL than the general population (Lan et al., 2015).
Clinical outcomes and HIV-related stigma
Prior research summarized some psycho-behavioral factors related to clinical
outcomes among PLWH. These factors included but are not limited to HIV-related
stigma (Bhat et al., 2015; Darlington & Hutson, 2017), treatment-related self-efficacy
(Zeng et al., 2020; Zhou, Li, Qiao, Shen, & Zhou, 2020), ART adherence (Adiga, Adiga,
& Bn, 2016; Arnsten et al., 2001; Reis, Lencastrez, Jonsson, & Guerra, 2020; Wood et
al., 2004), and psychological distress (Ajose, Mookerjee, Mills, Boulle, & Ford, 2012;
Gore-Felton & Koopman, 2008; Pence, 2009). Among these factors, HIV-related stigma,
as a chronic stressor among PLWH, is a well-established factor closely related to clinical
outcomes.
HIV-related stigma is defined as a “discrediting and tainting social label” because
of HIV. According to the Health Stigma Framework, HIV-related stigma included
internalized, anticipated, and enacted stigma (Earnshaw & Chaudoir, 2009; Earnshaw,
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Smith, Chaudoir, Amico, & Copenhaver, 2013), which reflect the cognitions, beliefs, and
experiences of discrimination against PLWH, respectively. Internalized stigma refers to
the cognitive process of believing that the negative attributes related to HIV are true of
the self (Earnshaw & Chaudoir, 2009; Earnshaw et al., 2013). PLWH with high levels of
internalized stigma would apply these negative beliefs to themselves and believe that they
are devalued or bad as compared to others (Quinn & Earnshaw, 2011; Sayles, Wong,
Kinsler, Martins, & Cunningham, 2009). Anticipated stigma makes PLWH believe that
they may receive negative treatment if others know their HIV status (Quinn & Earnshaw,
2011). It is closely related to the fears of being discriminated among PLWH. Enacted
stigma is the actual experience of being discriminated by others (Quinn & Earnshaw,
2011). When HIV status is known either through voluntary disclosure or unintended
disclosure, PLWH would be treated in stigmatizing ways. These three types of HIVrelated stigma could inhibit health-seeking behaviors, timely diagnosis, prevent PLWH
from treatment and care, and impair their health outcomes (Alonzo & Reynolds, 1995;
Andersson et al., 2020; Goffman, 1963). However, currently, limited research
investigated the direct impacts of internalized, anticipated, and enacted stigma on clinical
outcomes simultaneously. Instead, most extant research only focused on the overall HIVrelated stigma or one or more types (Fuster-Ruizdeapodaca, Molero, Holgado, &
Mayordomo, 2014; Logie et al., 2019; Parcesepe et al., 2020). These studies might ignore
the nuanced differences among them and could not adequately inform tailored
intervention to each type of stigma and clinical outcomes.
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HIV-related stigma in China
PLWH in China suffer from serious HIV-related stigma. The Chinese culture,
such as collectivism and family responsibilities, may cultivate HIV-related stigma against
PLWH (Liu et al., 2006). The collectivist culture subordinates individual interests to
those of the group and requires people in the same group to maintain dignity, respect, and
social status in the social structure (Hui & Triandis, 1986; Kleinman et al., 1995; MurrayJohnson et al., 2001; Triandis, Bontempo, & Villareal, 1988). People would be devalued
or condemned if they do not comply with the rules in collectivist culture. As HIV
infection is closely related to stigmatizing behaviors, such as commercial sex, casual sex,
and injection drug use, PLWH would be devalued by the collectivist society as the
collective value is considered to be destroyed by them (Liu et al., 2006). What is more,
the Chinese culture emphasizes family responsibilities, such as maintaining and
protecting family (males’ responsibilities) and taking care of the home, the children, and
the rest of the family (females’ responsibilities). Due to HIV, many PLWH suffer from
serious health burden and could not fully take the family responsibilities. Particularly,
some PLWH who are sexual minorities could not have children to maintain the family
bloodline, which would put them at risk of stigma (Li, Holroyd, Lau, & Li, 2015).
However, few studies investigated the negative impacts of HIV-related stigma on clinical
outcomes among PLWH in China.
PLWH in Guangxi are vulnerable to HIV-related stigma. Guangxi is a resourcelimited province located in southern China. Therefore, compared with other developed
provinces with relatively sufficient resources, Guangxi is more conservative in regard to
Chinese culture. Additionally, the HIV epidemic in Guangxi is a rural phenomenon with
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large number of PLWH living in rural areas, in low socioeconomic status, and being
infected mostly through sexual activity (Wang, 2013; Yang et al., 2019). For instance, an
existing study found that from 1996 to 2017, the primary routes of HIV transmission
changed from infection drug use to sexual contacts including heterosexual and male-tomale sexual activity (Chen et al., 2019). Hence, due to the conservative culture, limited
knowledge of HIV infection, and local HIV epidemic, PLWH in Guangxi may experience
high levels of HIV-related stigma. Therefore, investigations are needed to explore the
separate impacts of internalized, anticipated, and enacted stigma on clinical outcomes
among this vulnerable population, which could provide empirical evidences for stigma
intervention design among PLWH and improving their health outcomes.
Research goals and hypotheses
To address these knowledge gaps, the current study leveraged data derived from a
prospective cohort and hierarchical regression approach and aimed to investigate the
effects of internalized, anticipated, and enacted stigma on the three clinical outcomes
(i.e., CD4, viral suppression, and HRQoL) among PLWH in Guangxi, China. We
assumed that all three types of stigma had significant and negative impacts on clinical
outcomes.
4.3 Methods
Study design and setting
Data used in this study were derived from a prospective cohort study among
PLWH in Guangxi, China. From 2014 to 2018, Guangxi was consistently ranked third
across the 31 provinces in China in terms of the total number of HIV cases (Wu et al.,
2019). By 2018, there were over 86,000 PLWH reported in Guangxi (Guangxi Center for
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Disease Control and Prevention [CDC], 2018). With the assistance and collaboration of
Guangxi Center for Disease Control and Prevention (CDC), six major public
hospitals/clinics in five cities with the largest number of PLWH under care were selected
as study sites. The number of PLWH in each study site ranged from 1,386 to 7,389 at the
time of baseline assessment.
Participants
Using a systematic sampling approach, PLWH who fulfilled the eligibility were
invited to participate in the cohort study. The inclusion criteria for the cohort study were
PLWH who: 1) aged between 18 and 60 years old; 2) had a confirmed diagnosis of HIV;
and 3) had no plan to relocate outside of Guangxi in the next 12 months. PLWH who had
mental and/or physical inability to answer assessment questions and/or who were
currently incarcerated or institutionalized were excluded from the study. Additionally,
PLWH who were older than 60 years were excluded from the study due to aging-related
health issues (e.g., multiple chronic diseases and treatments, changes in physical and
cognitive abilities, increased vulnerability to stressors) which could confound the
outcome measures (High et al., 2012).
Recruitment and data collection
Before the data collection, all research associates from the local CDC and
hospitals/clinics received a three-day training course which covered topics on assessment
methodology and survey skills. A one-day booster training session was also conducted
prior to each of the follow-ups. The booster session briefly rehearsed the survey skills
and reviews research ethics. Based on the systematic sampling, once eligible PLWH were
randomly selected, the local team members confirmed the patients for eligibility,
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scheduled a meeting to discuss about the benefits and risks of the study, and invited them
to participate. After obtaining their written informed consent, the face-to-face interviews
were conducted in private rooms of the clinics. An interviewer-administered
questionnaire was used for data collection. Baseline assessment was conducted from
November 2017 to February 2018. The recruited participants were followed up at 6-, 12-,
18-, 24-, 30-, and 36- months. Longitudinal data at baseline, 6-, 12-, and 18-month
follow-ups were used in this study. Each participant received a gift (e.g., household
items) equivalent to US$5.00 (1 USD ≈ 6.5 Chinese Yuan at the time of the survey) at the
completion of the interview. The study protocol was approved by the Institutional
Review Boards at both University of South Carolina in the United States and Guangxi
CDC in China.
Measures
CD4 count
CD4 count of each participant at baseline, 6-, 12-, and 18- month follow-ups were
retrieved from their electronic health records. According to the guidelines for ART in
adults and adolescents with HIV (U.S. Department of Health and Human Services &
Panel on Antiretroviral Guidelines for Adults and Adolescents, 2017), the cut-off of 500
cells/µl has clinical implication in evaluating the normal immunologic functioning.
Therefore, CD4 count was categorized as a binary variable (< 500 and ≥ 500 cells/µl).
Viral suppression
Plasma viral load of each participant was collected from the electronic health
records at each timeframe and used to define viral suppression. As viral suppression is an
indicator of treatment efficacy, it was used as one of the primary outcomes rather than the
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original continuous value of viral load. Viral suppression refers to HIV RNA less than or
equal to 50 copies/ml in PLWH’s plasma (CDC & National Center for HIV/AIDS, Viral
Hepatitis, and TB Prevention, 2018).
Health-related quality of life (HRQoL)
Participants’ HRQoL were assessed using the 35- item Medical Outcomes Study
HIV Health Survey (MOS-HIV) (Wu et al., 1997). This scale measured 11 dimensions of
health including general health perception, physical functioning, role functioning, social
functioning, cognitive functioning, pain, mental health, energy/fatigue, health distress,
quality of life, and health transition. The sum score of each dimension was calculated and
transformed to the final score ranging from 0 to 100 as suggested by previous studies
(Delate & Coons, 2001; Hays & Shapiro, 1992; Ware & Sherbourne, 1992; Wu et al.,
1997). The total score of HRQoL was calculated using the sum scores of the 11dimension and then transformed to the score ranging from 0 to 100. The MOS-HIV
showed good reliability among the participants at baseline (Cronbach’s alpha = 0.93).
Sociodemographic characteristics
PLWH reported their sociodemographic characteristics including age (year), time
since HIV diagnosis (year), duration of ART (year), gender (0 = female, 1 = male),
marital status (1 = single/separated, 2 = married/cohabitated, 3 = divorced/widowed),
ethnicity (0 = Non-Han, 1 = Han), types of residence (1 = city, 2 = county, 3 = rural),
education attainment (0 = less than or equal to middle school, 1 = high school or above),
employment (1 = unemployed, 2 = part time, 3 = full time), levels of monthly income (1
= no more than 1,999 Yuan, 2 = 2,000~3,999 Yuan, 3 = at least 4,000 Yuan),
transmission modes (0 = others [transfusion/injection drug use/unknown/others], 1 =
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sexual activity), weight, and height. Body mass index (BMI) was calculated using weight
and height and categorized as underweight (less than 18.5), normal/healthy weight (18.5
~ 24.9), and overweight/obese (more than 24.9).
Internalized stigma
Internalized stigma was measured using an 8- item scale derived from the Berger
HIV Stigma Scale (Berger, Ferrans, & Lashley, 2001). These eight items were used to
assess the “negative self-image” among PLWH in the original scale. Participants were
asked to rate their agreement to the statement, including “I feel I’m not as good as others
because I have HIV”, “I feel guilty because I have HIV”, and “Having HIV makes me
feel unclean”. The response options were rated from “strongly disagree (1)” to “strongly
agree (4)”. The total score of these eight items was used as the indicator of internalized
stigma, with a higher score indicating a higher level of internalized stigma. This scale had
good reliability at baseline (Cronbach’s alpha = 0.94).
Anticipated stigma
Anticipated stigma was assessed using a 9- item scale derived from the Health
Stigma Framework (Earnshaw et al., 2013). This scale assessed the expectation of HIVrelated stigma from family members, community, and healthcare providers. Sample items
were “Family members will avoid touching me”, “Community managers will refuse to
provide me with social services”, and “Healthcare providers will treat me with less
respect”. The response options were “definitely not (1)”, “probably not (2)”, “not sure
(3)”, “probably (4)”, and “definitely (5)”. The sum score was used as a composite score
ranging from 9 to 45, with higher score indicating higher levels of anticipated stigma.
The Cronbach’s alpha of this scale at baseline assessment was 0.92.
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Enacted stigma
Enacted stigma was evaluated using the 16- item checklist adapted from a
previous study (Yi et al., 2015). PLWH were asked whether they had actual experiences
of being stigmatized due to HIV in the past six months, including “Being excluded from
social gathering or activities”, “Being excluded from family activities”, and “Being
physically assaulted”. Participants who answered “yes (1)” were considered to have the
experience of being stigmatized while those who answered “no (0)” were considered to
have no such experience. The total score of the 16 items was used as a composite score,
with a higher score indicating more experiences of being stigmatized in the last six
months. The enacted stigma scale also showed good reliability at baseline (Cronbach’s
alpha = 0.89).
ART self-efficacy
ART self-efficacy was assessed using a 10- item scale adapted from the Selfefficacy for Appropriate Medication Use Scale (SEAMS) (Risser, Jacobson, & Kripalani,
2007; Zhang et al., 2016). PLWH were asked “How confident are you that you can take
your medicines correctly under the following scenarios”? Sample items were “When you
take several different medicines each day” and “When you are away from home”. Item
response options were from “not confident (1)” to “confident (3)”. The sum score of
these ten items was used as a composite score ranging from 10 to 30, with a higher score
indicating a higher level of ART self-efficacy. The Cronbach’s alpha of the ART selfefficacy scale at baseline was 0.95.
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HIV symptom management self-efficacy
HIV symptom management self-efficacy was measured using six items from the
Self-efficacy for Managing Chronic Disease Scale (Eller et al., 2014) and four items
about participants’ confidence in symptom management (Lorig, Sobel, Ritter, Laurent, &
Hobbs, 2001). The four items evaluated participants’ confidence in keeping symptoms
from interfering with social functions, deciding when to see a doctor, forming a plan for
symptom management, and managing medication-induced side effects (Lorig et al.,
2001). The overall scale evaluated PLWH’s efficacy in controlling their HIV-related
symptoms. One sample item was “I am confident that I can manage HIV medication side
effects.” Item options ranged from “totally disagree (1)” to “totally agree (5)”. A
composite score of HIV symptom management self-efficacy was calculated by summing
these 10 items, with higher score indicating more confidence in HIV symptom
management. The HIV symptom management self-efficacy scale had good reliability at
baseline (Cronbach’s alpha = 0.96).
ART adherence
To minimize the self-report bias of self-report measures of ART adherence, a
multiple-item approach was employed to assess adherence behavior in the cohort study
(Chesney et al., 2000; Da, Li, Qiao, Zhou, & Shen, 2018; Simoni et al., 2006). Five items
derived from the Adult AIDS Clinical Trials Group (AACTG) adherence instrument were
adapted to ask participants about their levels of ART adherence (Chesney et al., 2000; Da
et al., 2018; Reynolds et al., 2007).
An overall adherence score was calculated according to the following procedure
(Da et al., 2018). First, participants reported the days of completing their prescribed ART
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doses within four specified timeframes (last three days, last weekend, last two weeks, last
month [30 days]). For the last three-day and weekend measures, participants were asked
to report the number of doses taken and the number of expected doses during these two
timeframes. Percentage adherence was calculated by dividing doses taken by doses
expected. For the one-month and two-week days taken measures, participants were asked
to report the number of days they took all doses of their HIV medication as prescribed.
Percentage adherence was calculated dividing the reported number of days by 30 days (or
14 days). These responses were then converted into a percentage of prescribed doses and
recoded into 0 (< 90%) or 1 (≥ 90% of prescribed doses) according to the Chinese
guideline for ART treatment. Second, whether participants adhered to their prescribed
doses (1 = always, 2 = very often, 3 = sometimes, 4 = rarely, 5 = never) was used as the
fifth adherence item. Participants who always adhered to their prescription were coded as
“yes (1)” while others were coded as “no (0)”. Finally, by summing scores of the above
five items, a composite score was calculated. The sum score ranges from 0 to 5. PLWH
who scored 5 were considered as optimal adherence to ART. The five adherence
measures showed acceptable reliability at baseline assessment (Cronbach’s alpha = 0.72).
Psychological distress
Psychological distress in this study included depression and anxiety. Depression
was assessed using the 10- item Center for Epidemiologic Studies-Depression (CES-D
10) Scale. The CES-D scale had been widely used, and its validity and reliability had
been established in Chinese population (Yu, Lin, & Hsu, 2013). The response options
ranged from “rarely or none of the time (0)” to “all of the time (3)”. The summed score
ranging from 0 to 30 was used to reflect the levels of depression, with a higher score
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indicating a higher level of depression. The CES-D scale had good reliability at baseline
assessment (Cronbach’s alpha= 0.85).
Anxiety was measured using the Brief Anxiety Scale (Zung, 1971), which had
been validated in Chinese population (Zhang, Liu, Li, Mao, & Yuan, 2015). PLWH were
asked their feelings (e.g., “I feel easily upset or panicked”, “I experience headache and a
sore neck”) about anxiety disorders in the past week. The original scale included 20 items
which were scored from “never or seldom (1)” to “often (4)”. The total score ranged from
20 to 80. However, due to issue of translation, two items (“My hands are usually dry and
warm”, “I fall asleep easily and get a good night’s rest”) could not capture the original
meanings, which result in a Cronbach’s alpha of 0.88 in the overall scale. After removing
these two items, the reliability was significantly improved (Cronbach’s alpha=0.88).
Therefore, the rest of the items were used to calculate the final anxiety score ranging
from 18 to 72, with higher score indicating more symptoms of anxiety.
Statistical analysis
Data analysis included descriptive statistics, bivariate analysis, and hierarchical
longitudinal analysis. Descriptive statistics were reported on all the variables used in this
study. Mean and standard deviation (SD) were used to describe the continuous variables
while frequencies and percentages were used for categorical variables. Changes of the
clinical outcomes and psycho-behavioral factors across the time were tested. Analysis of
variance (ANOVA) was used to test the changes of continuous variables while Chisquare test was used for that of categorical variables.
Hierarchical longitudinal analysis was conducted to carry out the research goals.
In longitudinal analysis, due to the study design, age, time since HIV diagnosis, duration
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of ART, employment, BMI, HIV-related stigma, ART self-efficacy, HIV symptom
management self-efficacy, depression, anxiety, and ART adherence were used as timevarying variables while gender, marital status, ethnicity, types of residence, education
attainment, levels of monthly income, and transmission modes were used as timeinvariant variables. Before the multivariable analysis, bivariate analysis was conducted to
examine the relationship between each clinical outcome and independent variables using
generalized linear mixed model. Crude odds ratio (OR) or regression coefficient and 95%
confidence intervals (CI) were reported in bivariate analysis. Sociodemographic
characteristics with p-values less than 0.10 were controlled as covariates in multivariable
analysis.
In hierarchical longitudinal analysis, for CD4 count and viral suppression,
generalized linear mixed model with categorical outcome was employed to examine my
hypotheses. First of all, covariates and duration of ART were controlled as confounders
in model 1 after adjusting for the repeated measurements. Moreover, psycho-behavioral
factors, such as ART self-efficacy, HIV symptom management self-efficacy, ART
adherence, depression, and anxiety, were added to model 1 and examined their impacts
on the outcomes (model 2). Finally, to examine the impacts of internalized, anticipated,
and enacted stigma on outcomes, these three types of stigma were added to model 2 and
tested in model 3 simultaneously. As CD4 count and viral suppression were binary
outcomes, the distribution was specified as “binomial distribution”, and link function was
defined as “logit link function”. To model the correlations of CD4 count and viral
suppression at baseline, 6-, 12-, and 18- month follow-ups, correlation structures (e.g.,
unstructured covariance, autoregressive covariance, exchangeable covariance, and
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independent covariance) were examined, and multiple indices (i.e., Queensland
Investment Corporation [QIC] and QICu) were used for evaluating the goodness of fit
(Cui & Qian, 2007). Model with the smallest values of the QIC and QICu was considered
as having the best model fit (Cui & Qian, 2007). If the best models selected by QIC and
QICu were inconsistent, QIC was used as the final criteria for model selection (Cui &
Qian, 2007). Adjusted OR (AOR) and its 95% CI were reported.
In terms of HRQoL, linear mixed effect model was employed. A similar
modelling procedure was conducted to examine the impacts of sociodemographic
characteristics, psycho-behavioral factors, and HIV-related stigma on HRQoL after
adjusting for the repeated measures. Besides the covariates and potential confounders,
CD4 count was adjusted in the analysis. Correlation structures were also examined, and
Log likelihood value, Akaike Information Criterion [AIC], Corrected AIC [AICC], and
Bayes Information Criterion [BIC] were used as the indicators for model selection
(Fitzmaurice, Laird, & Ware, 2011). Model with smaller AIC, AICC, BIC had better
model fit (Fitzmaurice et al., 2011). If the values of these indicators were inconsistent,
BIC was used as the final criteria for model selection. Regression coefficient (β) and its
95%CI were reported. Pseudo R square (R2) was reported to evaluate the amount of
variance being accounted for in each model (Edwards, Muller, Wolfinger, Qaqish, &
Schabenberger, 2008) during the process of hierarchical longitudinal analysis. All the
analyses were performed using SAS software version 9.4 (SAS Institute, Inc., Cary, NC).
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4.4 Results
Descriptive statistics
Table 4.1 shows the sociodemographic characteristics of PLWH at baseline.
Among the 1,198 PLWH, the average age at baseline was 39.0 (SD = 9.2) years old
ranging from 18 to 60. More than half of them were male (771 [64.4%]),
married/cohabitated (666 [56.2%]), had less than or equal to middle school education
(719 [60.0%]), and/or had full time employment (734 [61.7%]). More than one-third of
them were living in a city (536 [44.9%]) and/or had monthly income between 2,000 and
3,999 Yuan (584 [48.9%]).
In regard to the characteristics of HIV infection, the average time since HIV
diagnosis and duration of ART treatment were 5.5 (SD = 3.1) and 4.8 (SD = 3.0) years,
respectively. Nearly 70% of them (832 [69.7%]) were infected through sexual activity.
There were 94.3% (1,130/1,198) of the PLWH who achieved viral suppression but only
45.1% (540/1,198) of the participants who had their CD4 count equal to or higher than
500 cells/μl. The average score of HRQoL was 73.7 (SD = 13.1). There were 80.8%
(963/1,192) of the PLWH who had optimal ART adherence.
For psychosocial factors, the average scores of internalized, anticipated, and
enacted stigma were 16.3 (SD = 5.5), 23.2 (SD = 7.7), 0.9 (SD = 2.1), respectively. The
mean score of ART self-efficacy was 24.5 (SD = 5.0), and that of the HIV symptom
management self-efficacy was 33.5 (SD = 9.1). The averages of depression and anxiety
are shown in Table 4.2.
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Changes of clinical outcomes and predictors
Across the 6-, 12-, and 18- month follow-ups, study attrition rates were lower than
5.0% (Table 4.2). The changes of clinical outcomes (i.e., viral suppression and HRQoL)
were significant except CD4 count. As time increased, the percentage of PLWH who had
their CD4 count equal to or higher than 500 cells/μl increased from 45.1% (540/1,198) at
baseline to 47.0% (563/1,198) at 18-month follow-up (Figure 4.1). However, this change
was not significant (χ2 = 1.23, p > 0.05). Compared with CD4 count, the percentage of
PLWH who achieved viral suppression increased from 94.3% (1,130/1,198) to 97.8%
(1,135/1,161), and this change was significant (χ2 = 18.16, p < 0.01) (Figure 4.2).
Generally, participants’ HRQoL significantly decreased over time (Figure 4.3) although
the average score showed slight increases at 12-month follow-up.
In terms of the changes in psycho-behavioral factors, all of their changes were
statistically significant within the study period. Particularly, internalized (Figure 4.4a)
and anticipated (Figure 4.4b) stigma had slight changes at 6- and 12- month follow-ups
but decreased at 18- month follow up. Even though there were slight changes in between,
the average score of enacted stigma (Figure 4.4c) remained the same at baseline and 18month follow-up. Both scores of ART self-efficacy (Figure 4.5a) and HIV symptom
management self-efficacy (Figure 4.5b) at 18-month follow-up decreased as compared
with their baseline scores. The percentage of PLWH with optimal ART adherence
(Figure 4.6) increased from 80.8% (963/1,192) at baseline to 85.5% (983/1,150) at 12month and then decreased to 80.1% at 18-month follow-up. The changes of clinical
outcomes and predictors are shown in Table 4.2. Figures 4.7a and 4.7b show the changes
of depression and anxiety, respectively.
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Clinical outcome: CD4 count
Bivariate analysis
The results of bivariate analyses showed that as age increased, the probability of
PLWH with their CD4 count equal to or higher than 500 cells/μl decreased. PLWH who
were male, of Han ethnicity, and acquired HIV through sex activity also had lower
probability of having their CD4 count equal to or higher than 500 cells/μl. PLWH with
longer time since HIV diagnosis had higher probability of higher level of CD4 count
while the duration of ART treatment did not show a significant impact. Participants who
were single/separated, living in a county or city, had at least high school education,
and/or had monthly income at least 4,000 Yuan had higher probability of having their
CD4 count equal to or higher than 500 cells/μl. Both ART self-efficacy and HIV
symptom management self-efficacy had significant and positive impacts on CD4 count.
No significant relationships between HIV-related stigma, optimal ART adherence and
CD4 count were found. Table 4.3 shows the detailed results of bivariate analysis of
longitudinal CD4 count.
Hierarchical generalized linear mixed model of CD4 count
Hierarchical generalized linear mixed model was conducted to examine the
contribution of predictors on the variances in CD4 count. In step 1 (model 1),
sociodemographic characteristics with p-values less than 0.10 (i.e., age, gender, marital
status, ethnicity, types of residence, education attainment, levels of monthly income,
transmission modes, BMI) and duration of ART were entered into model 1 after adjusting
for repeated measures. In step 2 (model 2), psycho-behavioral factors, such as ART selfefficacy, HIV symptom management self-efficacy, ART adherence, depression, and
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anxiety, were added to model 1. Finally, internalized, anticipated, and enacted stigma
were added to model 2 simultaneously and tested their separate impacts on CD4 count in
model 3.
Table 4.4 shows the results of hierarchical generalized linear mixed model of
CD4 count. After adjusting for sociodemographic characteristics, duration of ART, and
time effect, model 1 explained 12.7% of the variances in outcome. PLWH who were
older (AOR = 0.71, 95%CI: 0.62 ~ 0.81), of Han ethnicity (AOR = 0.77, 95%CI: 0.62 ~
0.96), male (AOR = 0.60, 95%CI: 0.47 ~ 0.77), and/or underweight (AOR = 0.57, 95%CI:
0.44 ~ 0.73) had lower probability of having their CD4 count equal to or higher than 500
cells/μl. Participants with longer duration of ART treatment (AOR = 1.15, 95%CI: 1.03 ~
1.29), living in a county (AOR = 1.54, 95%CI: 1.14 ~ 2.09) or city (AOR = 1.60, 95%CI:
1.23 ~ 2.09), and/or those who were overweight/obese (AOR = 1.29, 95%CI: 1.05 ~ 1.58)
had higher probability of having higher levels of CD4 count. No significant relationships
between CD4 count and marital status, education attainment, levels of monthly income,
and transmission modes were found.
After adding psycho-behavioral factors to the model 1, model 2 explained an
additional 3.7% of the variance in CD4 count. In addition to the significant relationships
found in model 1, HIV symptom management self-efficacy (AOR = 1.17, 95%CI: 1.07 ~
1.28) and anxiety (AOR = 1.14, 95%CI: 1.01 ~ 1.27) were positively associated with the
probability of higher CD4 count. The time effect was significant (AOR = 1.05, 95%CI:
1.01 ~ 1.09), which meant that as time increased, the probability of PLWH having their
CD4 count equal to or higher than 500 cells/μl increased. ART self-efficacy and ART
adherence did not show significant impacts on CD4 count over time.
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In model 3, internalized, anticipated, and enacted stigma explained an additional
0.6% of the variance in CD4 count. Internalized (AOR = 1.00, 95%CI: 0.91 ~ 1.10),
anticipated (AOR = 1.07, 95%CI: 0.97 ~ 1.17), and enacted stigma (AOR = 0.99, 95%CI:
0.91 ~ 1.08) did not show significant impacts on CD4 count. The existing significant
relationships between CD4 count and time effect, age, duration of ART, gender,
ethnicity, types of residence, BMI, HIV symptom management self-efficacy, and anxiety
remained in model 3.
Clinical outcome: Viral suppression
Bivariate analysis
Bivariate analysis of viral suppression was conducted. Living in a city was
positively associated with the probability of viral suppression while being infected HIV
through sexual activity was negatively related to viral suppression. PLWH with longer
time since HIV diagnosis, duration of ART treatment, and higher levels of ART selfefficacy had higher probability of achieving viral suppression. No significant
relationships between viral suppression and internalized stigma, anticipated stigma,
enacted stigma, HIV symptom management self-efficacy, and ART adherence were
found. Results of bivariate analysis of viral suppression were shown in Table 4.5.
Hierarchical generalized linear mixed model of viral suppression
Results of hierarchical generalized linear mixed model of viral suppression
showed that model 1 explained 8.9% of the variances in viral suppression. The time
effect was statistically significant (AOR = 1.28, 95%CI: 1.13 ~ 1.46), which meant that as
time increased, the probability of achieving viral suppression among PLWH increased.
PLWH with longer duration of ART treatment (AOR = 1.51, 95%CI: 1.18 ~ 1.92) and/or
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living in a city (AOR = 1.68, 95%CI: 1.07 ~ 2.64) had higher probability of achieving
viral suppression.
After adding psycho-behavioral factors to model 1, model 2 explained an
additional 4.6% of variance in viral suppression. Time effect (AOR = 1.32, 95%CI: 1.16
~ 1.50) and duration of ART (AOR = 1.59, 95%CI: 1.23 ~ 2.05) were still significantly
associated with viral suppression while the positive impact of living in a city on viral
suppression (AOR = 1.51, 95%CI: 0.93 ~ 2.46) disappeared. PLWH with higher level of
ART self-efficacy (AOR = 1.29, 95%CI: 1.10 ~ 1.51) had higher probability of viral
suppression. The relationship between depression and viral suppression was marginally
significant (AOR = 0.83, 95%CI: 0.68 ~ 1.01). No significant relationships between viral
suppression and HIV symptom management self-efficacy, anxiety, and ART adherence
were found.
In model 3, internalized, anticipated, and enacted stigma explained an additional
1.7% of the variance in viral suppression. In addition to the existing significant
relationships in model 2, depression was significantly and negatively associated with the
probability of viral suppression (AOR = 0.82, 95%CI: 0.68 ~ 1.00) in model 3. None of
the internalized, anticipated, and enacted stigma had significant impacts on viral
suppression. Table 4.6 shows detailed results of hierarchical generalized linear mixed
model of viral suppression.
Clinical outcome: HRQoL
Bivariate analysis
Among the sociodemographic characteristics, being divorced/widowed was
significantly and negatively associated with HRQoL. PLWH who were living in a city or
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county, had full time employment, and/or had higher monthly income had better HRQoL
as compared to those living in rural areas, without employment, and/or with no more than
1,999 Yuan income each month.
In terms of the HIV-related characteristics, PLWH who were infected through
sexual activity had higher levels of HRQoL than those infected through other modes. No
significant relationships between HRQoL and time since HIV diagnosis and duration of
ART were found.
For the psycho-behavioral factors pertinent to HIV infection, ART self-efficacy,
HIV symptom management self-efficacy, and optimal ART adherence were positively
related to HRQoL while internalized, anticipated, and enacted stigma were negatively
related. Both depression and anxiety showed negative associations with HRQoL. Table
4.7 shows the detailed results of bivariate analysis of HRQoL.
Hierarchical generalized linear mixed model of HRQoL
Hierarchical generalized linear mixed model of HRQoL found that model 1
explained 2.9% of the variance in HRQoL. The time effect on HRQoL was marginally
significant (adjusted β = -0.25, 95%CI: -0.50 ~ 0.01). PLWH who were living in a city
(adjusted β = 2.15, 95%CI: 0.80 ~ 3.50) or county (adjusted β = 2.88, 95%CI: 1.29 ~
4.47), had full time employment (adjusted β = 3.01, 95%CI: 1.97 ~ 4.05), and/or had
higher income (at least 4,000 Yuan: adjusted β = 3.81, 95%CI: 2.10 ~ 5.53) had better
HRQoL as compared to those living in rural areas, without job, and/or with no more than
1,999 Yuan income each month. PLWH who were infected through sexual activity also
had better HRQoL than those infected through other modes (adjusted β = 1.43, 95%CI:
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0.18 ~ 2.67). As compared to PLWH who were married/cohabited, those who were
divorced/widowed had lower HRQoL (adjusted β = -2.60, 95%CI: -4.29 ~ -0.91).
After adding psycho-behavioral factors to model 1, model 2 explained an
additional 11.9% of variances in HRQoL. However, the significant relationships between
HRQoL and living in a city (adjusted β = -0.25, 95%CI: -1.02 ~ 0.52) or county (adjusted
β = -0.42, 95%CI: -1.32 ~ 0.48) disappeared. The impact of time on HRQoL became
significant and negative, which meant that as time increased, the HRQoL of PLWH
decreased significantly (adjusted β = -0.21, 95%CI: -0.40 ~ -0.03). In addition to other
significant relationships found in model 1, model 2 found that ART self-efficacy
(adjusted β = 1.72, 95%CI: 1.45 ~ 2.00), HIV symptom management self-efficacy
(adjusted β = 1.16, 95%CI: 0.87 ~ 1.44), and optimal ART adherence (adjusted β = 0.63,
95%CI: 0.00 ~ 1.26) were positively related to HRQoL while depression (adjusted β = 4.90, 95%CI: -5.26 ~ -4.55) and anxiety (adjusted β = -4.06, 95%CI: -4.41 ~ -3.70)
showed negative effects.
In model 3, internalized, anticipated, and enacted stigma explained an additional
1.0% of the variance in HRQoL. The significant impact of ART adherence on HRQoL
disappeared (adjusted β = 0.56, 95%CI: -0.06 ~ 1.18). In addition to other significant
relationships found in model 2, model 3 found that internalized (adjusted β = -0.78,
95%CI: -1.07 ~ -0.49), anticipated (adjusted β = -0.84, 95%CI: -1.12 ~ -0.55), and
enacted stigma (adjusted β = -0.83, 95%CI: -1.10 ~ -0.56) had significant and negative
impacts on HRQoL. Table 4.8 shows detailed results of hierarchical generalized linear
mixed model of HRQoL.
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4.5 Discussion
Using data from a prospective cohort and hierarchical longitudinal approach, this
study investigated the relationships between internalized, anticipated, enacted stigma and
three clinical outcomes. During the study period, all clinical outcomes had significant
changes except CD4 count. The three types of HIV-related stigma could explain
additional variance, though small, in clinical outcomes after controlling for
sociodemographic characteristics, psycho-behavioral factors, and other confounders.
Specifically, significant impacts of internalized, anticipated, and enacted stigma on
HRQoL were found, but these impacts were not found for CD4 count and viral
suppression. To the best of our knowledge, this was the first study exploring the separate
impacts of internalized, anticipated, and enacted stigma on three clinical outcomes from a
longitudinal perspective. The findings from this study have implications for future stigma
research and stigma reduction intervention.
Over time, participants in the current study who were on ART demonstrated
improved immunologic and virologic outcomes but decreased HRQoL. The improvement
of CD4 count and viral suppression emphasized the importance of linkage to, engage and
retention in HIV treatment and care after HIV diagnosis (Hogg, 2018). Most of the
PLWH included in this study reported optimal adherence behaviors, which had
significant and positive impacts on immunologic recovery and viral suppression. The
possible explanation for the decreased HRQoL among PLWH was that HRQoL is a
comprehensive indicator of health quality, which included physical health, psychological
health, social functioning, and perception about general health (Ashing-Giwa, 2005; Ruiz
Perez et al., 2005; Wu et al., 1997). In addition to immunologic functioning and viral
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suppression, PLWH still need to cope with drug side effects, comorbidities, HIV-related
stigma, and other psychological distress (Andersson et al., 2020; Lazarus et al., 2016;
Webster, 2019), which may also undermine their HRQoL.
HIV-related stigma could explain the variance in clinical outcomes and showed
significant impact on HRQoL but not on CD4 count and viral suppression. All three types
of HIV-related stigma had negative impacts on HRQoL. This finding was consistent with
that of previous studies (Logie, Ahmed, Tharao, & Loutfy, 2017; Logie et al., 2018; Rao
et al., 2012). The high levels of HIV-related stigma could cause mental health problems
and reduce social interaction, social support, and resource access among PLWH, which
prevent them from coping well with health issues related to HRQoL and result in
decreased HRQoL.
In terms of the non-significant relationships between stigma and CD4 count and
viral suppression, there are four possible explanations for these findings. First, as the
cohort study was conducted in clinics/hospitals, PLWH might have better immunologic
and virologic outcomes as compared to those who did not seek help in clinics/hospitals.
Second, only four-wave datasets were used in this study, which might limit the ability to
examine the significant associations among variables of interest. Third, some
confounders (e.g., CD4 count before ART) which were not controlled in this study might
also influence the relationships between HIV-related stigma and CD4 count and viral
suppression. Finally, stigma might not influence these two outcomes directly but through
psycho-behavioral mechanisms. For instance, a large number of research confirmed the
negative impacts of HIV-related stigma on ART adherence which was closely related to
CD4 count and viral suppression (Katz et al., 2013; Turan et al., 2017).
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Psycho-behavioral factors included in this study could explain large variance in
clinical outcomes before adding internalized, anticipated, and enacted stigma to the
model. After adding these three types of stigma to the final model, the effects of some
psycho-behavioral factors changed, which implied that these factors might be the
potential mechanisms underlying HIV-related stigma and clinical outcomes. For instance,
the significant impacts of ART adherence on HRQoL disappeared after stigma was added
to the final model. PLWH who suffered from higher levels of HIV-related stigma might
be less likely to adhere to ART, which in turn could increase viral load, impair their
immunologic functioning, and compromise their physical health as well as HRQoL
(Abdul Bari, 2017; Alsayed, Sereika, Albrecht, Terry, & Erlen, 2017). What is more, we
found that some psycho-behavioral factors had differential impacts on the three clinical
outcomes. For instance, viral suppression was significantly related to ART self-efficacy
but not to HIV symptom management self-efficacy while the inverse result was found in
CD4 count. This might be due to the differences between ART self-efficacy and HIV
symptom management self-efficacy. ART self-efficacy captured the confidence of
adhering to ART, which has close and direct impact on viral suppression (Risser et al.,
2007). In contrast, HIV symptom management self-efficacy captured the confidence of
managing HIV-related symptoms, such as drug side effects and disease progression,
which were closely associated with immunologic functioning and physical health (Eller
et al., 2014; Lorig et al., 2001; Zhou et al., 2020). This finding also implied that the
psycho-behavioral mechanisms of HIV-related stigma on clinical outcomes might be
different.
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Unexpectedly, the current study found that anxiety was positively related to CD4
count. CD4 count, the total numbers of CD4 T-cells in body, represents the immunologic
functioning and ability to fight with infections (Center for Disease Control and
Prevention [CDC], 2019). Generally, it could be boosted or enhanced by short-term
anxiety (Dhabhar, 2014; Hellmuth et al., 2017). Young adults are more likely to have
immune activation enhanced by short-term anxiety as younger age is associated with
better physical functioning which could enhance the immune system to cope with
stressors (Dhabhar, 2014; Hellmuth et al., 2017). In our study, nearly 75% of the PLWH
were younger than 45 years old (the bottom line of middle age). We conducted a
subgroup analysis and found that the positive relationship between anxiety and CD4
count only existed among PLWH under 45 years old (Appendix B). However, the longterm anxiety could suppress the immune response and increase the susceptibility of
chronic diseases (Dhabhar, 2014; Ohman, Bergdahl, Nyberg, & Nilsson, 2007).
Additionally, there may be gender difference in the relationship between anxiety and
CD4 count as prior research found that female were more likely to experience suboptimal
health outcomes than male when suffering from psychological distress (Stevens, Murphy,
& McKnight, 2003). The subgroup analysis by gender in the future may provide better
explanation on this finding.
The findings in this study have some implications for future research and
intervention. From the perspective of research, the large variance in clinical outcomes
explained by psycho-behavioral factors indicated that these factors might be the
mechanisms underlying HIV-related stigma and clinical outcomes. What is more, the
differential impacts of psycho-behavioral factors on the three clinical outcomes implied
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that the psycho-behavioral mechanisms of stigma on clinical outcomes might be different
(Earnshaw & Chaudoir, 2009; Earnshaw et al., 2013). These mechanisms are worth
future investigation. In terms of intervention design, the differential impacts of HIVrelated stigma on the three clinical outcomes implied that stigma interventions should be
tailored to each clinical outcome. For instance, as internalized, anticipated, and enacted
stigma was negatively associated with HRQoL, stigma reduction intervention, such as
HIV-related public health education implemented at both intrapersonal and interpersonal
levels (Rao et al., 2019), might be effective in improving HRQoL directly. In contrast,
due to the non-significant relationships between HIV-related stigma and CD4 count and
viral suppression, stigma reduction interventions may not be enough to improve these
two outcomes. To improve immunologic and virologic outcomes effectively,
interventions targeting treatment-related self-efficacy, ART adherence, and psychological
distress (Areri, Marshall, & Harvey, 2020), such as skill training and stress management,
are also very important. Particularly, these interventions should be tailored to some
sociodemographic characteristics, such as marital status, types of residence, and age
group.
There are some limitations that need to be acknowledged in this study. First, we
used self-report measures to capture some of the key factors. Therefore, self-report bias
might exist. For instance, due to the social desirability bias, the percentage of optimal
ART adherence among PLWH in this study might be overestimated (Stirratt et al., 2015).
Second, we only included the three common types of HIV-related stigma used in prior
research (Earnshaw & Chaudoir, 2009; Earnshaw et al., 2013; Turan et al., 2017).
However, other types of HIV-related stigma, such as disclosure concerns and concern
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with public attitudes toward PLWH (Abdul Bari, 2017; Berger et al., 2001), were not
considered in this study. For instance, the measure of internalized stigma was derived
from the HIV Stigma Scale which also captures disclosure concerns (Berger et al., 2001).
The disclosure concerns may influence clinical outcomes through preventing disclosure
behaviors among PLWH and limiting their resource access as well as impeding
adherence behaviors (Omarzu, 2000; Qiao, Li, & Stanton, 2013). Third, this study only
included some well-investigated psycho-behavioral factors, such as ART self-efficacy,
HIV symptom management self-efficacy, ART adherence, depression, and anxiety.
However, other psycho-behavioral factors, such as positive coping and avoid coping, may
also contribute to clinical outcomes (Ironson et al., 2005). Fourth, only limited
percentages of variance in clinical outcomes explained by the independent variables. This
might be due to some confounders which were not controlled in the analysis. Future
research considering more potential confounders are needed. Fifth, PLWH in this study
were recruited from the hospitals/clinics. Therefore, they might have better clinical
outcomes and lower HIV-related stigma as compared to those who did not seek help in
the healthcare settings, which might influence the relationship between stigma and
clinical outcomes. Finally, as the participants were recruited from Guangxi, China,
cautions are needed when generalizing the findings from this study to other areas in
China or other cultural settings.
4.6 Conclusion
HIV-related stigma could explain additional information of clinical outcomes and
show different impacts. Future studies are called for investigating the psycho-behavioral
mechanisms of HIV-related stigma on clinical outcomes. To improve clinical outcomes
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among PLWH effectively, interventions are warrant to not only target HIV-related stigma
at both intrapersonal and interpersonal levels but also to promote resilience which could
alleviate the negative impacts of HIV-related stigma.
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Table 4.1 Sociodemographic characteristics of PLWH at baseline assessment
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Variables
Sample size
Age in years (Mean, SD)
Time since HIV diagnosis in years (Mean, SD)
Duration of ART in years (Mean, SD)
Gender
Male
Female
Marriage
Single/separated
Married/cohabitated
Divorced/widowed
Ethnicity
Han
Non-Han
Types of residence
City
County
Rural
Education attainment
Less than or equal to middle school
High school or above
Employment
Unemployed
Part time
Full time
Levels of monthly income
No more than 1,999 Yuan

Missing data (%)
0 (0.0)
0 (0.0)
66 (5.5)
0 (0.0)

N (%)
1,198 (100.0)
39.0 (±9.2)
5.5 (±3.1)
4.8 (±3.0)
771 (64.4)
427 (35.6)

12 (1.0)
360 (30.4)
666 (56.2)
160 (13.4)
1 (0.0)
778 (65.0)
419 (35.0)
3 (0.0)
536 (44.9)
231 (19.3)
428 (35.8)
0 (0.0)
719 (60.0)
479 (40.0)
9 (0.8)
220 (18.5)
235 (19.8)
734 (61.7)
3 (0.0)
370 (31.0)

2,000 ~ 3,999 Yuan
At least 4,000 Yuan
Transmission modes
Sexual activity
Others
Body Mass Index
Underweight
Normal/healthy weight
Overweight/obese

584 (48.9)
241 (20.2)
5 (0.4)
832 (69.7)
361 (30.3)
0 (0.0)
161 (13.4)
873 (72.9)
164 (13.7)
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Table 4.2 Changes of clinical outcomes and predictors among PLWH
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Variables
Baseline
6-month
12-month
Sample sizes (n, %)
1,198 (100.0) 1,197 (99.9) 1,163 (97.1)
Attrition rates (n, %)
1 (0.1)
35 (2.9)
Clinical outcomes
CD4 count (n, %)
Less than 500 cells/μl
658 (54.9)
657 (54.8)
656 (54.8)
500 cells/μl or more
540 (45.1)
541 (45.2)
542 (45.2)
Viral suppression (n, %)
Yes
1,130 (94.3)
1,145 (95.8) 1,109 (95.4)
No
68 (5.7)
50 (4.2)
54 (4.6)
Health-related quality of life (Mean, SD)
73.7 (±13.1)
71.2 (±13.4) 74.0 (±12.4)
Predictors
Internalized stigma (Mean, SD)
16.3 (±5.5)
17.0 (±5.0)
15.5 (±4.7)
Anticipated stigma (Mean, SD)
23.2 (±7.7)
22.6 (±7.2)
21.2 (±6.8)
Enacted stigma (Mean, SD)
0.9 (±2.1)
0.8 (±2.2)
0.4 (±1.3)
ART self-efficacy (Mean, SD)
24.5 (±5.0)
23.7 (±5.0)
24.5 (±5.0)
HIV symptom management self-efficacy (Mean, SD)
33.5 (±9.1)
34.1 (±7.5)
34.2 (±7.6)
Depression (Mean, SD)
6.6 (±4.7)
7.5 (±5.0)
7.0 (±4.7)
Anxiety (Mean, SD)
26.9 (±6.4)
27.5 (±6.9)
25.7 (±6.0)
ART adherence (n, %)
Optimal
963 (80.8)
981 (82.2)
983 (85.5)
Suboptimal
229 (19.2)
213 (17.8)
167 (14.5)
Note: SD: Standard deviation; a: Chi-square test; b: ANOVA; **: p < 0.01; ***: p < 0.001.

18-month
1,161 (96.9)
37 (3.1)

χ2/ F values
1.23a

635 (53.0)
563 (47.0)
18.16a***
1,135 (97.8)
26 (2.2)
72.1 (±13.3)
16.0 (±5.1)
22.0 (±7.1)
0.9 (±1.3)
24.2 (±5.3)
32.6 (±8.5)
7.1 (±5.0)
27.3 (±6.7)
928 (80.1)
230 (19.9)

11.50b***
18.28b***
15.89b***
16.41b***
6.08b***
9.94b***
7.45b***
18.24b***
13.38b**

Table 4.3 Bivariate analysis of longitudinal CD4 count
Variables
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Age in years
Time since HIV diagnosis in years
Duration of ART in years
Gender
Male
Female
Marital status
Single/separated
Married/cohabitated
Divorced/widowed
Ethnicity
Han
Non-Han
Types of residence
City
County
Rural
Education attainment
Less than or equal to middle school
High school or above
Employment
Unemployed
Part time
Full time

CD4 count (< 500 cells/μl vs. ≥ 500 cells/μl)
Crude OR (95%CI)
0.96 (0.95~0.97)
1.04 (1.01~1.07)
1.01 (0.98~1.05)

p-value
<0.001***
0.011*
0.421
<0.001***

0.72 (0.59~0.88)
Reference
0.006**
1.36 (1.10~1.70)
Reference
0.88 (0.65~1.18)
0.81 (0.66~0.99)
Reference

0.044*
<0.001***

2.18 (1.74~2.73)
1.78 (1.35~2.35)
Reference
<0.001***
Reference
1.64 (1.34~2.00)
0.107
Reference
0.93 (0.73~1.19)
1.13 (0.91~1.41)
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Levels of monthly income
No more than 1,999 RMB
Reference
2,000 ~ 3,999 RMB
1.06 (0.85~1.33)
At least 4,000 RMB
1.81 (1.37~2.39)
Transmission modes
Sexual activity
0.80 (0.64~0.99)
Others
Reference
Body Mass Index
Underweight
0.87 (0.68~1.12)
Normal/healthy weight
Reference
Overweight/obese
1.30 (0.99~1.70)
Internalized stigma
0.99 (0.98~1.01)
Anticipated stigma
1.00 (0.99~1.01)
Enacted stigma
0.98 (0.95~1.02)
ART self-efficacy
1.02 (1.01~1.04)
HIV symptom management self-efficacy
1.03 (1.02~1.04)
Depression
0.99 (0.98~1.01)
Anxiety
1.00 (0.99~1.01)
ART adherence (n, %)
Optimal
0.96 (0.80~1.15)
Suboptimal
Reference
Note: OR: Odds ratio; CI: Confidence interval; *: p < 0.05; **: p < 0.01; ***: p < 0.001.

<0.001***

0.041*

0.070

0.299
0.962
0.309
0.009**
0.001***
0.222
0.787
0.644

Table 4.4 Hierarchical generalized linear mixed model of CD4 count
Variables
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Step 1: Sociodemographic characteristics
Time
Age in years
Duration of ART in years
Gender
Male
Female
Marital status
Single/separated
Married/cohabitated
Divorced/widowed
Ethnicity
Han
Non-Han
Types of residence
City
County
Rural
Education attainment
Less than or equal to middle school
High school or above
Levels of monthly income
No more than 1,999 Yuan
2,000 ~ 3,999 Yuan
At least 4,000 Yuan

Model 1 (n=1,119)

AOR (95% CI)
Model 2 (n=1,073)

Model 3 (n=1,066)

1.04 (1.00~1.08)
0.71 (0.62~0.81)***
1.15 (1.03~1.29)*

1.05 (1.01~1.09)*
0.72 (0.63~0.83)***
1.18 (1.05~1.32)**

1.05 (1.01~1.09)*
0.72 (0.63~0.83)***
1.18 (1.05~1.33)**

0.60 (0.47~0.77)***

0.59 (0.46~0.76)***
Reference

0.59 (0.46~0.76)***

1.21 (0.90~1.62)

1.22 (0.91~1.64)
Reference
0.88 (0.63~1.23)

1.21 (0.90~1.63)

0.77 (0.62~0.96)*

0.77 (0.62~0.96)*
Reference

0.77 (0.62~0.96)*

1.60 (1.23~2.09)***
1.54 (1.14~2.09)**

1.52 (1.16~1.98)**
1.47 (1.08~2.00)*
Reference

1.52 (1.16~1.99)**
1.47 (1.08~2.01)*

0.87 (0.62~1.21)

0.88 (0.63~1.24)

1.27 (0.98~1.64)

Reference
1.24 (0.96~1.61)

1.23 (0.95~1.59)

1.10 (0.86~1.41)
1.34 (0.97~1.85)

Reference
1.09 (0.85~1.40)
1.31 (0.94~1.82)

1.08 (0.84~1.39)
1.28 (0.92~1.78)
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Transmission modes
Sexual activity
1.04 (0.82~1.32)
0.85 (0.66~1.08)
Others
Reference
Body Mass Index
Underweight
0.57 (0.44~0.73)***
0.75 (0.57~0.99)*
Normal/healthy weight
Reference
*
Overweight/obese
1.29 (1.05~1.58)
1.39 (1.04~1.87)*
Step 2: Psycho-behavioral factors
ART self-efficacy
1.00 (0.91~1.09)
HIV symptom management self-efficacy
1.17 (1.07~1.28)***
Depression
0.94 (0.84~1.05)
Anxiety
1.14 (1.01~1.27)*
ART adherence (n, %)
Optimal
0.99 (0.81~1.20)
Suboptimal
Reference
Step 3: HIV-related stigma
Internalized stigma
Anticipated stigma
Enacted stigma
2
Pseudo R
0.127
0.164
∆R2
0.037
Note: AOR: Adjusted odds ratio; CI: Confidence interval; *: p < 0.05; **: p < 0.01; ***: p < 0.001.

0.85 (0.66~1.09)
0.75 (0.57~1.00)*
1.39 (1.04~1.87)*
1.00 (0.92~1.09)
1.19 (1.08~1.30)***
0.92 (0.82~1.04)
1.14 (1.01~1.28)*
0.97 (0.80~1.19)

1.00 (0.91~1.10)
1.07 (0.97~1.17)
0.99 (0.91~1.08)
0.170
0.006

Table 4.5 Bivariate analysis of longitudinal viral suppression
Variables
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Age in years
Time since HIV diagnosis in years
Duration of ART in years
Gender
Male
Female
Marital status
Single/separated
Married/cohabitated
Divorced/widowed
Ethnicity
Han
Non-Han
Types of residence
City
County
Rural
Education attainment
Less than or equal to middle school
High school or above
Employment
Unemployed
Part time
Full time

Viral suppression (Yes vs. No)
Crude OR (95%CI)
0.97 (0.80~1.17)
1.39 (1.10~1.74)
1.18 (1.09, 1.28)

p-value
0.729
0.006**
<0.001***
0.962

0.99 (0.65~1.51)
Reference
0.835
0.88 (0.56~1.37)
Reference
0.91 (0.49~1.68)
0.244
1.28 (0.85~1.93)
Reference
0.079
1.59 (1.01~2.51)
1.13 (0.66~1.94)
Reference
0.108
Reference
1.42 (0.93~2.19)
0.712
Reference
1.11 (0.72~1.70)
0.96 (0.68~1.36)
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Levels of monthly income
No more than 1,999 RMB
Reference
2,000 ~ 3,999 RMB
0.83 (0.52~1.32)
At least 4,000 RMB
0.88 (0.49~1.58)
Transmission modes
Sexual activity
0.60 (0.38~0.96)
Others
Reference
Body Mass Index
Underweight
1.30 (0.75~2.26)
Normal/healthy weight
Reference
Overweight/obese
0.89 (0.53~1.50)
Internalized stigma
1.02 (0.88~1.18)
Anticipated stigma
1.03 (0.90~1.18)
Enacted stigma
0.96 (0.88~1.05)
ART self-efficacy
1.04 (1.01~1.07)
HIV symptom management self-efficacy
1.01 (0.99~1.03)
Depression
0.90 (0.78~1.03)
Anxiety
0.97 (0.80~1.17)
ART adherence (n, %)
Optimal
0.93 (0.64~1.34)
Suboptimal
Reference
Note: OR: Odds ratio; CI: Confidence interval; *: p < 0.05; **: p < 0.01; ***: p < 0.001.

0.726

0.031*

0.545

0.785
0.688
0.359
0.011*
0.161
0.118
0.729
0.685

Table 4.6 Hierarchical generalized linear mixed model of viral suppression
Variables

AOR (95% CI)
Model 2 (n=1,080)
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Model 1 (n=1,108)
Model 3 (n=1,073)
Step 1: Sociodemographic characteristics
Time
1.28 (1.13~1.46)***
1.32 (1.16~1.50)***
1.31 (1.15~1.49)***
***
***
Duration of ART in years
1.51 (1.18~1.92)
1.59 (1.23~2.05)
1.58 (1.22~2.04)***
Transmission modes
Sexual activity
0.70 (0.44~1.13)
0.68 (0.42~1.10)
0.70 (0.43~1.13)
Others
Reference
Types of Residence
City
1.51 (0.93~2.46)
1.53 (0.94~2.51)
1.68 (1.07~2.64)*
County
1.21 (0.71~2.08)
1.24 (0.72~2.16)
1.29 (0.73~2.26)
Rural
Reference
Step 2: Psycho-behavioral factors
ART self-efficacy
1.29 (1.10~1.51)**
1.32 (1.12~1.55)***
HIV symptom management self-efficacy
1.06 (0.89~1.26)
1.07 (0.90~1.28)
Depression
0.83 (0.68~1.01)†
0.82 (0.68~1.00)*
Anxiety
1.23 (0.99~1.54)
1.21 (0.96~1.53)
ART adherence (n, %)
Optimal
0.82 (0.54~1.25)
0.76 (0.49~1.17)
Suboptimal
Reference
Step 3: HIV-related stigma
Internalized stigma
0.98 (0.84~1.13)
Anticipated stigma
1.12 (0.94~1.33)
Enacted stigma
1.06 (0.92~1.23)
Pseudo R2
0.089
0.135
0.152
2
∆R
0.046
0.017
Note: AOR: Adjusted odds ratio; CI: Confidence interval; †: Marginal significance (0.05 ≤ p ≤ 0.06); *: p < 0.05; **: p < 0.01; ***: p
< 0.001.

Table 4.7 Bivariate analysis of longitudinal health-related quality of life
Variables
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Sociodemographic characteristics
Age in years
Time since HIV diagnosis in years
Duration of ART in years
Gender
Male
Female
Marital status
Single/separated
Married/cohabitated
Divorced/widowed
Ethnicity
Han
Non-Han
Types of residence
City
County
Rural
Education attainment
Less than or equal to middle school
High school or above
Employment
Unemployed
Part time
Full time

Health-related Quality of Life
Crude β (95%CI)

p-value

-0.31 (-0.88~0.27)
-0.18 (-0.76~0.39)
-0.13 (-0.72~0.46)

0.266
0.533
0.661

0.53 (-0.66~1.73)
Reference

0.383
0.004**

0.47 (-0.83~1.76)
Reference
-2.62 (-4.36~-0.88)
0.532
-0.38 (-1.59~0.82)
Reference
<0.001***
2.91 (1.63~4.18)
2.98 (1.37~4.58)
Reference
0.407
Reference
0.50 (-0.68~1.67)
<0.001***
Reference
-0.86 (-2.02~0.30)
3.28 (2.26~4.30)
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Levels of monthly income
No more than 1,999 RMB
Reference
2,000 ~ 3,999 RMB
1.61 (0.32~2.90)
At least 4,000 RMB
5.76 (4.15~7.37)
Transmission modes
Sexual activity
1.96 (0.71~3.20)
Others
Reference
Body Mass Index
Underweight
-0.41 (-1.72~0.91)
Normal/healthy weight
Reference
Overweight/obese
0.91 (-0.42~2.24)
Predictors
Internalized stigma
-4.85 (-5.19~-4.51)
Anticipated stigma
-4.22 (-4.56~-3.87)
Enacted stigma
-4.48 (-4.81~-4.15)
ART self-efficacy
5.02 (4.68~5.36)
HIV symptom management self-efficacy
4.43 (4.07~4.79)
Depression
-8.74 (-9.01~-8.48)
Anxiety
-8.56 (-8.85~-8.28)
ART adherence (n, %)
Optimal
4.42 (3.53~5.30)
Suboptimal
Reference
CD4 count (n, %)
Less than 500 cells/μl
Reference
500 cells/μl or more
0.80 (-0.06~1.66)
Note: CI: Confidence interval; *: p < 0.05; **: p < 0.01; ***: p < 0.001.

<0.001***

0.002**

0.310

<0.001***
<0.001***
<0.001***
<0.001***
<0.001***
<0.001***
<0.001***
<0.001***
0.068

Table 4.8 Hierarchical generalized linear mixed model of health-related quality of life
Variables
Model 1 (n=1,113)
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Step 1: Sociodemographic
characteristics
Time
Age
Time since HIV diagnosis
Marital status
Single/separated
Married/cohabitated
Divorced/widowed
Types of residence
City
County
Rural
Employment
Unemployed
Part time
Full time
Levels of monthly income
No more than 1,999 RMB
2,000 ~ 3,999 RMB
At least 4,000 RMB
Transmission modes
Sexual activity
Others

Adjusted β (95%CI)
Model 2 (n=1,090)
Model 3 (n=1,083)

-0.25 (-0.51~0.01)†
0.62 (-0.03~1.27)
-0.02 (-0.60~0.57)

-0.21 (-0.40~-0.03)*
-0.19 (-0.56~0.18)
-0.19 (-0.52~0.14)

-0.19 (-0.37~0.00)*
-0.07 (-0.43~0.30)
-0.17 (-0.50~0.15)

-0.50 (-1.94~0.95)

-0.42 (-1.23~0.39)
Reference
-1.17 (-2.12~-0.22)*

-0.38 (-1.19~0.43)

-0.25 (-1.02~0.52)
-0.42 (-1.32~0.48)
Reference

-0.13 (-0.89~0.64)
-0.17 (-1.06~0.72)

-2.60 (-4.29~-0.91)**
2.15 (0.80~3.50)**
2.88 (1.29~4.47)***

-1.27 (-2.21~-0.33)**

-0.92 (-2.08~0.26)
3.01 (1.97~4.05)***

Reference
-0.29 (-1.08~0.50)
1.82 (1.12~2.51)***

-0.28 (-1.07~0.50)
1.87 (1.18~2.56)***

0.69 (-0.62~2.01)
3.81 (2.10~5.53)***

Reference
0.52 (0.11~1.59)*
1.15 (0.18~2.12)*

0.77 (0.03~1.51)*
1.19 (0.23~2.16)*

1.43 (0.18~2.67)*

0.87 (0.17~1.57)*
Reference

0.84 (0.15~1.54)*
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CD4 count
Less than 500 cells/μl
0.51 (-0.36~1.38)
500 cells/μl or above
Step 2: Psycho-behavioral factors
ART self-efficacy
HIV symptom management self-efficacy
Depression
Anxiety
ART adherence (n, %)
Optimal
Suboptimal
Step 3: HIV-related stigma
Internalized stigma
Anticipated stigma
Enacted stigma
2
Pseudo R
0.029
∆R2
Note: CI: Confidence interval; *: p < 0.05; **: p < 0.01; ***: p < 0.001.

0.28 (-0.28~0.83)
Reference
1.72 (1.45~2.00)***
1.16 (0.87~1.44)***
-4.90 (-5.26~-4.55)***
-4.06 (-4.41~-3.70)***
0.63 (0.00~1.26)*
Reference
0.148
0.119

0.33 (-0.22~0.88)
1.49 (1.21~1.77)***
0.83 (0.54~1.12)***
-4.32 (-4.68~-3.96)***
-3.83 (-4.19~-3.48)***
0.56 (-0.06~1.18)
-0.78 (-1.07~-0.49)***
-0.84 (-1.12~-0.55)***
-0.83 (-1.10~-0.56)***
0.158
0.010
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Figure 4.1 Change of CD4 count among PLWH
Note: PLWH: People living with HIV; Low: CD4 count less than 500 copies/μl; High:
CD4 count equal to or higher than 500 copies/μl.
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Figure 4.2 Change of viral suppression among PLWH
Note: PLWH: People living with HIV; No: Viral non-suppressed; Yes: Viral suppressed.
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Figure 4.3 Change of HRQoL among PLWH
Note: PLWH: People living with HIV; HRQoL: Health-related quality of life.
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Figure 4.4 Changes of internalized, anticipated, and enacted stigma among PLWH
Note: PLWH: People living with HIV.
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Note: PLWH: People living with HIV.
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Note: PLWH: People living with HIV.
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CHAPTER 5
LONGITUDINAL PSYCHO-BEHAVIORAL MECHANISMS OF
INTERNALIZED, ANTICIPATED, AND ENACTED STIGMA ON
CLINICAL OUTCOMES AMONG PLWH: A PROSPECTIVE COHORT
STUDY
5.1 Abstract
Prior research suggested the different mechanisms of internalized, anticipated,
and enacted stigma on clinical outcomes among people living with HIV (PLWH).
However, currently few studies examined these mechanisms from a longitudinal
perspective, especially for those from resource-limited settings. Based on the Health
Stigma Framework, this study leveraged data from a prospective cohort and longitudinal
mediation analysis to test the psycho-behavioral mechanisms of HIV-related stigma on
clinical outcomes among PLWH in Guangxi, China.
Data were derived from a prospective cohort among PLWH which was conducted
in Guangxi, China. The primary outcomes were CD4 count, viral suppression, and healthrelated quality of life (HRQoL). Latent growth curve modelling was employed to test the
mediating effects of psycho-behavioral factors (i.e., ART self-efficacy, HIV symptom
management self-efficacy, ART adherence) between each type of stigma and clinical
outcomes.
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None of the three types of stigma had direct impacts on CD4 count and viral
suppression, but the direct impacts of internalized (β = -0.184, 95% Confidence Interval
[CI]: -0.264 ~ -0.104) and enacted stigma (β = -0.302, 95% CI: -0.431 ~ -0.173) were
found in HRQoL. ART self-efficacy, HIV symptom management self-efficacy, and ART
adherence could mediate the indirect pathways from HIV-related stigma to viral
suppression but these effects were not found for CD4 count. ART self-efficacy could
consistently mediate the impacts of the three types of stigma on HRQoL but the
mediating effect of HIV symptom management self-efficacy was only found in the
pathway between anticipated stigma and HRQoL (β = -0.062, 95% CI: -0.086 ~ -0.037).
Across the three types of HIV-related stigma, ART self-efficacy could consistently
mediate their impacts on ART adherence. Similarly, only anticipated stigma could affect
ART adherence through reducing HIV symptom management self-efficacy (β = -0.005,
95% CI: -0.010 ~ 0.000).
The psycho-behavioral mechanisms were different by different types of HIVrelated stigma and clinical outcomes. Future stigma research should consider the
characteristics of each type of HIV-related stigma and clinical outcomes and use the
relevant theoretical knowledge to frame the pathways between them. Interventions
aiming to improve clinical outcomes should be tailored to internalized, anticipated, and
enacted stigma and target the relevant psycho-behavioral pathways.
5.2 Introduction
HIV-related stigma refers to devaluing, shaming, and prejudice towards people
living with HIV (PLWH) (Chollier, Tomkinson, & Philibert, 2016; Herek, 2016). Stigma
is a major barrier to efforts to control the global HIV epidemic. As a social phenomenon,
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HIV-related stigma exists when labeling, stereotype, and discrimination occur in a power
structure (Earnshaw & Chaudoir, 2009; Earnshaw, Smith, Chaudoir, Amico, &
Copenhaver, 2013). It could induce social inequalities and influence the health of PLWH.
A large body of evidence has demonstrated that HIV-related stigma is closely associated
with psychological distress and risk behaviors (Logie & Gadalla, 2009; Tavakkoli et al.,
2014), and it is also an impediment to disclosure, treatment adherence, and healthcare
access (Chollier et al., 2016; Katz et al., 2013; Sweeney & Vanable, 2016). These
negative impacts impair the psychological and physical wellbeing of PLWH.
Clinical outcomes, such as CD4 count, viral load, and health-related quality of life
(HRQoL), are important indicators for evaluating treatment efficacy, as well as
psychological and physical wellbeing of PLWH. CD4 count and viral load are critical
indictors reflecting immunologic functioning and viral suppression (Bentwich, 2005;
Marsh et al., 2019). Low CD4 count and high viral load speed up the disease progression
and increase the risk of opportunistic infection in PLWH. PLWH who have normal
immunologic functioning and who have achieved viral suppression still need to cope with
other challenges, such as psychological distress, potential side effect of antiretroviral
therapy (ART), and comorbidities. Therefore, HRQoL is a comprehensive construct
reflecting health quality (Andersson et al., 2020; Lazarus et al., 2016; Webster, 2019). It
assesses the disease burden across four main dimensions including psychological health,
physical health, social functioning, and perception about general health (Ashing-Giwa,
2005; Ruiz Perez et al., 2005; Wu, Hays, Kelly, Malitz, & Bozzette, 1997).
Prior research conceptualized the mechanisms underlying HIV-related stigma and
clinical outcomes, especially for the different types of HIV-related stigma (Earnshaw &
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Chaudoir, 2009; Earnshaw et al., 2013; Turan et al., 2017). According to the Health
Stigma Framework, HIV-related stigma can be categorized as internalized, anticipated,
and enacted stigma (Earnshaw & Chaudoir, 2009; Earnshaw et al., 2013; Turan et al.,
2017). Internalized stigma refers to internalized shame and is the recognition of stigma
about oneself (Quinn & Earnshaw, 2011; Sayles, Wong, Kinsler, Martins, &
Cunningham, 2009). Anticipated stigma is the belief of being discriminated among
PLWH if others know their HIV status (Quinn & Earnshaw, 2011). Enacted stigma is the
actual experience of being stigmatized among PLWH after their HIV status is known by
others (Quinn & Earnshaw, 2011). The three types of HIV-related stigma impair clinical
outcomes through affective and/or behavioral problems (Earnshaw & Chaudoir, 2009;
Earnshaw et al., 2013; Turan et al., 2017).
Two well-investigated psycho-behavioral mechanisms of HIV-related stigma on
clinical outcomes are psychological distress and ART adherence, and these mechanisms
might be different across various levels of internalized, anticipated, and enacted stigma.
For instance, the overall HIV-related stigma could negatively affect CD4 count through
its impacts on depressive symptoms and ART adherence (Logie et al., 2019; Rao et al.,
2012; Wang et al., 2009; Wood et al., 2004). In a test of Health Stigma Framework,
Earnshaw and colleagues found that internalized, anticipated, and enacted stigma had
different impacts on psychological, behavioral, and physical health outcomes (Earnshaw
et al., 2013). Internalized stigma was closely associated with psychological wellbeing and
treatment-related behaviors (e.g., medical visit, ART adherence) but not with
comorbidities and CD4 count (Earnshaw & Chaudoir, 2009; Earnshaw et al., 2013). In
contrast, anticipated and enacted stigma are the expectation and experiences of being

115

stigmatized by others (Earnshaw & Chaudoir, 2009), and they were significantly related
to treatment-related behaviors, comorbidities, and CD4 count but not to psychological
wellbeing (Earnshaw et al., 2013). The findings suggested that the mediators between
internalized, anticipated, enacted stigma and clinical outcomes might be different, and
studies are needed to confirm these mechanisms. Additionally, most previous studies
only investigated how HIV-related stigma influences clinical outcomes through the
impacts on psychological distress. These studies might ignore the importance of
psychological resources, especially for the treatment-related psychological resources
(Turan et al., 2017).
Psychological resources, such as treatment-related self-efficacy, are important
mechanisms through which HIV-related stigma may impact clinical outcomes (Turan et
al., 2017). Psychological resources refer to the tools, skills, confidences, and motivations
that PLWH use to cope with stressful events, keep daily routines, and maintain their
health (Turan et al., 2017). HIV-related stigma may cause PLWH to believe that they are
less capable and confident in dealing with treatment-related issues (i.e., medical visits,
adherence behaviors), which may result in low self-efficacy related to ART adherence
and suboptimal clinical outcomes (Seghatol-Eslami et al., 2017). For instance, using
cross-sectional data, our research team found that the indirect effect from anticipated
stigma to ART adherence through ART self-efficacy was significant (Zeng et al., 2020).
However, limited studies have investigated the mechanisms of HIV-related stigma on
clinical outcomes through psychological resources from a longitudinal perspective.
To address these knowledge gaps, the current study aims to examine the psychobehavioral mechanisms of three types of HIV-related stigma (i.e., internalized,
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anticipated, enacted stigma) on clinical outcomes using data derived from a prospective
cohort study in Guangxi, China. Guangxi, a resource-limited province located in the
southern China, was ranked third across the 31 provinces in terms of the total number of
HIV cases (Wu, Chen, Scott, & McGoogan, 2019). The HIV epidemic in Guangxi could
be described as a rural phenomenon with large number of PLWH living in rural areas,
from low socioeconomic status, and being infected mostly through sexual activity (Wang,
2013; Yang et al., 2019). Therefore, PLWH in Guangxi are at risk of HIV-related stigma
and suboptimal clinical outcomes because of the traditional culture, limited HIV
knowledge, and local HIV transmission patterns. Based on the Health Stigma
Framework, we developed a conceptual model (Figure 4.8) and hypothesized that: (1) all
three types of HIV-related stigma could influence clinical outcomes directly and
indirectly; and (2) the psycho-behavioral mechanisms of stigma on clinical outcomes
would be different by internalized, anticipated, and enacted stigma. Particularly, ART
self-efficacy, HIV symptom management self-efficacy, and ART adherence were the
psycho-behavioral mechanisms tested in this study.
5.3 Methods
Study setting and participants
Data derived from a prospective cohort study was used to accomplish the aims of
this study. The original cohort was developed in Guangxi, China in November 2017.
Using a systematic sampling approach, PLWH were recruited from six major public
hospitals/clinics in five cities with largest number of HIV patients under care. PLWH
who were aged between 18 and 60 years old, had a confirmed diagnosis of HIV, and had
no plans to relocate outside of Guangxi in the next 12- month were considered as the
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eligible participants. Those who had mental/physical inabilities to finish the survey
and/or who were currently incarcerated/institutionalized were excluded from the study.
Recruitment and data collection
The recruitment and data collection for this parent study have been described in
detail elsewhere (Zeng et al., 2020). Briefly, once eligible PLWH were selected, local
research assistants confirmed the patients for eligibility, scheduled a time to introduce the
cohort study, and invited them to participate. After obtaining their written informed
consent, research assistants had a one-on-one interview with patient in a private room of
hospitals/clinics. Interviewers described the purpose of the assessment, assured
participants of their confidentiality, and introduced the study aims and questionnaire. The
interviewers provided assistance during the survey when needed. With an estimated 5%
refusal rate, a total of 1,198 PLWH were recruited and finished the baseline assessment
from November 2017 to February 2018. PLWH were followed up at 6-, 12-, 18-, 24-, 30, and 36- months. Longitudinal data at baseline, 6-, 12-, and 18-month follow-ups were
used in this study. Upon the completion of each assessment, all participants received a
gift (e.g., household items) equivalent to US$ 5.00. The study protocol was approved by
the Institutional Review Boards at both University of South Carolina in the United States
and Guangxi CDC in China.
Measures
Clinical outcomes
Clinical outcomes included CD4 count, viral suppression, and HRQoL. Both CD4
count and viral load were retrieved from PLWH’s electronic health records. Using 500
cells/µl as a cutoff (U.S. Department of Health and Human Services & Panel on

118

Antiretroviral Guidelines for Adults and Adolescents, 2017), CD4 count was categorized
as a binary variable to evaluate the normal immunologic functioning. Viral suppression
was defined as viral load less than or equal to 50 copies/ml in PLWH’s plasma (Center
for Disease Control and Prevention [CDC], 2018).
HRQoL was assessed using the 35- item Medical Outcomes Study HIV Health
Survey (MOS-HIV) (Wu et al., 1997). It covered 11 dimensions of health quality
including general health perception, physical functioning, role functioning, social
functioning, cognitive functioning, pain, mental health, energy/fatigue, health distress,
quality of life, and health transition. The score of each dimension was calculated and
transformed to a score ranging from 0 to 100 (Delate & Coons, 2001; Hays & Shapiro,
1992; Ware & Sherbourne, 1992; Wu et al., 1997). The final score was the sum score of
the 11- dimension and then transformed using the same method. A higher score of
HRQoL indicated a higher level of HRQoL. The MOS-HIV scale showed good reliability
among the participants in this study (Cronbach’s alpha = 0.93).
Sociodemographic characteristics
Sociodemographic characteristics at baseline were used in this study. These
characteristics included age, gender, marital status, ethnicity, types of residence,
education attainment, employment, levels of monthly income, weight, and height. Weight
and height were used to calculate body mass index (BMI), which was categorized as
underweight (less than 18.5), normal/healthy weight (18.5 ~ 24.9), or overweight/obese
(more than 24.9). HIV-related characteristics, such as time since HIV diagnosis, duration
of ART, and transmission modes, were also included in the current study.
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HIV-related stigma
Three common types of HIV-related stigma (i.e., internalized, anticipated, enacted
stigma) were used in this study. Internalized stigma was measured using 8- item derived
from the Berger HIV Stigma Scale (Berger, Ferrans, & Lashley, 2001), which captured
“negative self-image” among PLWH. Anticipated stigma was assessed using 9- item
derived from the Health Stigma Framework (Earnshaw et al., 2013). It evaluated the
expectation of HIV-related stigma from family members, as well as in community and
healthcare settings. Enacted stigma was evaluated using the 16-item checklist adapted
from a previous study (Yi et al., 2015), which asked PLWH about their experiences of
being stigmatized due to their HIV status in the last six months. The sum score of each
type of HIV-related stigma was calculated, with a higher score indicating a higher level
of stigma. All of these scales had good reliability at baseline (internalized stigma:
Cronbach’s alpha = 0.94; anticipated stigma: Cronbach’s alpha=0.92; enacted stigma:
Cronbach’s alpha = 0.89). As most of the PLWH reported that they did not have any
overt experiences of being stigmatized (n = 846 [71.3%] at baseline), enacted stigma was
categorized as a binary variable to define stigmatized experiences (0 = no, 1 = yes) using
zero as a cutoff.
Psycho-behavioral mediators
Psycho-behavioral mediators included in this study were ART self-efficacy, HIV
symptom management self-efficacy, and ART adherence. ART self-efficacy was
measured using the 10- item scale adapted from the Self-efficacy for Appropriate
Medication Use Scale (SEAMS) (Risser, Jacobson, & Kripalani, 2007; Zhang et al.,
2016). HIV symptom management self-efficacy was measured using six items from the
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Self-efficacy for Managing Chronic Disease Scale (Eller et al., 2014) and four items
about participants’ confidence in symptom management (Lorig, Sobel, Ritter, Laurent, &
Hobbs, 2001). The sum score of each self-efficacy was calculated according to relevant
guidelines. A high score indicated a higher level of self-efficacy. Both of these two scales
had good reliability at baseline (ART self-efficacy: Cronbach’s alpha = 0.95; HIV
symptom management self-efficacy: Cronbach’s alpha = 0.96).
ART adherence was measured using five items adapted from the Adult AIDS
Clinical Trials Group (AACTG) adherence instrument. Four items were used to ask
PLWH about the days of completing their prescribed ART doses within four specified
timeframes (last three days, last weekend, last two weeks, last month [30 days]).
Percentage adherence of each timeframe was calculated based on a previous study (Da,
Li, Qiao, Zhou, & Shen, 2018). Then, the percentage was categorized as a binary variable
(0: < 90.0%; 1: ≥ 90%) according to the Chinese guideline for ART treatment. The fifth
item was used to ask PLWH whether they adhered to their prescribed doses (1 = always,
2 = very often, 3 = sometimes, 4 = rarely, 5 = never). Participants who always adhered to
their prescription were coded as “yes (1)” while others were coded as “no (0)”. The sum
score of these five items was calculated. PLWH who scored five were considered as
having optimal adherence to ART. The adherence measures showed acceptable reliability
at baseline (Cronbach’s alpha = 0.72).
Psychological confounders
Depression and anxiety at baseline were controlled for as potential psychological
confounders in this study. Depression was assessed using the 10- item Center for
Epidemiologic Studies-Depression (CES-D 10) Scale, which had been validated in
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Chinese population (Yu, Lin, & Hsu, 2013). The Cronbach’s alpha of this scale was 0.85
at baseline assessment. Anxiety was measured using the Brief Anxiety Scale (Zung,
1971), which also had been validated in Chinese culture (Zhang, Liu, Li, Mao, & Yuan,
2015). The original scale included 20 items, which asked PLWH about their feelings of
anxiety disorder during last week. However, due to translation, two items (“My hands are
usually dry and warm”, “I fall asleep easily and get a good night’s rest”) could not reflect
their original meanings, which resulted in Cronbach’s alpha of 0.80 in the overall scale.
According to the exploratory factor analysis, the reliability was significantly improved
after deleting these two items (Cronbach’s alpha = 0.88). The sum score of each scale
was generated. PLWH with higher scores in these two scales had higher levels of
psychological distress.
Statistical analysis
Statistical analysis included descriptive statistics, latent growth curve modelling
(LGCM), bivariate analysis, and mediation analysis. First, sociodemographic
characteristics were described using mean (standard deviation [SD]) for continuous
variables and frequency (percentage [%]) for categorical variables.
Second, measurement models of all key variables in conceptual model were
constructed using unconditional LGCM. As this study focused on examining the
longitudinal mediating effects of psycho-behavioral mediators, the changes of all
variables of interest were defined as linear trend (time scores: 0, 1, 2, 3). What is more,
using linear trend to define change patterns could reduce the risk of model
misidentification. LGCM with continuous outcomes were used for internalized stigma,
anticipated stigma, ART self-efficacy, HIV symptom management self-efficacy, and
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HRQoL while LGCM with binary outcomes were used for enacted stigma, ART
adherence, CD4 count, and viral suppression. In the process of LGCM with binary
outcomes, logit link function was specified. Multiple indices, such as χ2, χ2/degree of
freedom (df), p-value, Comparative Fit Index (CFI), Tucker-Lewis Index (TLI), Root
Mean Square Error of Approximation (RMSEA), and Standardized Root Mean Residual
(SRMR), were used to evaluate the model fit of each measurement model. For continuous
variables, smaller χ2 value, χ2/df ≤ 3.00, p > 0.05, CFI > 0.95, TLI > 0.95, RMSEA ≤
0.06, and SRMR ≤ 0.08 indicated better model fit (Hu & Bentler, 1999; Muthen &
Muthen, 2018). In terms of binary variables, smaller χ2 value, χ2/df ≤ 3.00, p > 0.05
indicated better model fit (Muthen & Muthen, 2018; Schermelleh-Engel, Moosbrugger,
& Müller, 2003). Mean and standard error (SE) were used to describe intercept and slope
while r was used to describe the correlation between them. Since all continuous variables
were not in normal distribution, using their original values to construct measurement
models could not obtain good model fits and capture the information of all participants.
With the consideration of interpretation, standardized transformation was employed to reestimate the intercepts and slopes of all continuous variables before mediation analysis.
Third, the estimated intercepts and slopes of all key variables in conceptual model
were output for bivariate analysis. Spearman correlation analysis was used to examine the
correlations among intercepts or slopes of all key variables. Bivariate analyses of the
slopes of clinical outcomes (i.e., CD4 count, viral suppression, HRQoL) and
sociodemographic characteristics and psychological confounders were conducted.
Spearman correlation analysis was used for examining the correlations between
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continuous variables while Wilcoxon rank-sum test or Kruskal-Wallis test were used for
the relationships between slopes and categorical variables.
Finally, intercepts and slopes of all key variables were used for mediation analysis
after adjusting for covariates with p-values less than 0.05 in bivariate analyses. First of
all, intercept and slope were specified as correlating with each other for each key
variable, and path model was constructed based on the conceptual model. Moreover, to
improve model fit, based on the model trimming strategy (Ullman, 2001), paths with nonsignificant p-values were deleted. Furthermore, path model was modified to improve the
model fit based on the modification indices and theoretical knowledge (Ullman, 2001; J.
Wang & Wang, 2019). Path coefficient and its 95% confidence interval (CI),
standardized coefficient, and p-value were reported. Finally, longitudinal mediating
effects from the slopes of HIV-related stigma to those of clinical outcomes through the
slopes of psycho-behavioral mediators were tested using bias-corrected bootstrap
procedure based 1,000 bootstrap samples (Wang & Wang, 2019). Bias-corrected 95%CI
of the indirect paths were reported (MacKinnon, Lockwood, Hoffman, West, & Sheets,
2002). Delta z score was used as a statistics to evaluate indirect effects (Muthen &
Muthen, 2018). Robust maximum likelihood estimation (estimator = MLR) was used to
estimate the parameters, and full information maximum likelihood (FIML) estimation
approach was used to handle missing data. Same indices, such as χ2, χ2/df, p-values, CFI,
TLI, RMSEA, and SRMR, were used to assess the model fit.
Bivariate analyses were performed using SAS software version 9.4 (SAS Institute,
Inc., Cary, NC). LGCM and mediation analysis were performed using Mplus version 7.0
(Muthen & Muthen, Los Angeles, CA).
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5.4 Results
Descriptive statistics
Among the 1,198 PLWH, the average age and time since HIV diagnosis were
39.0 (SD = 9.2) and 5.5 (SD = 3.1), respectively. More than 60.0% of them were male
(771 [64.4%]) and/or infected through sexual activity (832 [69.7%]). There were 72.9%
(873/1,198) of the participants in normal/healthy weight. Table 5.1 shows detailed
information of sociodemographic characteristics among participants at baseline.
Table 5.2 shows descriptive statistics of key factors in conceptual model across
the four-wave datasets. The average attrition rate of these four-wave datasets was less
than 5.0%. Nearly 45.0% of participants had CD4 counts equal to or higher than 500
cells/μl, and 95.0% of participants had achieved viral suppression. The average score of
HRQoL across the four-wave follow-up was higher than 70.0 out of 100.0.
The percentages of PLWH who had experiences of being stigmatized for each
assessment were 28.7% (341/1,187), 21.6% (258/1,195), 16.6% (193/1,159), and 22.4%
(260/1,158), respectively. More than 80.0% of the PLWH at each assessment had optimal
self-report ART adherence.
Measurement models
Results of unconditional LGCM revealed that the measurement models of
categorical outcomes (i.e., enacted stigma, ART adherence, CD4 count, viral
suppression) were good except that of CD4 count. The mean values of these variables
reflected the log probabilities of having stigmatized experiences, optimal adherence,
normal CD4 count, and viral suppression among PLWH at baseline assessment. Only the
slopes of enacted stigma and CD4 count were statistically significant, which suggested
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that there were significant changes in the probabilities of stigmatized experiences (slope
= -0.224, p < 0.01) and normal CD4 count (slope = 0.140, p < 0.05) across the time.
In terms of the continuous variables (i.e., internalized stigma, anticipated stigma,
ART self-efficacy, HIV symptom management self-efficacy, HRQoL), the measurement
models had adequate model fits except that of internalized stigma (χ2/df =14.846,
RMSEA=0.108, CFI = 0.876, TLI = 0.851, SRMR = 0.059). The intercepts of these
continuous variables reflected their initial levels among PLWH at baseline. Only the
slopes of internalized stigma (slope = -0.237, p < 0.001), anticipated stigma (slope = 0.476, p < 0.001), and HIV symptoms management self-efficacy (slope = -0.324, p <
0.001) were statistically significant, which meant that these factors had significant
changes over time. The unsatisfied model fits in continuous variables suggested that
transformation was needed before the mediation analysis. After standardization, all of the
measurement models had good model fits. Table 5.3 shows the model fits of
measurement models before and after standardization, and Table 5.4 shows the parameter
estimation of each measurement model.
Bivariate analysis
Table 5.5 shows the correlation matrices of intercepts and slopes among variables
of interest. The correlation matrix of intercepts found that the intercept of internalized
stigma was significantly and negatively associated with that of HRQoL (r = -0.48) but
not with those of CD4 count (r = 0.01) and viral suppression (r = -0.01). Similar findings
could be found in the relationships between the intercepts of anticipated stigma, CD4
count, viral suppression, and HRQoL. The intercept of enacted stigma was significantly
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and negatively related to those of CD4 count (r = -0.07), viral suppression (r = -0.06),
and HRQoL (r = -0.31).
Correlation matrix of slopes found that all slopes of internalized (r = -0.33),
anticipated (r = -0.25), and enacted stigma (r = -0.22) were significantly and negatively
associated with that of HRQoL, but only the slope of internalized stigma was
significantly correlated with that of CD4 count (r = 0.08). No significant relationships
were found between the slopes of all three HIV-related stigma and that of viral
suppression. Unexpectedly, the slope of HIV symptom management self-efficacy was
negatively related to the slope of CD4 count (r = -0.07, p < 0.05).
Tables 5.6, 5.7, and 5.8 show the bivariate analyses of the slopes of CD4 count,
viral suppression, and HRQoL, respectively. Significant relationships were found in the
slope of CD4 count and age, time since HIV diagnosis, duration of ART, gender,
ethnicity, types of residence, education attainment, transmission modes, depression, and
anxiety at baseline. The slope of viral suppression was significantly associated with
baseline time since HIV diagnosis, duration of ART, and depression. In terms of HRQoL,
only marital status, transmission modes, depression, and anxiety were significantly
associated with the slope of HRQoL.
Path model and mediation analysis
CD4 count
After adjusting for covariates with p-values less than 0.05 in bivariate analysis,
path model with CD4 count as a primary outcome was constructed based on the
conceptual model. Model fit indices revealed that the original model did not have a good
model fit (χ2/df = 11.282, p < 0.001, RMSEA = 0.093, CFI = 0.665, TLI = 0.654, SRMR =
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0.090). Using model trimming strategy, insignificant paths were deleted (Appendix C).
The model fit did not have significant change (χ2/df = 15.218, p < 0.001, RMSEA = 0.109,
CFI = 0.678, TLI = 0.657, SRMR = 0.108). Based on the modification indices (Appendix
D) and theoretical knowledge, correlations among the intercepts of key variables were
added to the existing model, and the model fit had significant improvement (χ2/df =
5.506, p < 0.001, RMSEA = 0.061, CFI = 0.922, TLI = 0.891, SRMR = 0.062) (Table 5.9).
Table 5.10 shows the coefficients of final model with CD4 count as an outcome.
The slope of ART adherence was negatively associated with the slope of CD4 count (β =
-0.058, p = 0.034). The positive change of ART adherence led to negative change in CD4
count. The slopes of all three types of HIV-related stigma were negatively associated
with that of ART self-efficacy (internalized stigma: β = -0.114, p < 0.001; anticipated
stigma: β = -0.123, p < 0.001; enacted stigma: β = -0.197, p < 0.001). These implied that
the increases of internalized, anticipated, and enacted stigma led to the decrease of ART
self-efficacy. The slope of HIV symptom management self-efficacy was significantly
related to the slope of anticipated stigma (β = -0.062, p < 0.001) but not to that of
internalized stigma (β = -0.012, p = 0.199). This path implied that only the increase of
anticipated stigma could result in the decrease of HIV symptom management selfefficacy. The slope of ART adherence was negatively associated with that of enacted
stigma (β = -0.057, p = 0.005) and positively related to the slopes of ART self-efficacy (β
= 0.066, p < 0.001) and HIV symptom management self-efficacy (β = 0.079, p = 0.045).
Result of mediation analysis found that none of the indirect paths from the slopes
of HIV-related stigma to that of CD4 count were statistically significant. However,
significant indirect effects from the slopes of HIV-related stigma to the slope of ART
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adherence were found in the final model. The increases of internalized (β = -0.007, delta
z = -3.031, p = 0.002), anticipated (β = -0.008, delta z = -3.371, p = 0.001), and enacted
stigma (β = -0.013, delta z = -3.312, p = 0.001) resulted in the decreases of ART
adherence through reducing the changes of ART self-efficacy. Table 5.11 shows detailed
results of mediation analysis of CD4 count.
Viral suppression
A path model with viral suppression as an outcome was constructed based on the
conceptual model after adjusting for the significant covariates in bivariate analysis. The
original model did not have a good model fit (χ2/df = 18.841, p < 0.001, RMSEA = 0.122,
CFI = 0.763, TLI = 0.711, SRMR = 0.111) (Table 5.9). Insignificant paths were deleted
based on the model trimming strategy (Appendix C). However, the model fit did not have
significant improvement (χ2/df = 17.393, p < 0.001, RMSEA = 0.117, CFI = 0.763, TLI =
0.734, SRMR = 0.111). The final model had good model fit (χ2/df = 5.248, p < 0.001,
RMSEA = 0.060, CFI = 0.946, TLI = 0.924, SRMR = 0.059) after adding the correlations
among the intercepts of key variables based on the modification indices and theoretical
knowledge.
Table 5.12 shows the coefficients of the final model. The change of ART
adherence could negatively influence the change of viral suppression (β = -0.035, p =
0.003). The slopes of internalized (β = -0.112, p < 0.001), anticipated (β = -0.123, p <
0.001), and enacted stigma (β = -0.196, p < 0.001) was negatively associated with that of
ART self-efficacy. The change of HIV symptom management self-efficacy was
significantly related to the change of anticipated stigma (β = -0.061, p < 0.001) but not to
that of internalized stigma (β = -0.012, p = 0.210). The slope of ART adherence was
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negatively associated with that of enacted stigma (β = -0.056, p = 0.005) and positively
related to the slopes of ART self-efficacy (β = 0.066, p < 0.001) and HIV symptom
management self-efficacy (β = 0.080, p = 0.045).
Results of mediation analysis found that the series mediating effect from the
slopes of HIV-related stigma, ART self-efficacy, ART adherence to that of viral
suppression were statistically significant (internalized stigma: β = 0.000, delta z = 2.125,
p = 0.034; anticipated stigma: β = 0.000, delta z = 2.269, p = 0.023; enacted stigma: β =
0.000, delta z = 2.118, p = 0.034). The increases of HIV-related stigma resulted in the
decrease of ART self-efficacy, which in turn led to the decrease of ART adherence. The
decrease of ART adherence resulted in the increase of viral suppression. However, the
effect sizes of these indirect paths were close to zero. The changes of internalized (β = 0.007, delta z = -3.009, p = 0.003), anticipated (β = -0.008, delta z = -3.364, p = 0.001),
enacted stigma (β = -0.013, delta z = -3.308, p = 0.001) could reduce the change of ART
adherence through their negative impacts on the change of ART self-efficacy. Table 5.13
shows the results of mediation analysis of viral suppression.
Health-related quality of life (HRQoL)
A similar modelling procedure was used to construct the path model of HRQoL.
The final model showed an adequate model fit (χ2/df = 6.760, p < 0.001, RMSEA = 0.069,
CFI = 0.926, TLI = 0.876, SRMR = 0.065) (Table 5.9).
Table 5.14 shows the coefficients of the final model with HRQoL as an outcome.
Both the changes of internalized (β = -0.184, p < 0.001) and enacted stigma (β = -0.302, p
< 0.001) negatively influence the change of HRQoL while the changes of ART selfefficacy (β = 0.386, p < 0.001) and HIV symptom management self-efficacy (β = 0.999, p
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< 0.001) showed positive effects. The increases of three types of HIV-related stigma
resulted in the decrease of ART self-efficacy but only the increase of anticipated stigma
led to the decrease of HIV symptoms management self-efficacy (β = -0.062, p < 0.001).
The change of ART adherence was negatively associated with the change of enacted
stigma (β = -0.053, p = 0.003) but positively related to that of ART self-efficacy (β =
0.065, p < 0.001) and HIV symptom management self-efficacy (β = -0.087, p = 0.019).
Results of mediation analysis revealed that all three types of HIV-related stigma
could affect the change of HRQoL through the impacts on the change of ART selfefficacy (internalized stigma: β = -0.049, delta z = -3.766, p < 0.001; anticipated stigma:
β = -0.047, delta z = -3.903, p < 0.001; enacted stigma: β = -0.082, delta z = -4.265, p <
0.001). The increases of HIV-related stigma led to the decrease of ART self-efficacy,
which in turn resulted in the decrease of HRQoL. Only anticipated stigma could lead to
the negative change of HRQoL through the negative impact on HIV symptom
management self-efficacy (β = -0.062, delta z = -4.960, p < 0.001). Similarly, internalized
(β = -0.008, delta z = -3.202, p = 0.001), anticipated (β = -0.008, delta z = -3.309, p =
0.001), and enacted stigma (β = -0.014, delta z = -3.396, p = 0.001) led to the negative
change of ART adherence through their negative impacts on ART self-efficacy.
However, only anticipated stigma affected the change of ART adherence through its
negative impact on the change of HIV symptom management self-efficacy (β = -0.005,
delta z = -2.055, p = 0.040). The results of mediation analysis of HRQoL are shown in
Table 5.15.
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5.5 Discussion
Using data derived from a prospective cohort study and longitudinal mediation
analysis, the current study investigated the mechanisms of different types of HIV-related
stigma (i.e., internalized, anticipated, and enacted stigma) on clinical outcomes (i.e., CD4
count, viral suppression, and HRQoL) through psycho-behavioral paths. Results of
longitudinal mediation analyses found that internalized, anticipated, and enacted stigma
had different direct impacts on the three clinical outcomes, and their mechanisms on
clinical outcomes were also different. Psychological resources could mediate the
relationship between HIV-related stigma and health outcomes. To our knowledge, this is
the first study exploring the differential psycho-behavioral mechanisms of HIV-related
stigma on clinical outcomes based on the Health Stigma Framework. The findings from
this study have important implications for stigma research and practical intervention.
Internalized, anticipated, and enacted stigma may affect HRQoL through their
impacts on psychological resources. All three types of HIV-related stigma could decrease
ART self-efficacy, which in turn affects HRQoL. This finding was consistent with that of
the previous study (Zeng et al., 2020). Additionally, our study leveraged cohort data and
longitudinal mediation analysis to test the impacts of HIV-related stigma on ART selfefficacy and how these impacts influenced HRQoL sequentially. PLWH with high levels
of internalized and anticipated stigma might be more likely to have negative cognitions
and beliefs about themselves (Earnshaw & Chaudoir, 2009; Earnshaw et al., 2013; Quinn
& Earnshaw, 2011). What is more, PLWH who had stigmatized experiences might have
low levels of motivation to engage in and maintain their HIV care and to utilize
healthcare resources (Quinn & Earnshaw, 2011). These negative beliefs and low
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motivation are closely related to the confidence in ART adherence and medical visit,
which in turn might affect the physical wellbeing of PLWH. This study also found that
only anticipated stigma impaired HRQoL through reducing HIV symptom management
self-efficacy. Compared with internalized and enacted stigma, anticipated stigma captures
the fears of being mistreated in family, community, and healthcare settings, which may
have strong association with the confidence in managing HIV-related symptoms,
maintaining daily routine, and controlling disease progression (Eller et al., 2014; Lorig et
al., 2001; Quinn & Earnshaw, 2011). The low confidence in these aspects could affect the
multiple dimensions of HRQoL, such as pain, social functioning, cognitive functioning,
physical health, and mental health (Wu et al., 1997).
Psychological resources and ART adherence could mediate the relationship
between HIV-related stigma and viral suppression, but such mediating effects were not
found in the indirect pathways from stigma to CD4 count. Unexpectedly, the serial
mediating effects from HIV-related stigma, ART self-efficacy, ART adherence to viral
suppression were significant and positive even though the effect sizes were small. This
might be due to the negative association between changes of ART adherence and viral
suppression in path model. The Health Belief Model and perception of disease severity
could be used to explain this finding (Gao, Nau, Rosenbluth, Scott, & Woodward, 2000;
Spire et al., 2002). PLWH with better health and lower perception of disease severity
might be less like to adhere to ART (Gao et al., 2000). For instance, Gao and colleagues
(2000) found that asymptomatic PLWH had lower perception of disease severity, which
in turn resulted in suboptimal adherence as compared to those with symptoms. In our
study, more than 90.0% of the participants achieved viral suppression but only 63.9% of
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the PLWH had consistently optimal adherence across the four-wave dataset.
Additionally, it often only takes no longer than three months to achieve viral suppression
after ART initiation. The low perception of risk and short duration to suppress viral load
may make PLWH perceive that it may not cause serious consequences if they
occasionally miss some of the prescribed doses, especially in the situations of suffering
from discrimination or stigma. We also conducted a multiple group mediation analysis
based on the baseline CD4 count (0: < 500 cells/µl; 1: ≥ 500 cells/µl), and the results
confirmed our explanation. The negative relationship between slopes of ART adherence
and viral suppression was only found in PLWH with CD4 count equal to or higher than
500 cells/µl, and the serial mediating effects from HIV-related stigma, ART self-efficacy,
ART adherence to viral suppression were not significant in both two groups (Appendix
E). However, psychological resources and ART adherence did not show a mediating
effect between HIV-related stigma and CD4 count. The possible explanation for these
findings was that the change of CD4 count is usually affected by multiple factors, such as
the CD4 count before ART initiation, age, and duration of ART (i-base, 2016, 2019).
Additionally, it often takes a long time to see changes in CD4 count (i-base, 2016, 2019).
Future studies with long-term follow-up and considering more confounders are needed to
confirm this finding.
HIV-related stigma could deter ART adherence through reducing ART selfefficacy. This finding was consistent with that of a previous study (Zeng et al., 2020).
PLWH with negative cognitions about themselves, beliefs about being discriminated in
family, community and healthcare settings, and/or stigmatized experiences might have
few confidence and motivation to adhere to ART regimens, which might lead to
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suboptimal adherence behaviors (Earnshaw & Chaudoir, 2009; Earnshaw et al., 2013;
Quinn & Earnshaw, 2011; Zeng et al., 2020). In terms of the inconsistent mediating effect
of HIV symptom management self-efficacy between anticipated stigma and ART
adherence across the three models, this might be due to the weak correlation between the
change of anticipated stigma and that of HIV symptom management self-efficacy. Even
though both changes of anticipated stigma and HIV symptom management self-efficacy
were significant in the unstandardized measurement models, the changes were small
which may result in limited influence on each other.
The findings from this study had some important implications for stigma research
and intervention. From the research perspective, the differential psycho-behavioral
mechanisms of HIV-related stigma on the three clinical outcomes implies that future
stigma research should consider the characteristics of each type of HIV-related stigma
and clinical outcome and use these knowledge to frame the pathways between them.
Additionally, psychological resources, such as ART self-efficacy, could mediate the
relationship between HIV-related stigma and ART adherence and clinical outcomes. This
finding confirmed that psychological resources are important mechanisms of stigma and
health outcomes and future research are needed to explore their role, in addition to the
psychological distress, such as depression and anxiety (Turan et al., 2017). In terms of the
practical implication, to reduce the negative impacts of HIV-related stigma on health
outcomes, multilevel interventions tailored to different types of stigma are needed. As
internalized and anticipated stigma refer to the negative cognition process and beliefs at
the intrapersonal level, which could make PLWH believe that the negative attributes
related to HIV are true of the self, feel fear of being stigmatized, and avoid retaining in
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care (Earnshaw & Chaudoir, 2009; Earnshaw et al., 2013), psychological counseling and
resilience-based interventions, such as coping strategies, emotional regulation, and stress
management, could alleviate their negative influences (Rao et al., 2019). In contrast,
enacted stigma involves the stigmatized experiences from others or in the public.
Therefore, structural intervention, such as public health education, could potentially
correct misinformation and misunderstandings about HIV and reduce discrimination
against PLWH (Rao et al., 2019). What is more, the significant mediating effect of
treatment-related self-efficacy suggested that interventions promoting confidence and
motivation to health behaviors, such as skills training, self-management, and problemsolving, are also very effective in buffering the negative influences of HIV-related
stigma, maintaining treatment-related behaviors, and improving clinical outcomes (Areri,
Marshall, & Harvey, 2020).
Although this study is innovative in examining the longitudinal mechanisms of
HIV-related stigma on clinical outcomes, some limitations need to be acknowledged.
First, self-report measures were employed to assess variables of interest, which might
result in self-report bias. For instance, the ART adherence in this study might be
overestimated because of social desirability bias even though we used a multiple item
approach to assess the variable (Stirratt et al., 2015). To assess ART adherence
adequately, objective measurement tools, such as biomarkers and device-based
measurement, are needed. Additionally, due to social desirability bias, the percentage of
PLWH with stigmatized experiences might be underestimated. There were more than
70% of the PLWH without stigmatized experiences in the last 6 months. Future research
is needed to improve the validity of the measure of enacted stigma. Second, ART self-
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efficacy, HIV symptom management self-efficacy, and ART adherence were the major
psycho-behavioral mechanisms examined in this study. However, other psychobehavioral factors, such as resilience and positive coping, may also mediate the
relationship between stigma and clinical outcomes (Turan et al., 2017). Future studies are
needed to investigate their mediating roles.
Third, the measurement model of CD4 count did not have a good model fit, which
might threaten the internal validity of the findings in this study. However, we also
constructed the measurement model of CD4 count with free estimation, but its model fit
was worse than the current model (χ2/df = 9.77, p < 0.001). The possible reason for the
unsatisfied model fit may be that we constructed the measurement model using the binary
variable of CD4 count which only provided limited information for modelling. Future
studies with CD4 count as a continuous variable are needed to confirm our finding.
Fourth, only four waves of data across the two-year project were used in this study,
which might limit the ability for capturing significant changes among variables of
interest. Fifth, PLWH in this study were recruited from the hospitals/clinics. Therefore,
they might have better clinical outcomes, lower HIV-related stigma, and higher
treatment-related self-efficacy as compared to those who were not engaged in care in
hospitals/clinics. These characteristics might restrict our ability to test the conceptual
model. Future studies with diverse PLWH are needed to test the conceptual model of the
current study. Sixth, survey approach was employed to investigate the research
hypotheses in this study. However, to obtain a comprehensive picture of the cultural
context, qualitative studies could be used in future to collect more detailed information in
order to explain the complex mechanisms of HIV-related stigma on clinical outcomes.
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Finally, as this study was conducted in Guangxi, China, cautions are needed when
generalizing the findings from this study to other areas of China or other cultural settings.
5.6 Conclusion
Findings from this study support that HIV-related stigma affects important
clinical outcomes through differential psycho-behavioral mechanisms. Future stigma
studies should consider the characteristics of each type of stigma and clinical outcomes
when framing the pathways between them. Psychological resources are important
mechanisms between stigma and health outcomes and should be incorporated into future
stigma research. To improve clinical outcomes among PLWH effectively, future
intervention studies should also target psychological resources, improve resilience, and
maintain optimal adherence behaviors besides the three types of HIV-related stigma at
both intrapersonal and interpersonal levels.
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Table 5.1 Sociodemographic characteristics of PLWH at baseline assessment (n=1,198)
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Variables
Age in years (Mean, SD)
Time since HIV diagnosis in year (Mean, SD)
Duration of ART in years (Mean, SD)
Gender
Male
Female
Marital status
Single/ separated
Married/ cohabitated
Divorced/ widowed
Ethnicity
Han
Non-Han
Types of residence
City
County
Rural
Transmission modes
Sexual activity
Others
Note: SD: Standard deviation.

N (%)
39.0 (±9.2)
5.5 (±3.1)
4.8 (±3.0)
771 (64.4)
427 (35.6)
360 (30.4)
666 (56.2)
160 (13.4)
778 (65.0)
419 (35.0)
536 (44.9)
231 (19.3)
428 (35.8)
832 (69.7)
361 (30.3)

Variables
Depression (Mean, SD)
Anxiety (Mean, SD)
Education attainment
Less than or equal to middle school
High school or above
Employment
Unemployed
Part time
Full time
Levels of monthly income
No more than 1,999 RMB
2,000 ~ 3,999 RMB
At least 4,000 RMB
Body Mass Index
Underweight
Normal/healthy weight
Overweight/obese

N (%)
6.6 (±4.7)
26.9 (±6.4)
719 (60.0)
479 (40.0)
220 (18.5)
235 (19.8)
734 (61.7)
370 (31.0)
584 (48.9)
241 (20.2)
161 (13.4)
873 (72.9)
164 (13.7)

Table 5.2 Descriptive statistics of key variables across the four-wave datasets
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Variables
Sample sizes (n, %)
Attrition rates (n, %)
Clinical outcomes
CD4 count (n, %)
Less than 500 cells/μl
500 cells/μl or more
Viral suppression (n, %)
Yes
No
Health-related quality of life (Mean, SD)
Predictors
Internalized stigma (Mean, SD)
Anticipated stigma (Mean, SD)
Enacted stigma (Mean, SD)
Yes
No
ART self-efficacy (Mean, SD)
HIV symptom management self-efficacy (Mean, SD)
ART adherence (n, %)
Optimal
Suboptimal
Note: SD: Standard deviation.

Baseline
1,198 (100.0)
-

6-month
1,197 (99.9)
1 (0.1)

12-month
1,163 (97.1)
35 (2.9)

18-month
1,161 (96.9)
37 (3.1)

658 (54.9)
540 (45.1)

657 (54.8)
541 (45.2)

656 (54.8)
542 (45.2)

635 (53.0)
563 (47.0)

1,130 (94.3)
68 (5.7)
73.7 (±13.1)

1,145 (95.8)
50 (4.2)
71.2 (±13.4)

1,109 (95.4)
54 (4.6)
74.0 (±12.4)

1,135 (97.8)
26 (2.2)
72.1 (±13.3)

16.3 (±5.5)
23.2 (±7.7)

17.0 (±5.0)
22.6 (±7.2)

15.5 (±4.7)
21.2 (±6.8)

16.0 (±5.1)
22.0 (±7.1)

341 (28.7)
846 (71.3)
24.5 (±5.0)
33.5 (±9.1)

258 (21.6)
937 (78.4)
23.7 (±5.0)
34.1 (±7.5)

193 (16.6)
966 (83.4)
24.5 (±5.0)
34.2 (±7.6)

260 (22.4)
898 (77.6)
24.2 (±5.3)
32.6 (±8.5)

963 (80.8)
229 (19.2)

981 (82.2)
213 (17.8)

983 (85.5)
167 (14.5)

928 (80.1)
230 (19.9)

Table 5.3 Measurement models of key variables
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Variables
Unstandardized
Internalized stigma
Anticipated stigma
Enacted stigma
ART self-efficacy
HIV symptom management self-efficacy
ART adherence
CD4 count
Viral suppression
Health-related quality of life
Standardized
Internalized stigma
Anticipated stigma
ART self-efficacy
HIV symptom management self-efficacy
Health-related quality of life

χ2

χ2/df

p-values

RMSEA

CFI

TLI

SRMR

74.223
39.330
32.314
39.850
58.320
38.166
86.861
32.038
77.526

14.846
7.866
3.231
7.970
11.664
3.817
8.686
3.204
15.505

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

0.108
0.076
0.076
0.094
0.110

0.876
0.930
0.942
0.926
0.900

0.851
0.917
0.931
0.912
0.880

0.059
0.034
0.048
0.081
0.074

0.880
4.503
8.584
17.241
16.649

0.176
0.901
1.717
3.448
3.330

0.972
0.480
0.127
0.004
0.005

0.000
0.000
0.024
0.045
0.044

1.000
1.000
0.994
0.983
0.984

1.009
1.001
0.993
0.980
0.981

0.007
0.011
0.019
0.031
0.032

Table 5.4 Parameter estimation of measurement models
Variables

Intercept
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Mean
SE
Unstandardized
Internalized stigma
0.148
16.538***
Anticipated stigma
0.200
22.955***
***
Enacted stigma
0.122
-1.498
ART self-efficacy
0.139
24.222***
HIV symptom management self-efficacy
0.223
32.209***
***
ART adherence
0.186
2.478
CD4 count
0.214
-0.887***
***
Viral suppression
0.738
7.676
Health-related quality of life
0.374
73.091***
Standardized
Internalized stigma
-0.002
0.145
Anticipated stigma
0.000
0.199
ART self-efficacy
0.004
0.135
HIV symptom management self-efficacy
0.025
0.222
Health-related quality of life
0.020
0.363
Note: SE: Standard error; *: p < 0.05; **: p < 0.01; ***: p < 0.001.

Slope
Mean

SE

Correlation between
Intercept and slope

-0.237***
-0.476***
-0.224***
0.007
-0.324***
-0.138
0.140*
-0.456
-0.191

0.061
0.082
0.069
0.059
0.088
0.088
0.065
0.337
0.145

-0.579***
-0.428***
-0.578***
-0.408***
0.018
-0.757***
-0.641***
-0.796***
-0.364***

0.000
-0.007
0.000
-0.015
-0.034

0.060
0.083
0.058
0.086
0.141

-0.580***
-0.428***
-0.414***
-0.054
-0.368***

Table 5.5 Correlation matrix of intercepts and slopes among variables of interest
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Variables
1.
2.
Intercepts
1. Internalized stigma
1.00
2. Anticipated stigma
1.00
0.47***
***
3. Enacted stigma
0.25
0.24***
***
4. ART self-efficacy
-0.37
-0.29***
5. HIV symptom management
-0.42*** -0.40***
self-efficacy
6. ART adherence
-0.01
-0.003
7. CD4 count
0.01
0.03
8. Viral suppression
-0.01
0.02
9. Health-related quality of life
-0.48*** -0.35***
Slopes
1. Internalized stigma
1.00
2. Anticipated stigma
1.00
0.36***
***
3. Enacted stigma
0.17
0.13***
***
4. ART self-efficacy
-0.21
-0.20***
5. HIV symptom management
-0.13*** -0.24***
self-efficacy
6. ART adherence
-0.04
-0.05
7. CD4 count
0.04
0.08**
8. Viral suppression
-0.03
-0.03
9. Health-related quality of life
-0.33*** -0.25***
Note: *: p < 0.05; **: p < 0.01; ***: p < 0.001.

3.

4.

5.

1.00
-0.15***
-0.23***

1.00
0.57***

1.00

-0.06*
-0.07*
-0.06*
-0.31***

0.16***
0.09**
0.07*
0.51***

0.08**
0.16***
0.03
0.55***

1.00
-0.15***
-0.03

1.00
0.21***

1.00

-0.09**
0.04
0.06
-0.22***

0.16***
-0.02
0.03
0.35***

0.09**
-0.07*
-0.03
0.24***

6.

7.

8.

9.

1.00
-0.01
0.09**
0.10***

1.00
0.06
0.05

1.00
0.06

1.00

1.00
-0.05
-0.03
0.09**

1.00
0.01
-0.02

1.00
0.01

1.00

Table 5.6 Bivariate analysis of the change (slope) in CD4 count
Variables

Slope of CD4 count
r or mean (SD)
0.09
-0.14
-0.11

p-value

Age in years
0.001**
Time since HIV diagnosis in years
<0.001***
Duration of ART in years
<0.001***
Gender
0.001**
Male
0.18 (0.54)
Female
0.07 (0.59)
Marital status
0.956
Single/separated
0.14 (0.56)
Married/cohabitated
0.14 (0.56)
Divorced/widowed
0.14 (0.59)
Ethnicity
0.007**
Han
0.17 (0.56)
Non-Han
0.08 (0.56)
Types of residence
<0.001***
City
0.09 (0.56)
County
0.07 (0.61)
Rural
0.25 (0.52)
Education attainment
<0.001***
Less than or equal to middle school
0.19 (0.56)
High school or above
0.07 (0.56)
Employment
0.263
Unemployed
0.13 (0.55)
Part time
0.08 (0.59)
Full time
0.16 (0.56)
Levels of monthly income
0.155
No more than 1,999 RMB
0.14 (0.56)
2,000 ~ 3,999 RMB
0.17 (0.56)
At least 4,000 RMB
0.08 (0.57)
Transmission modes
<0.001***
Sexual activity
0.17 (0.57)
Others
0.07 (0.57)
Body Mass Index
0.593
Underweight
0.17 (0.56)
Normal/healthy weight
0.14 (0.56)
Overweight/obese
0.10 (0.58)
Depression
-0.06
0.032*
Anxiety
-0.07
0.013*
Note: SD: Standard deviation; *: p < 0.05; **: p < 0.01; ***: p < 0.001. All variables
were selected at baseline assessment.
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Table 5.7 Bivariate analysis of the change (slope) in viral suppression
Variables

Slope of viral
suppression
r or mean (SD)
0.01
-0.09
-0.09

p-value

Age in years
0.835
Time since HIV diagnosis in years
0.002**
Duration of ART in years
0.002**
Gender
0.536
Male
-0.45 (0.43)
Female
-0.47 (0.36)
Marital status
0.798
Single/separated
-0.44 (0.43)
Married/cohabitated
-0.46 (0.41)
Divorced/widowed
-0.49 (0.33)
Ethnicity
0.267
Han
-0.46 (0.40)
Non-Han
-0.45 (0.41)
Types of residence
0.098
City
-0.48 (0.37)
County
-0.48 (0.35)
Rural
-0.42 (0.47)
Education attainment
0.536
Less than or equal to middle school
-0.45 (0.42)
High school or above
-0.47 (0.38)
Employment
0.767
Unemployed
-0.46 (0.40)
Part time
-0.48 (0.35)
Full time
-0.45 (0.42)
Levels of monthly income
0.846
No more than 1,999 RMB
-0.47 (0.36)
2,000 ~ 3,999 RMB
-0.45 (0.42)
At least 4,000 RMB
-0.45 (0.42)
Transmission modes
0.654
Sexual activity
-0.45 (0.43)
Others
-0.49 (0.33)
Body Mass Index
0.520
Underweight
-0.49 (0.33)
Normal/healthy weight
-0.46 (0.40)
Overweight/ obese
-0.43 (0.46)
Depression
0.07
0.019*
Anxiety
0.03
0.260
Note: SD: Standard deviation; *: p < 0.05; **: p < 0.01; ***: p < 0.001. All variables
were selected at baseline assessment.
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Table 5.8 Bivariate analysis of the change (slope) in HRQoL
Variables

Slope of HRQoL
r or mean (SD)
-0.01
-0.01
0.01

p-value

Age in years
0.699
Time since HIV diagnosis in years
0.871
Duration of ART in years
0.767
Gender
0.448
Male
-0.03 (0.87)
Female
-0.04 (0.93)
Marital status
0.001**
Single/separated
0.05 (0.83)
Married/cohabitated
-0.11 (0.91)
Divorced/widowed
0.12 (0.97)
Ethnicity
0.102
Han
-0.07 (0.90)
Non-Han
0.03 (0.87)
Types of residence
0.413
City
-0.02 (0.88)
County
0.02 (0.87)
Rural
-0.08 (0.93)
Education attainment
0.078
Less than or equal to middle school
-0.06 (0.93)
High school or above
0.01 (0.83)
Employment
0.096
Unemployed
0.09 (1.04)
Part time
0.03 (0.93)
Full time
-0.09 (0.83)
Levels of monthly income
0.291
No more than 1,999 RMB
0.03 (0.97)
2,000 ~ 3,999 RMB
-0.06 (0.89)
At least 4,000 RMB
-0.09 (0.78)
Transmission modes
<0.001***
Sexual activity
-0.09 (0.88)
Others
0.09 (0.92)
Body Mass Index
0.357
Underweight
-0.13 (0.89)
Normal/healthy weight
-0.03 (0.89)
Overweight/obese
0.03 (0.91)
Depression
0.34
<0.001***
Anxiety
0.35
<0.001***
Note: SD: Standard deviation; *: p <0.05; **: p < 0.01; ***: p < 0.001. All variables were
selected at baseline assessment.
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Table 5.9 Model fits of path models
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Models
χ2 value
χ2/df
CD4 count
Original model
2042.024
Model trimming
1887.032
Final model
523.066
Viral suppression
Original model
1695.716
Model trimming
1704.493
Final model
456.600
HRQoL
Original model
3267.940
Model trimming
3227.936
Final model
527.293
Note: HRQoL: Health-related quality of life.

p-value

RMSEA

CFI

TLI

SRMR

11.282
15.218
5.506

<0.001 0.093
<0.001 0.109
<0.001 0.061

0.665
0.678
0.922

0.654
0.657
0.891

0.090
0.108
0.062

18.841
17.393
5.248

<0.001 0.122
<0.001 0.117
<0.001 0.060

0.763
0.763
0.946

0.711
0.734
0.924

0.111
0.111
0.059

23.014
26.900
6.760

<0.001 0.138
<0.001 0.148
<0.001 0.069

0.476
0.481
0.926

0.432
0.429
0.876

0.154
0.168
0.065

Table 5.10 Path coefficients (CD4 count)
Paths
β
Std.β
95% CI
SE
p-value
IS ---» ARTS
-0.114
-0.127
-0.170~-0.058
0.029
<0.001***
AS ---» ARTS
-0.123
-0.131
-0.177~-0.070
0.027
<0.001***
ES ---» ARTS
-0.197
-0.133
-0.278~-0.116
0.041
<0.001***
IS ---» ARTM
-0.012
-0.041
-0.030~0.006
0.009
0.199
AS ---» ARTM
-0.062
-0.199
-0.080~-0.044
0.009
<0.001***
ES ---» MED
-0.057
-0.055
-0.096~-0.018
0.020
0.005**
ARTS ---» MED
0.066
0.095
0.039~0.092
0.014
<0.001***
ARTM ---» MED
0.079
0.038
0.002~0.157
0.040
0.045*
MED ---» CD4 count
-0.058
-0.038
-0.111~-0.004
0.027
0.034*
Note: IS: Internalized stigma; AS: Anticipated stigma; ES: Enacted stigma; ARTS: ART
self-efficacy; ARTM: HIV symptom management self-efficacy; MED: ART adherence;
CI: Confidence interval; SE: Standard error; *: p < 0.05; **: p < 0.01; ***: p < 0.001.
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Table 5.11 Results of longitudinal mediation analysis (CD4 count)
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Effects
β
Std.β
95% CI
SE
p-value
From IS to CD4 count
Indirect effect
IS ---» ARTS ---» MED ---» CD4 count
0.000
0.000
0.000~0.001
0.000
0.094
IS ---» ARTM ---» MED ---» CD4 count
0.000
0.000
0.000~0.000
0.000
0.431
From AS to CD4 count
Indirect effect
AS ---» ARTS ---» MED ---» CD4 count
0.000
0.000
0.000~0.001
0.000
0.076
AS ---» ARTM ---» MED---» CD4 count
0.000
0.000
0.000~0.001
0.000
0.175
From ES to CD4 count
Indirect effect
ES ---» MED ---» CD4 count
0.003
0.002
0.000~0.009
0.002
0.106
ES ---» ARTS ---» MED ---» CD4 count
0.001
0.000
0.000~0.002
0.000
0.082
From IS to MED
Indirect effect
IS ---» ARTS ---» MED
-0.007
-0.012
-0.014~-0.003
0.002
0.002**
IS ---» ARTM ---» MED
-0.001
-0.002
-0.004~0.000
0.001
0.328
From AS to MED
Indirect effect
AS ---» ARTS ---» MED
-0.008
-0.012
-0.013~-0.004
0.002
0.001***
AS ---» ARTM ---» MED
-0.005
-0.008
-0.011~0.000
0.003
0.057
From ES to MED
Indirect effect
ES ---» ARTS ---» MED
-0.013
-0.013
-0.021~-0.006
0.004
0.001***
Direct effect
-0.057
-0.055
-0.097~-0.019
0.020
0.005**
Note: IS: Internalized stigma; AS: Anticipated stigma; ES: Enacted stigma; ARTS: ART self-efficacy; ARTM: HIV symptom
management self-efficacy; MED: ART adherence; CI: Confidence interval; SE: Standard error; *: p < 0.05; **: p < 0.01; ***: p <
0.001.

Table 5.12 Path coefficients (Viral suppression)
Paths
β
Std.β
95% CI
SE
p-value
IS ---» ARTS
-0.112
-0.125
-0.167~-0.056
0.028
<0.001***
AS ---» ARTS
-0.123
-0.130
-0.176~-0.069
0.027
<0.001***
ES ---» ARTS
-0.196
-0.133
-0.277~-0.115
0.041
<0.001***
IS ---» ARTM
-0.012
-0.040
-0.030~0.007
0.009
0.210
AS ---» ARTM
-0.061
-0.196
-0.079~-0.043
0.009
<0.001***
ES ---» MED
-0.056
-0.055
-0.095~-0.017
-0.056
0.005**
ARTS ---» MED
0.066
0.095
0.039~0.093
0.066
<0.001***
ARTM ---» MED
0.080
0.038
0.002~0.157
0.080
0.045*
MED ---» VS
-0.035
-0.032
-0.058~-0.012
-0.035
0.003**
Note: IS: Internalized stigma; AS: Anticipated stigma; ES: Enacted stigma; ARTS: ART
self-efficacy; ARTM: HIV symptom management self-efficacy; MED: ART adherence;
VS: Viral suppression; CI: Confidence interval; SE: Standard error; *: p < 0.05; **: p <
0.01; ***: p < 0.001.
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Table 5.13 Results of longitudinal mediation analysis (Viral suppression)
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Effects
β
Std.β
95% CI
SE
p-value
From IS to VS
Indirect effect
IS ---» ARTS ---» MED ---» VS
0.000
0.000
0.000~0.001
0.000
0.034*
IS ---» ARTM ---» MED ---» VS
0.000
0.000
0.000~0.000
0.000
0.387
From AS to VS
Indirect effect
AS ---» ARTS ---» MED ---» VS
0.000
0.000
0.000~0.001
0.000
0.023*
AS ---» ARTM ---» MED---» VS
0.000
0.000
0.000~0.000
0.000
0.123
From ES to VS
Indirect effect
ES ---» MED ---» VS
0.002
0.002
0.000~0.005
0.001
0.053
ES ---» ARTS ---» MED ---» VS
0.000
0.000
0.000~0.001
0.000
0.034*
From IS to MED
Indirect effect
IS ---» ARTS ---» MED
-0.007
-0.012
-0.013~-0.003
0.002
0.003**
IS ---» ARTM ---» MED
-0.001
-0.002
-0.004~0.000
0.001
0.336
From AS to MED
Indirect effect
AS ---» ARTS ---» MED
-0.008
-0.012
-0.013~-0.004
0.002
0.001***
AS ---» ARTM ---» MED
-0.005
-0.007
-0.010~0.000
0.003
0.058
From ES to MED
Indirect effect
ES ---» ARTS ---» MED
-0.013
-0.013
-0.021~-0.006
0.004
0.001**
Direct effect
-0.056
-0.055
-0.097~-0.019
0.020
0.005**
Note: IS: Internalized stigma; AS: Anticipated stigma; ES: Enacted stigma; ARTS: ART self-efficacy; ARTM: HIV symptom
management self-efficacy; MED: ART adherence; VS: Viral suppression; CI: Confidence interval; SE: Standard error; *: p < 0.05; **:
p < 0.01; ***: p < 0.001.

Table 5.14 Path coefficients (Health-related quality of life)
Paths
β
Std.β
95% CI
SE
p-value
IS ---» ARTS
-0.126
-0.140 -0.182~-0.069
0.026
<0.001***
AS ---» ARTS
-0.121
-0.128 -0.174~-0.067
0.027
<0.001***
ES ---» ARTS
-0.211
-0.143 -0.293~-0.129
0.040
<0.001***
IS ---» ARTM
-0.007
-0.022 -0.025~0.012
0.008
0.431
AS ---» ARTM
-0.062
-0.199 -0.080~-0.044
0.009
<0.001***
ES ---» MED
-0.053
-0.052 -0.092~-0.014
0.018
0.003**
ARTS ---» MED
0.065
0.094
0.038~0.092
0.012
<0.001***
ARTM ---» MED
0.087
0.041
0.009~0.164
0.037
0.019*
IS ---» HRQoL
-0.184
-0.128 -0.264~-0.104
0.038
<0.001***
ES ---» HRQoL
-0.302
-0.127 -0.431~-0.173
0.060
<0.001***
ARTS ---» HRQoL
0.386
0.241
0.297~0.475
0.041
<0.001***
ARTM ---» HRQoL
0.999
0.204
0.749~1.248
0.121
<0.001***
Note: IS: Internalized stigma; AS: Anticipated stigma; ES: Enacted stigma; ARTS: ART
self-efficacy; ARTM: HIV symptom management self-efficacy; MED: ART adherence;
HRQoL: Health-related quality of life; CI: Confidence interval; SE: Standard error; *: p <
0.05; **: p < 0.01; ***: p < 0.001.
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Table 5.15 Results of longitudinal mediation analysis (HRQoL)
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Effects
β
Std.β
95% CI
SE
p-value
From IS to HRQoL
Indirect effect
IS ---» ARTS ---» HRQoL
-0.049
-0.034
-0.074~-0.023
0.013
<0.001***
IS ---» ARTM ---» HRQoL
-0.007
-0.005
-0.025~0.012
0.009
0.482
Direct effect
-0.184
-0.128
-0.264~-0.104
0.041
<0.001***
From AS to HRQoL
Indirect effect
AS ---» ARTS ---» HRQoL
-0.047
-0.031
-0.070~-0.023
0.012
<0.001***
ARTS ---» ARTM ---» HRQoL
-0.062
-0.041
-0.086~-0.037
0.012
<0.001***
From ES to HRQoL
Indirect effect
ES ---» ARTS ---» HRQoL
-0.082
-0.034
-0.119~-0.044
0.019
<0.001***
Direct effect
-0.302
-0.127
-0.431~-0.173
0.066
<0.001***
From IS to MED
Indirect effect
IS ---» ARTS ---» MED
-0.008
-0.013
-0.013~-0.003
0.003
0.001**
IS ---» ARTM ---» MED
-0.001
-0.001
-0.002~0.001
0.001
0.539
From AS to MED
Indirect effect
AS ---» ARTS ---» MED
-0.008
-0.012
-0.012~-0.003
0.002
0.001**
AS ---» ARTM ---» MED
-0.005
-0.008
-0.010~0.000
0.003
0.040*
From ES to MED
Indirect effect
ES ---» ARTS ---» ARTM
-0.014
-0.013
-0.022~-0.006
0.004
0.001**
Direct effect
-0.053
-0.052
-0.092~-0.014
0.020
0.008**
Note: IS: Internalized stigma; AS: Anticipated stigma; ES: Enacted stigma; ARTS: ART self-efficacy; ARTM: HIV symptom
management self-efficacy; MED: ART adherence; HRQoL: Health-related quality of life; CI: Confidence interval; SE: Standard error;
*: p < 0.05; **: p < 0.01; ***: p < 0.001.

Figure 5.1 Conceptual model

162

Figure 5.2 Final path model of CD4 count
Note: IS: Internalized stigma; AS: Anticipated stigma; ES: Enacted stigma; ARTS: ART
self-efficacy; ARTM: HIV symptom management self-efficacy; MED: ART adherence;
*: p < 0.05; **: p < 0.01; ***: p < 0.001; Covariates, such as duration of ART,
depression, anxiety, were controlled in this model. All pathways in modification indices
were omitted in this model but could be found in the Appendix D.
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Figure 5.3 Final path model of viral suppression
Note: IS: Internalized stigma; AS: Anticipated stigma; ES: Enacted stigma; ARTS: ART
self-efficacy; ARTM: HIV symptom management self-efficacy; MED: ART adherence;
VS: Viral suppression; *: p < 0.05; **: p < 0.01; ***: p < 0.001; Covariates, such as
duration of ART, depression, anxiety, were controlled in this model. All pathways in
modification indices were omitted in this model but could be found in the Appendix D.

164

Figure 5.4 Final path model of HRQoL
Note: IS: Internalized stigma; AS: Anticipated stigma; ES: Enacted stigma; ARTS: ART
self-efficacy; ARTM: HIV symptom management self-efficacy; MED: ART adherence;
HRQoL: Health-related quality of life; *: p < 0.05; **: p < 0.01; ***: p < 0.001;
Covariates, such as time since HIV diagnosis, depression, anxiety, baseline CD4 count,
were controlled in this model. All pathways in modification indices were omitted in this
model but could be found in the Appendix D.
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CHAPTER 6
DISCUSSION
6.1 Summary of the dissertation
Leveraging data derived from a prospective cohort study and longitudinal analytic
approach, this dissertation aims to investigate two research questions: 1) the impacts of
HIV-related stigma on clinical outcomes after accounting for psycho-behavioral factors
and covariates; and 2) the psycho-behavioral mechanisms underlying HIV-related stigma
and clinical outcomes among PLWH in Guangxi, China. The findings generating from
this dissertation partially confirmed the hypotheses and had important implication for
research and practices. This chapter summarizes the research findings first. Then, the
strengths and limitations of this dissertation are discussed. Moreover, this chapter gives
detailed discussion to the implication of research findings and future direction for stigma
research as well as intervention. Finally, it presents key research conclusions based on the
findings.
Using hierarchical longitudinal analytic approach, Study 1 explored whether
internalized, anticipated, and enacted stigma had different impacts on the three clinical
outcomes (i.e., CD4, viral suppression, HRQoL) after accounting for psycho-behavioral
factors and sociodemographic characteristics. The results revealed that the three types of
HIV-related stigma could explain additional variance of each clinical outcome.
Internalized, anticipated, and enacted stigma were negatively associated with HRQoL but
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not with CD4 count and viral suppression. Psycho-behavioral factors could explain large
variance of clinical outcomes, and some of their impacts changed after adding HIVrelated stigma to the model. These findings implied that 1) HIV-related stigma might
have different impacts on different clinical outcomes; 2) psycho-behavioral factors might
mediate the relationship between stigma and clinical outcomes; 3) these psychobehavioral mechanisms might be different by each type of stigma and clinical outcomes.
Based on the findings in Study 1, Study 2 employed longitudinal mediation
analysis to examine the psycho-behavioral mechanisms of HIV-related stigma on clinical
outcomes. None of the three types of stigma had direct impacts on CD4 count and viral
suppression, but the direct impacts of internalized and enacted stigma were found in
HRQoL. The psycho-behavioral mechanisms were also different by each type of HIVrelated stigma and clinical outcomes. Treatment-related self-efficacy (i.e., ART selfefficacy, HIV symptom management self-efficacy) and ART adherence could mediate
the indirect pathways from HIV-related stigma to viral suppression but these effects were
not found in CD4 count. The serial mediating effects from HIV-related stigma, ART selfefficacy, ART adherence to viral suppression were different by baseline CD4 count. ART
self-efficacy could consistently mediate the impacts of three stigma on HRQoL but the
mediating effect of HIV symptom management self-efficacy was only found in the
pathway between anticipated stigma and HRQoL. Across the three types of HIV-related
stigma, ART self-efficacy could consistently mediate their impacts on ART adherence.
Similarly, only anticipated stigma could affect ART adherence through reducing HIV
symptom management self-efficacy. These findings confirmed Earnshaw and her
colleagues’ hypotheses which emphasized the potentially distinct mechanisms of
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internalized, anticipated, and enacted stigma on clinical outcomes (Earnshaw &
Chaudoir, 2009; Earnshaw et al., 2013). Additionally, this study added value to prior
research by confirming the mechanisms of psychological resources. Finally, this study
suggested that future stigma research should consider the characteristics of each type of
HIV-related stigma and clinical outcome and use these knowledge to frame the pathways
between them.
6.2 Strengths and limitations
Strengths
This dissertation has several strengths. First, data used in this dissertation were
derived from the four-wave assessment in a prospective cohort among PLWH in
Guangxi, China. The high quality longitudinal data and low attrition rates across the time
ensured that this dissertation had strong ability for causal inference as compared to the
previous studies in cross sectional design (Earnshaw et al., 2013; Logie et al., 2019; Rao
et al., 2012; Rao et al., 2019; Turan, Budhwani, et al., 2017; Turan et al., 2016). Second,
participants in the cohort were vulnerable to HIV-related stigma as most of them from
rural areas, had low SES, and experienced the influences of traditional culture and local
HIV epidemic (Li et al., 2015; Wang, 2013; Yang et al., 2019). Third, in addition to
immunologic and virologic outcomes, this dissertation emphasized the importance of
HRQoL which could give comprehensive assessment to health quality (Ashing-Giwa,
2005; Ruiz Perez et al., 2005; Wu et al., 1997).
Fourth, in the contrast to existing studies which predominantly focused on the
overall HIV-related stigma or one or more types (Fuster-Ruizdeapodaca et al., 2014;
Logie et al., 2019; Parcesepe et al., 2020), this dissertation considered the three common
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types of HIV-related stigma simultaneously and investigated their separate impacts and
mechanisms on clinical outcomes. Fifth, as suggested by Turan and his colleagues
(Turan, Hatcher, et al., 2017), psychological resources are important mechanisms
between HIV-related stigma and health outcomes. Therefore, this dissertation
incorporated ART self-efficacy and HIV symptom management self-efficacy into
conceptual framework and investigated whether they could mediate the pathways
between stigma and clinical outcomes. Finally, leveraging LGCM and longitudinal
mediation analysis, the second study of this dissertation explored how the changes of
HIV-related influenced those of clinical outcomes through psycho-behavioral pathways.
These methods and results could provide robust research evidence to support the
causality between stigma and health outcomes and confirm the mediating roles of ART
self-efficacy, HIV symptom management self-efficacy, and ART adherence.
Limitations
Besides the strengths, there were some limitations that need to be acknowledged.
First, the cohort study was conducted in clinical settings/hospitals, which might result in
better health outcomes among participants. Additionally, as compared with PLWH who
did not engage in care or seek help in clinics, the participants in this dissertation might
have lower HIV-related stigma and higher treatment-related self-efficacy, which might
also threaten the internal and external validity of our findings. For instance, there were
more than 70% of the PLWH without stigmatized experiences in the last 6 months.
Future studies with diverse PLWH recruited from both clinics and other settings are
needed. Second, due to age-related issues, PLWH who were older than 60 years were
excluded from the cohort study. However, as compared to young adults, older PLWH
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may experience higher levels of HIV-related stigma and often engage in maladaptive
stigma management strategies (e.g., non-disclosure and suboptimal ART adherence),
which may also result in suboptimal clinical outcomes (Emlet, 2014). Third, only fourwave datasets were used in this dissertation, which might limit the ability to see
significant changes among variables of interest and confirm the causality among them.
Fourth, self-report measures were employed to evaluate variables of interest, which might
result in self-reported bias. For instance, the ART adherence in this dissertation might be
overestimated because of social desirability bias even though we used a multiple-item
approach to assess the variable (Stirratt et al., 2015). To improve the validity of
adherence measurement and assess adherence adequately, objective measurement tools,
such as biomarkers and device-based measurement, are needed. Additionally, due to
social desirability bias, the stigmatized experiences might be underestimated in Study 2.
Future studies are needed to improve the validity of this measure. Fifth, this dissertation
only focused on three common types of HIV-related stigma, such as internalized,
anticipated, and enacted stigma. However, there are also other types of HIV-related
stigma, such as disclosure concerns and concern with public attitudes toward PLWH,
which were defined by other stigma measurement tools and used in previous studies but
were not included in this dissertation (Abdul Bari, 2017; Berger et al., 2001). These types
of HIV-related stigma may also influence clinical outcomes through different psychobehavioral mechanisms. For instance, the measure of internalized stigma was derived
from the HIV Stigma Scale which also captures disclosure concerns (Berger et al., 2001).
The disclosure concerns may influence clinical outcomes through impeding disclosure
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behaviors among PLWH and limiting their resource access (Omarzu, 2000; Qiao, Li, &
Stanton, 2013).
Sixth, although this dissertation emphasized the importance of psychological
resources and used treatment-related self-efficacy to reflect them, other psychological
resources, such as resilience, positive coping, and avoid coping, may also mediate the
relationship between stigma and clinical outcomes (Turan, Hatcher, et al., 2017). Future
studies are needed to investigate their mediating roles. Seventh, as CD4 count and viral
load were categorized as binary variables based on the clinical implication in
immunologic recovery and viral suppression, only limited information of these two
outcomes were used in the data analysis. Eighth, due to study design, some of the
sociodemographic characteristics, such as levels of monthly income and marital status,
were only collected at baseline. However, these characteristics may change during the
follow-ups, have time-varying effects on health outcomes, and thus should be controlled
in future research. Ninth, survey approach was employed to investigate the research
hypotheses in this dissertation. However, in the contrast to quantitative study, qualitative
studies could obtain a comprehensive picture of the cultural context and give better
understanding of the complex mechanisms of HIV-related stigma on clinical outcomes.
Finally, the cohort study was conducted in Guangxi, China, cautions are needed when
generalizing the findings from this dissertation to other areas of China, other cultural
settings, or other countries.
6.3 Implications
This dissertation has important implications for both HIV-related stigma research
and practices. From the research perspective, the significant direct and indirect impacts of
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HIV-related stigma on HRQoL suggested that HIV-related stigma might not only
influence immunologic and virologic outcomes but also impair the overall health quality
of PLWH. In addition to immunologic and virologic outcomes, future stigma research are
called for investigating its mechanisms on HRQoL among PLWH, especially for those
under treatment as they need to cope with the challenges (e.g., drug side effects,
opportunistic infections, mental health problems) besides immunologic recovery and viral
suppression (Lazarus et al., 2016). Moreover, the differential direct and indirect impacts
of internalized, anticipated, and enacted stigma on the three clinical outcomes suggested
that the mechanisms of them on clinical outcomes might be different (Earnshaw &
Chaudoir, 2009; Earnshaw et al., 2013). Research only focusing on overall HIV-related
stigma or one or more type may ignore the nuanced differences among them and may not
inform effective interventions to alleviate their impacts on clinical outcomes.
Furthermore, the significant mediating roles of psychological resources between stigma
and health outcomes implied that they are an important psychological mechanism besides
psychological distress, such as depression and anxiety (Turan, Hatcher, et al., 2017). The
investigation on their mediating roles could inform future positive psychology
interventions which could buffer the negative impacts of stigma. Finally, the application
of latent growth curve modelling and longitudinal mediation analysis in this dissertation
could examine the pathways among the changes of key variables rather than the
associations of mean values (Cheong et al., 2003). Therefore, findings in this dissertation
have implication in promoting the future application of these approach to examine
mechanisms from a longitudinal perspective.
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Regarding to the implication for practical interventions, interventions aiming to
promote clinical outcomes should target both HIV-related stigma and psycho-behavioral
mediators. As internalized, anticipated, and enacted stigma may influence clinical
outcomes through different mechanisms, effective stigma interventions should be tailored
to their characteristics. For instance, internalized and anticipated stigma reflect the
negative cognition process and beliefs at the intrapersonal level, which might result in the
mental health disorders, risk behaviors, and suboptimal clinical outcomes among PLWH
(Earnshaw & Chaudoir, 2009; Earnshaw et al., 2013). Individual interventions targeting
internalized and anticipated stigma, such as psychological counselling and resiliencebased interventions (e.g., coping strategies, emotion regulation, stress management),
could alleviate their negative impacts (Rao et al., 2019). In contrast, enacted stigma
represents the actual stigmatized experiences from others or in the public. Hence,
structural interventions, such as public health education and public campaigns, may
reduce the misunderstanding and discrimination against PLWH (Rao et al., 2019).
Additionally, as the conservative social culture in China is one of the causes of HIVrelated stigma, structural interventions targeting the social culture and correcting the
misinformation about HIV may be effective in reducing the HIV-related stigma at the
intrapersonal level or in the social environment (Auerbach, 2009). In this dissertation, as
we found that HIV-related stigma had direct impacts on the HRQoL, structural
interventions targeting the social culture may be also effective in improving the overall
health quality among PLWH.
Interventions should be also tailored to different clinical outcomes. For example,
as all three types of HIV-related stigma could impair HRQoL directly, the
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aforementioned stigma reduction interventions could improve HRQoL effectively.
However, since stigma could only influence CD4 count and viral suppression indirectly,
intervention should also target the psycho-behavioral mechanisms besides HIV-related
stigma. The significant mediating effects of treatment-related self-efficacy suggested that
interventions promoting confidence and motivation to health behaviors, such as skill
training, self-management, and problem-solving, might be effective in buffering the
negative influences of HIV-related stigma, maintaining treatment-related behaviors, and
improving clinical outcomes (Areri, Marshall, & Harvey, 2020). As PLWH with optimal
clinical outcomes may have low perception of disease severity which may result in
suboptimal ART adherence, missed medical appointments, and health outcomes,
behavioral interventions, such as daily reminder and self-management, are also needed to
maintain or improve adherence behaviors (Gao, Nau, Rosenbluth, Scott, & Woodward,
2000; Guo et al., 2020a; Spire et al., 2002).
6.4 Future direction
Future direction for both research design and implementation are needed to
improve the quality of this dissertation and confirm its research findings. From the
perspective of research design, prospective cohort design could provide high quality
longitudinal data which are helpful to examine the causality between stigma and clinical
outcomes. Additionally, long-term follow-ups embedded in prospective cohort study
could allow us to capture the significant changes among variables of interest and test the
associations. What is more, participants recruited from both clinics and other settings
(e.g., community) may have differences in key variables and could provide rich
information for causal inference. Furthermore, the improvement of measurement tools
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among key variables, such as ART adherence and enacted stigma, could capture their
information accurately and ensure the findings have good internal validity. For example,
the antiretroviral concentration in biological samples (e.g., hair, saliva, blood) among
PLWH may be an objective indicator of ART adherence and could avoid the influence of
self-report bias (Zhang, Qiao, Yang, & Li, 2020). Finally, the significant impacts of some
sociodemographic characteristics, such as marital status, levels of monthly income, and
types of residence, on clinical outcomes implied that they might have different impacts
on HIV-related stigma and health outcomes over time. During research design and data
collection, the time-varying effects of these variables should be considered and assessed.
In terms of implementation-related research, some future direction regarding
research ideas and data analysis could provide comprehensive information and
justification of the findings in this dissertation. First, besides HIV-related stigma, PLWH
in Guangxi may suffer from other types of stigma, such as stigma related to poverty,
sexual identity, and gender (Ghiasvand et al., 2020; Turan, Hatcher, et al., 2017), which
were not examined in this dissertation. The intersectionality of these stigma reflects the
multiple interlocking systems of privilege and oppression at macro, social-structural
level, and influence clinical outcomes through complex pathways (Bowleg, 2012;
Collins, 2015; Ghiasvand et al., 2020). The investigation of intersecting stigma could
provide additional picture of how the clinical outcomes of PLWH from different
identities are influenced through the psycho-behavioral pathways (Turan, Hatcher, et al.,
2017). These findings may inform future interventions tailored to PLWH of different
identities, which could improve health outcomes effectively. Second, internalized,
anticipated, and enacted stigma are three common types of HIV-related stigma used in
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prior research, but they may not influence clinical outcomes independently. Instead, they
may interact with each other, form different profiles (e.g., high internalized and
anticipated stigma but low enacted stigma), and affect clinical outcomes through different
psycho-behavioral mechanisms (Earnshaw & Chaudoir, 2009; Earnshaw et al., 2013;
Turan, Budhwani, et al., 2017; Turan, Hatcher, et al., 2017). The investigation on these
profiles may elaborate the potentially distinct psycho-behavioral mechanisms better than
the findings in the current dissertation or at least justify the current findings.
Third, HRQoL covers 11 dimensions, such as physical functioning, social
functioning, cognitive functioning, pain, and mental health (Wu et al., 1997), but it was
used as a composite score in this dissertation, which might ignore the plausible different
mechanisms of HIV-related stigma on different dimensions of HRQoL. Future
investigation on these mechanisms could uncover the complex pathways between stigma
and different domains of HRQoL and provide empirical evidences to inform targeted
interventions to improve the overall health quality among PLWH. Fourth, some
sociodemographic or HIV infection characteristics, such gender, time since HIV
diagnosis or infection stages, may moderate the mechanisms of clinical outcomes
underlying HIV-related stigma. For example, Mahajan and colleagues suggested that
PLWH in asymptomatic period might be less vulnerable to HIV-related stigma than those
with symptoms as they did not have physical manifestations of HIV, had stable capability
of maintaining daily routine, and were difficult to identify as different in the public
(Mahajan et al., 2008). The different levels of HIV-related stigma by disease stages may
influence their impacts on psychological and physical wellbeing among PLWH. Studies
on these moderating effects or subgroup analysis by different sociodemographic
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characteristics could examine for whom under which disease stages, the conceptual
model of this dissertation may work. These investigations could provide evidence for
tailoring stigma reduction intervention to PLWH of different stages of infection.
6.5 Conclusion
Building from the Health Stigma Framework and prior research, this dissertation
provided further investigation on the separate impacts and mechanisms of internalized,
anticipated, and enacted stigma on clinical outcomes. In accordance with the Health
Stigma Framework, different impacts and mechanisms of HIV-related stigma on clinical
outcomes were detected. Psychological resources and ART adherence could mediate the
pathways from stigma to clinical outcomes. Future studies are needed to examine these
mechanisms among PLWH of different backgrounds in both clinics and community
settings. Interventions aiming to improve clinical outcomes should be tailored to
internalized, anticipated, and enacted stigma at both intrapersonal and interpersonal levels,
target relevant psycho-behavioral pathways, promote the resilience, and
maintain/improve the adherence behaviors of PLWH.
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APPENDIX A
CORRELATION STRUCTURE AND MODEL SELECTION
Table A.1 Model fit of generalized linear mixed model of CD4 count in Step 1
Models
Model 1
Model 2
Model 3
Model 4

Covariance
Unstructured
Autoregressive
Exchange
Independent

QIC
5968.9531
5853.5086
5851.2879
5852.5399

QICu
5918.4927
5803.0767
5800.5255
5798.7923

Table A.2 Model fit of generalized linear mixed model of CD4 count in Step 2
Models
Model 1
Model 2
Model 3
Model 4

Covariance
Unstructured
Autoregressive
Exchange
Independent

QIC
5766.6410
5635.9332
5635.3364
5619.7931

QICu
5718.2486
5591.3602
5591.0257
5563.2591

Table A.3 Model fit of generalized linear mixed model of CD4 count in Step 3
Models
Model 1
Model 2
Model 3
Model 4

Covariance
Unstructured
Autoregressive
Exchange
Independent

QIC
5712.1213
5606.9331
5606.6371
5592.1565
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QICu
5665.2957
5565.1331
5564.8352
5532.9077

Table A.4 Model fit of generalized linear mixed model of viral suppression in Step 1
Models
Model 1
Model 2
Model 3
Model 4

Covariance
Unstructured
Autoregressive
Exchange
Independent

QIC
1518.2168
1518.7922
1518.7236
1518.0639

QICu
1509.9828
1510.3066
1509.9804
1509.4087

Table A.5 Model fit of generalized linear mixed model of viral suppression in Step 2
Models
Model 1
Model 2
Model 3
Model 4

Covariance
Unstructured
Autoregressive
Exchange
Independent

QIC
1452.6661
1452.3487
1455.1258
1453.6036

QICu
1445.5917
1444.7407
1445.9396
1442.9401

Table A.6 Model fit of generalized linear mixed model of viral suppression in Step 3
Models
Model 1
Model 2
Model 3
Model 4

Covariance
Unstructured
Autoregressive
Exchange
Independent

QIC
1430.8067
1430.1513
1432.9292
1431.5986
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QICu
1425.5541
1424.1176
1424.6779
1420.7865

Table A.7 Model fit of generalized linear mixed model of HRQoL in Step 1
Models
Model 1
Model 2
Model 3
Model 4
Model 5

Covariance
Unstructured
Compound symmetry
Heterogeneous compound symmetry
Autoregressive
Heterogeneous autoregressive

-2 Res Log Likelihood
34365.3
34365.3
34365.3
34365.3
34365.3

AIC
34369.3
34371.3
34371.3
34371.3
34371.3

AICC
34369.3
34371.3
34371.3
34371.3
34371.3

BIC
34379.4
34386.5
34386.5
34386.5
34386.5

AIC
30169.1
30171.1
30171.1
30171.1
30171.1

AICC
30169.1
30171.1
30171.1
30171.1
30171.1

BIC
30179.3
30186.4
30186.4
30186.4
30186.4

AIC
29816.7
29818.7
29818.7
29818.7
29818.7

AICC
29816.7
29818.7
29818.7
29818.7
29818.7

BIC
29826.9
29834.0
29834.0
29834.0
29834.0

Table A.8 Model fit of generalized linear mixed model of HRQoL in Step 2
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Models
Model 1
Model 2
Model 3
Model 4
Model 5

Covariance
Unstructured
Compound symmetry
Heterogeneous compound symmetry
Autoregressive
Heterogeneous autoregressive

-2 Res Log Likelihood
30165.1
30165.1
30165.1
30165.1
30165.1

Table A.9 Model fit of generalized linear mixed model of HRQoL in Step 3
Models
Model 1
Model 2
Model 3
Model 4
Model 5

Covariance
Unstructured
Compound symmetry
Heterogeneous compound symmetry
Autoregressive
Heterogeneous autoregressive

-2 Res Log Likelihood
29812.7
29812.7
29812.7
29812.7
29812.7

APPENDIX B
SUBGROUP ANALYSIS OF CD4 COUNT
Table B.1 Hierarchical generalized linear mixed model of CD4 count among PLWH under 45 years old
Variables
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Step 1: Sociodemographic characteristics
Time
Age in years
Duration of ART in years
Gender
Male
Female
Marital status
Single/separated
Married/cohabitated
Divorced/widowed
Ethnicity
Han
Non-Han
Types of residence
City
County

Model 1 (n=824)

AOR (95% CI)
Model 2 (n=788)

Model 3 (n=782)

1.04 (0.99~1.08)
0.69 (0.55~0.86)***
1.17 (1.02~1.35)*

1.05 (1.00~1.10)*
0.70 (0.56~0.87)**
1.21 (1.04~1.40)*

1.05 (1.00~1.10)*
0.69 (0.55~0.87)**
1.21 (1.04~1.40)*

0.69 (0.51~0.93)*

0.68 (0.50~0.92)*
Reference

0.68 (0.51~0.92)*

1.06 (0.77~1.46)

1.06 (0.77~1.47)
Reference
0.84 (0.54~1.30)

1.05 (0.76~1.45)

0.87 (0.68~1.11)

0.86 (0.67~1.11)
Reference

0.87 (0.67~1.12)

1.77 (1.30~2.41)***
1.62 (1.15~1.29)**

1.65 (1.21~2.26)**
1.51 (1.06~2.14)*

1.67 (1.22~2.29)**
1.51 (1.06~2.15)*

0.84 (0.54~1.29)

0.85 (0.55~1.32)
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Rural
Education attainment
Less than or equal to middle school
High school or above
Levels of monthly income
No more than 1,999 Yuan
2,000 ~ 3,999 Yuan
At least 4,000 Yuan
Transmission modes
Sexual activity
Others
Body Mass Index
Underweight
Normal/healthy weight
Overweight/obese
Step 2: Psycho-behavioral factors
ART self-efficacy
HIV symptom management self-efficacy
Depression
Anxiety
ART adherence (n, %)
Optimal
Suboptimal
Step 3: HIV-related stigma
Internalized stigma
Anticipated stigma
Enacted stigma
Pseudo R2
∆R2

Reference

1.25 (0.94~1.67)

Reference
1.25 (0.93~1.67)

1.22 (0.91~1.63)

0.91 (0.69~1.22)
1.20 (0.83~1.73)

Reference
0.92 (0.69~1.23)
1.17 (0.80~1.70)

0.91 (0.68~1.21)
1.13 (0.78~1.65)

0.88 (0.67~1.15)

0.88 (0.67~1.16)
Reference

0.88 (0.66~1.16)

0.57 (0.43~0.74)***

0.71 (0.53~0.95)*
Reference
1.45 (1.01~2.07)*

0.72 (0.53~0.96)*

0.98 (0.88~1.08)
1.21 (1.09~1.34)**
0.88 (0.77~0.99)*
1.16 (1.02~1.33)*

0.98 (0.88~1.08)
1.22 (1.10~1.36)***
0.87 (0.76~0.99)*
1.16 (1.02~1.33)*

0.93 (0.74~1.16)
Reference

0.92 (0.74~1.15)

1.41 (1.09~1.82)**

0.115
-

0.159
0.042

Note: AOR: Adjusted odds ratio; CI: Confidence interval; *: p < 0.05; **: p < 0.01; ***: p < 0.001.

1.46 (1.02~2.10)*

0.98 (0.88~1.09)
1.07 (0.97~1.20)
0.98 (0.89~1.08)
0.165
0.006

Table B.2 Hierarchical generalized linear mixed model of CD4 count among PLWH older than 45 years
Variables
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Step 1: Sociodemographic characteristics
Time
Age in years
Duration of ART in years
Gender
Male
Female
Marital status
Single/separated
Married/cohabitated
Divorced/widowed
Ethnicity
Han
Non-Han
Types of residence
City
County
Rural
Education attainment
Less than or equal to middle school
High school or above
Levels of monthly income
No more than 1,999 Yuan
2,000 ~ 3,999 Yuan
At least 4,000 Yuan
Transmission modes
Sexual activity
Others

Model 1 (n=295)

AOR (95% CI)
Model 2 (n=286)

Model 3 (n=283)

1.03 (0.95~1.12)
0.89 (0.52~1.50)
1.19 (0.96~1.49)

1.06 (0.97~1.15)
0.89 (0.52~1.54)
1.21 (0.97~1.51)

1.05 (0.96~1.14)
0.92 (0.53~1.57)
1.22 (0.98~1.53)

0.44 (0.27~0.71)***

0.44 (0.27~0.72)***
Reference

0.45 (0.28~0.73)**

1.84 (0.81~4.20)

1.79 (0.80~4.05)
Reference
0.81 (0.46~1.42)

1.77 (0.78~4.02)

0.53 (0.33~0.86)**

0.49 (0.30~0.79)**
Reference

0.48 (0.29~0.77)**

1.17 (0.67~2.05)
1.32 (0.67~2.61)

1.18 (0.67~2.09)
1.46 (0.73~2.93)
Reference

1.17 (0.66~2.06)
1.46 (0.73~2.90)

0.81 (0.46~1.43)

0.80 (0.46~1.41)

1.32 (0.72~2.40)

Reference
1.23 (0.68~2.24)

1.23 (0.67~2.23)

1.70 (1.03~2.81)*
1.29 (0.61~2.73)

Reference
1.64 (0.99~2.71)
1.38 (0.65~2.93)

1.67 (1.01~2.75)*
1.40 (0.66~2.96)

0.74 (0.44~1.26)

0.76 (0.45~1.30)
Reference

0.79 (0.47~1.33)
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Body Mass Index
Underweight
Normal/healthy weight
Overweight/obese
Step 2: Psycho-behavioral factors
ART self-efficacy
HIV symptom management self-efficacy
Depression
Anxiety
ART adherence (n, %)
Optimal
Suboptimal
Step 3: HIV-related stigma
Internalized stigma
Anticipated stigma
Enacted stigma
Pseudo R2
∆R2

0.56 (0.30~1.05)
1.08 (0.75~1.56)

0.118
-

1.01 (0.47~2.21)
Reference
1.34 (0.79~2.29)

1.00 (0.46~2.20)

1.09 (0.90~1.31)
1.01 (0.83~1.22)
1.19 (0.96~1.48)
1.05 (0.83~1.32)

1.11 (0.92~1.34)
1.04 (0.85~1.26)
1.13 (0.90~1.41)
1.07 (0.85~1.35)

1.17 (0.74~1.84)
Reference

1.11 (0.71~1.75)

0.147
0.029

Note: AOR: Adjusted odds ratio; CI: Confidence interval; *: p < 0.05; **: p < 0.01; ***: p < 0.001.

1.31 (0.76~2.24)

1.14 (0.95~1.38)
1.05 (0.87~1.27)
1.01 (0.85~1.20)
0.155
0.008

APPENDIX C
ORIGINAL PATH MODELS
Table C.1 Original path model with CD4 count as an outcome
Paths
β
SE
p-value
IS ---» ARTS
-0.105
0.030
<0.001
AS ---» ARTS
-0.134
0.028
<0.001
ES ---» ARTS
-0.211
0.042
<0.001
IS ---» ARTM
-0.028
0.009
0.003
AS ---» ARTM
-0.064
0.009
<0.001
ES ---» ARTM†
0.023
0.014
0.095
†
IS ---» MED
0.005
0.012
0.701
AS ---» MED†
-0.006
0.013
0.646
ES ---» MED
-0.056
0.020
0.006
ARTS ---» MED
0.063
0.014
<0.001
ARTM ---» MED
0.104
0.041
0.012
IS ---» CD4 count†
0.016
0.019
0.376
†
AS ---» CD4 count
-0.023
0.018
0.213
ES ---» CD4 count†
0.048
0.031
0.118
ARTS ---» CD4 count†
0.015
0.019
0.425
†
ARTM ---» CD4 count
-0.021
0.058
0.714
MED ---» CD4 count
-0.056
0.027
0.040
Note: IS: Internalized stigma; AS: Anticipated stigma; ES: Enacted stigma; ARTS: ART
self-efficacy; ARTM: HIV symptom management self-efficacy; MED: ART adherence;
SE: Standard error; †: Insignificant paths were deleted in model trimming process.

209

Table C.2 Original path model with viral suppression as an outcome
Paths
β
SE
p-value
IS ---» ARTS
-0.105
0.026
<0.001
AS ---» ARTS
-0.134
0.028
<0.001
ES ---» ARTS
-0.211
0.041
<0.001
IS ---» ARTM
-0.028
0.008
<0.001
AS ---» ARTM
-0.064
0.008
<0.001
ES ---» ARTM†
0.023
0.012
0.063
†
IS ---» MED
0.005
0.012
0.687
AS ---» MED†
-0.006
0.013
0.632
ES ---» MED
-0.056
0.018
0.002
ARTS ---» MED
0.063
0.013
<0.001
ARTM ---» MED
0.104
0.038
0.006
IS ---» VS†
-0.005
0.007
0.511
†
AS ---» VS
-0.008
0.008
0.287
ES ---» VS†
0.012
0.011
0.273
ARTS ---» VS†
0.005
0.008
0.508
†
ARTM ---» VS
0.013
0.023
0.570
MED ---» VS
-0.036
0.011
0.001
Note: IS: Internalized stigma; AS: Anticipated stigma; ES: Enacted stigma; ARTS: ART
self-efficacy; ARTM: HIV symptom management self-efficacy; MED: ART adherence;
VS: Viral suppression; SE: Standard error; †: Insignificant paths were deleted in model
trimming process.
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Table C.3 Original path model with HRQoL as an outcome
Paths
β
SE
p-value
IS ---» ARTS
-0.106
0.027
<0.001
AS ---» ARTS
-0.133
0.028
<0.001
ES ---» ARTS
-0.213
0.042
<0.001
IS ---» ARTM
-0.029
0.008
<0.001
AS ---» ARTM
-0.063
0.009
<0.001
ES ---» ARTM†
0.023
0.013
0.066
†
IS ---» MED
0.003
0.012
0.821
AS ---» MED†
-0.005
0.013
0.690
ES ---» MED
-0.056
0.019
0.003
ARTS ---» MED
0.063
0.013
<0.001
ARTM ---» MED
0.120
0.039
0.002
IS ---» HRQoL
-0.186
0.040
<0.001
AS ---» HRQoL†
-0.080
0.042
0.056
ES ---» HRQoL
-0.309
0.061
<0.001
ARTS ---» HRQoL
0.374
0.042
<0.001
ARTM ---» HRQoL
0.977
0.131
<0.001
MED ---» HRQoL†
0.064
0.058
0.271
Note: IS: Internalized stigma; AS: Anticipated stigma; ES: Enacted stigma; ARTS: ART
self-efficacy; ARTM: HIV symptom management self-efficacy; MED: ART adherence;
HRQoL: Health-related quality of life; SE: Standard error; †: Insignificant paths were
deleted in model trimming process.
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APPENDIX D
MODIFICATION INDICES
Table D.1 Adjusted paths and modification indices in the final model with CD4 count as an outcome
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Paths
Internalized stigma (intercept) «---» Enacted stigma (intercept)
Anticipated stigma (intercept) «---» Enacted stigma (intercept)
Anticipated stigma (intercept) «---» Internalized stigma (intercept)
ART self-efficacy (intercept) «---» Enacted stigma (intercept)
ART self-efficacy (intercept) «---» Internalized stigma (intercept)
ART self-efficacy (intercept) «---» Anticipated stigma (intercept)
HIV symptom management self-efficacy (intercept) «---» Enacted stigma (intercept)
HIV symptom management self-efficacy (intercept) «---» Internalized stigma (intercept)
HIV symptom management self-efficacy (intercept) «---» Anticipated stigma (intercept)
HIV symptom management self-efficacy (intercept) «---» ART self-efficacy (intercept)
HIV symptom management self-efficacy (intercept) «---» CD4 (intercept)
ART adherence (intercept) «---» ART self-efficacy (intercept)
Age «---» Internalized stigma (intercept)
Age «---» HIV symptom management self-efficacy (intercept)
Age «---» CD4 count (intercept)
Age «---» HIV symptom management self-efficacy (slope)
Note: «---»: Correlation.

M.I.
73.625
72.268
234.313
27.724
131.110
96.334
47.763
161.181
134.812
299.680
27.551
46.115
24.803
20.415
49.498
13.576

E.P.C
0.631
0.864
4.033
-0.414
-2.228
-2.746
-0.814
-3.700
-4.864
5.675
1.642
0.471
3.228
-4.934
-9.535
-0.160

StdYX E.P.C
0.183
0.208
0.351
-0.130
-0.254
-0.260
-0.156
-0.257
-0.281
0.430
0.073
0.115
0.114
-0.116
-0.203
-0.102

Table D.2 Adjusted paths and modification indices in the final model with viral suppression as an outcome
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Paths
Internalized stigma (intercept) «---» Enacted stigma (intercept)
Anticipated stigma (intercept) «---» Enacted stigma (intercept)
Anticipated stigma (intercept) «---» Internalized stigma (intercept)
ART self-efficacy (intercept) «---» Enacted stigma (intercept)
ART self-efficacy (intercept) «---» Internalized stigma (intercept)
ART self-efficacy (intercept) «---» Anticipated stigma (intercept)
HIV symptom management self-efficacy (intercept) «---» Enacted stigma (intercept)
HIV symptom management self-efficacy (intercept) «---» Internalized stigma (intercept)
HIV symptom management self-efficacy (intercept) «---» Anticipated stigma (intercept)
HIV symptom management self-efficacy (intercept) «---» ART self-efficacy (intercept)
ART adherence (intercept) «---» ART self-efficacy (intercept)
Duration of infection «---» ART self-efficacy (intercept)
Depression «---» ART self-efficacy (intercept)
Depression «---» HIV symptom management self-efficacy (intercept)
Depression «---» ART self-efficacy (slope)
Note: «---»: Correlation.

M.I.
73.625
72.268
234.314
27.724
131.110
96.334
47.763
161.181
134.812
299.680
46.115
25.634
36.162
20.404
11.855

E.P.C
0.631
0.864
4.033
-0.414
-2.228
-2.746
-0.814
-3.700
-4.864
5.675
0.471
-9.603
-5.499
-6.186
0.586

StdYX E.P.C
0.183
0.208
0.351
-0.130
-0.254
-0.260
-0.156
-0.257
-0.281
0.430
0.115
-0.142
-0.168
-0.116
0.099

Table D.3 Adjusted paths and modification indices in the final model with HRQoL as an outcome

214

Paths
Internalized stigma (intercept) «---» Enacted stigma (intercept)
Anticipated stigma (intercept) «---» Enacted stigma (intercept)
Anticipated stigma (intercept) «---» Internalized stigma (intercept)
ART self-efficacy (intercept) «---» Enacted stigma (intercept)
ART self-efficacy (intercept) «---» Internalized stigma (intercept)
ART self-efficacy (intercept) «---» Anticipated stigma (intercept)
HIV symptom management self-efficacy (intercept) «---» Enacted stigma (intercept)
HIV symptom management self-efficacy (intercept) «---» Internalized stigma (intercept)
HIV symptom management self-efficacy (intercept) «---» Anticipated stigma (intercept)
HIV symptom management self-efficacy (intercept) «---» ART self-efficacy (intercept)
ART adherence (intercept) «---» ART self-efficacy (intercept)
HRQoL (intercept) «---» Enacted stigma (intercept)
HRQoL (intercept) «---» Internalized stigma (intercept)
HRQoL (intercept) «---» Anticipated stigma (intercept)
HRQoL (intercept) «---» ART self-efficacy (intercept)
HRQoL (intercept) «---» HIV symptom management self-efficacy (intercept)
Depression «---» Enacted stigma (intercept)
Depression «---» Internalized stigma (intercept)
Depression «---» Anticipated stigma (intercept)
Depression «---» ART self-efficacy (intercept)
Depression «---» HIV symptom management self-efficacy (intercept)
Depression «---» HRQoL (Intercept)
Anxiety «---» Enacted stigma (intercept)
Anxiety «---» Internalized stigma (intercept)

M.I.
73.126
70.822
224.261
32.002
127.472
93.166
44.665
160.770
129.133
294.952
46.716
117.539
180.932
165.358
281.787
271.441
13.551
22.219
24.140
21.149
25.208
39.347
47.065
51.010

E.P.C
0.630
0.861
3.932
-0.445
-2.182
-2.695
-0.793
-3.692
-4.780
5.630
0.470
-2.524
-7.678
-10.605
10.789
15.955
0.380
1.235
1.620
-1.446
-1.944
-4.788
1.261
3.197

StdYX E.P.C
0.184
0.208
0.347
-0.142
-0.253
-0.259
-0.153
-0.259
-0.279
0.431
0.116
-0.278
-0.309
-0.353
0.473
0.424
0.076
0.091
0.094
-0.113
-0.090
-0.127
0.181
0.171

Anxiety «---» Anticipated stigma (intercept)
Anxiety «---» ART self-efficacy (intercept)
Anxiety «---» HIV symptom management self-efficacy (intercept)
Anxiety «---» HRQoL (intercept)
CD4 count «---» ART self-efficacy (intercept)
CD4 count «---» HIV symptom management self-efficacy (intercept)
Duration of infection «---» CD4 count
Note: «---»: Correlation.

38.316
20.793
36.581
117.803
12.091
28.874
19.360

3.882
-1.601
-3.769
-11.319
0.120
0.318
0.195

0.168
-0.089
-0.140
-0.219
0.086
0.138
0.125
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Paths
Group: CD4 count < 500 cells/μl (n= 658)
Internalized stigma ---» ART self-efficacy
Anticipated stigma ---» ART self-efficacy
Enacted stigma ---» ART self-efficacy
Internalized stigma ---» HIV symptom management self-efficacy
Anticipated stigma ---» HIV symptom management self-efficacy
Enacted stigma ---» ART adherence
ART self-efficacy ---» ART adherence
HIV symptom management self-efficacy ---» ART adherence
ART adherence ---» Viral suppression
Group: CD4 count ≥ 500 cells/μl (n= 540)
Internalized stigma ---» ART self-efficacy
Anticipated stigma ---» ART self-efficacy
Enacted stigma ---» ART self-efficacy
Internalized stigma ---» HIV symptom management self-efficacy
Anticipated stigma ---» HIV symptom management self-efficacy

β

Std.β

SE

-0.124
-0.113
-0.133
-0.008
-0.068
-0.040
0.083
0.049
-0.027

-0.142
-0.122
-0.097
-0.025
-0.211
-0.041
0.117
0.024
-0.023

0.039
0.036
0.054
0.013
0.013
0.027
0.019
0.056
0.016

0.001**
0.002**
0.014*
0.562
<0.001***
0.144
<0.001***
0.384
0.102

-0.096
-0.142
-0.297
-0.016
-0.052

-0.103
-0.146
-0.183
-0.057
-0.176

0.045
0.042
0.069
0.013
0.014

0.032*
0.001**
<0.001***
0.209
<0.001***

p-value

Enacted stigma ---» ART adherence
-0.080
-0.073
ART self-efficacy ---» ART adherence
0.045
0.066
HIV symptom management self-efficacy ---» ART adherence
0.123
0.056
ART adherence ---» Viral suppression
-0.045
-0.048
Note: CI: Confidence interval; SE: Standard error; *: p<0.05; **: p<0.01; ***: p<0.001.

0.032
0.019
0.054
0.017

0.011*
0.017*
0.022*
0.008**
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Table E.2 Results of longitudinal mediation analysis of viral suppression by baseline CD4 count
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Effects
Group: CD4 count < 500 cells/μl (n= 658)
From IS to VS
Indirect effect
IS ---» ARTS ---» MED ---» VS
IS ---» ARTM ---» MED ---» VS
From AS to VS
Indirect effect
AS ---» ARTS ---» MED ---» VS
AS ---» ARTM ---» MED ---» VS
From ES to VS
Indirect effect
ES ---» MED ---» VS
ES ---» ARTS ---» MED ---» VS
From IS to MED
Indirect effect
IS ---» ARTS ---» MED
IS ---» ARTM ---» MED
From AS to MED
Indirect effect
AS ---» ARTS ---» MED
AS ---» ARTM ---» MED
From ES to MED
Indirect effect
ES ---» ARTS ---» MED
Direct effect

β

Std.β

SE

p-value

0.000
0.000

0.000
0.000

0.000
0.000

0.174
0.779

0.000
0.000

0.000
0.000

0.000
0.000

0.183
0.501

0.001
0.000

0.001
0.000

0.001
0.000

0.319
0.258

-0.011
0.000

-0.017
-0.001

0.004
0.001

0.009**
0.740

-0.009
-0.003

-0.014
-0.005

0.004
0.004

0.012*
0.398

-0.011
-0.040

-0.011
-0.041

0.005
0.027

0.034*
0.144
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Group: CD4 count ≥ 500 cells/μl (n= 540)
From IS to VS
Indirect effect
IS ---» ARTS ---» MED ---» VS
0.000
0.000
0.000
0.227
IS ---» ARTM ---» MED ---» VS
0.000
0.000
0.000
0.320
From AS to VS
Indirect effect
AS ---» ARTS ---» MED ---» VS
0.000
0.000
0.000
0.113
AS ---» ARTM ---» MED ---» VS
0.000
0.000
0.000
0.119
From ES to VS
Indirect effect
ES ---» MED ---» VS
0.004
0.003
0.002
0.072
ES ---» ARTS ---» MED ---» VS
0.001
0.001
0.000
0.132
From IS to MED
Indirect effect
IS ---» ARTS ---» MED
-0.004
-0.007
0.003
0.150
IS ---» ARTM ---» MED
-0.002
-0.003
0.002
0.292
From AS to MED
Indirect effect
AS ---» ARTS ---» MED
-0.006
-0.010
0.003
0.039**
AS ---» ARTM ---» MED
-0.006
-0.010
0.004
0.067
From ES to MED
Indirect effect
ES ---» ARTS ---» MED
-0.013
-0.012
0.007
0.044*
Direct effect
-0.080
-0.073
0.032
0.011*
Note: IS: Internalized stigma; AS: Anticipated stigma; ES: Enacted stigma; ARTS: ART self-efficacy; ARTM: HIV symptom
management self-efficacy; MED: ART adherence; VS: Viral suppression; CI: Confidence interval; SE: Standard error; *: p < 0.05; **:
p < 0.01; ***: p < 0.001.

